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Abstract 
 
The management of trauma has been transformed by recent conflict and by improvements 
in understanding of the response to injury, particularly coagulopathy.  Clotting abnormalities 
can appear early after trauma and have multiple causes, including tissue injury, shock and 
the effects of treatment.  There is increasing understanding of the contribution of 
coagulation molecules to these abnormalities.  Platelets are recognised as being central to 
the clotting cascade in the current cell-based model of coagulation but have been 
incompletely studied after traumatic injury. 
There has been widespread adoption of the practice of “haemostatic resuscitation” using 
blood products rather than crystalloid fluids with a high ratio of plasma to red blood cells to 
correct the coagulopathy of trauma while restoring the patient’s physiology.  The British 
Armed Forces have pushed this forward of the hospital using physician-led medical teams.  
However, this practice has unquantified benefit and potential for harm, and is a logistical 
challenge. 
The first study in this thesis assesses whether available clinical data support the use of 
prehospital transfusion.  It compared recipients of the treatment with similarly injured 
controls.  Although mortality was halved, confounding changes in hospital transfusion 
practice made it impossible to rely on these data to establish the efficacy of prehospital 
transfusion. 
To allow further study, an animal model of complex military trauma was developed.  The 
author focused on developing a flow cytometry assay for the assessment of platelet 
activation and response to in vitro stimulation.  This was successful.  The performance of the 
assay was assessed in the context of the animal model.  Surgical preparation of the model 
appeared to affect the expression of the relevant activation marker.  While the assay proved 
incompatible with unavoidable constraints of the model, its development acted as the basis 
for the establishment of a human platelet study of combat casualties in Afghanistan. 
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Chapter 1.  Introduction 
 
The period from 2001 to 2014 saw the longest sustained period of medium- and high-
intensity conflict involving UK and US armed forces since the Second World War.  
During this period there has been a revolution in many aspects of the care of trauma 
patients, both in military (Blackbourne et al., 2012) and civilian practice (Howell, 2014).  
For the UK Armed Forces, the deployment to Helmand Province, Afghanistan saw the 
highest rate of casualties and the most intense medical effort.  A combination of the 
type of combat, dominated by the use of improvised explosive devices, the protective 
equipment worn by servicemen and the advances in the speed and quality of 
immediate medical care produced a patient population characterised by a high 
incidence of severe injury comprising blast exposure, extensive soft tissue injury and 
traumatic amputations. 
 
Haemorrhage remains one of the most serious threats to the lives of such patients.  It 
is the leading cause of preventable battlefield death (Hodgetts, Mahoney and Kirkman, 
2007; Kelly et al., 2008).  The use of tourniquets and other prehospital interventions 
has had a large impact on the initial fatality of such injuries, meaning that severely 
injured patients who have had significant bleeding are now more likely to be recovered 
to medical care.  The challenge of managing such patients has been met through new 
practices, including prehospital transfusion (O’Reilly et al., 2014) and changes to the 
way blood products are used (Borgman et al., 2007), which are themselves based on a 
new understanding of the mechanisms underlying traumatic bleeding and 
coagulopathy.  That new understanding began in the civilian sphere (Brohi et al., 2003) 
and the entire process has been characterised by a free exchange of ideas and practice 
between military and civilian clinicians and researchers. 
 
While prehospital transfusion has a long history, its introduction into British military 
practice is seen as one of the key changes in trauma care during this long decade of 
conflict.  However, that change was made on the basis of expert opinion rather than 
evidence.  The first study detailed in this thesis arose from an attempt to correct this 
by examining the available clinical information.  An assessment of the impact of 
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prehospital transfusion on mortality using human data from Afghanistan was 
performed.  This demonstrated that confounding changes in clinical practice meant 
that the independent effect of prehospital transfusion could not be established.  This 
supported the use of an animal model to examine the issue. 
 
The use of an animal model provided the opportunity to study aspects of coagulopathy 
in far more detail than could be achieved in human subjects.  Assessment of several 
aspects of coagulation was an existing part of animal models of trauma in use at Dstl 
Porton Down.  However, the role of platelets, which lie at the heart of the coagulation 
process, had not been addressed.  As a suitable model was set up, the author (under 
guidance and supervision) therefore developed an assay to assess platelet function.  
Implementation of this assay in the animal model demonstrated unexpected effects of 
the surgical preparation of the model on platelet activation. 
 
There are therefore two distinct components to the work described: first, a human 
data study, which demonstrated the need for an animal model and, second, the 
development and validation of a platelet flow cytometry assay which was undertaken 
by the author in the context of that model. 
 
Chapter 2 begins with an exploration of the mechanisms of battlefield injury, including 
blast, followed by an examination of the body’s pathophysiological response, with a 
particular emphasis on coagulation.  The development and evidence base of the 
resuscitation of trauma patients is examined in Chapter 3.  Chapter 4 is a study of the 
available human data on patients who receive prehospital transfusion. 
 
In Chapter 5 there is discussion of important elements of the techniques that are used 
in the remainder thesis: coagulation assays, flow cytometry and animal models.  
Chapter 6 describes the development of a flow cytometry assay of platelet function.  
Chapter 7 describes an assessment of the functioning of this assay in an experimental 
setting.  Chapter 8 concludes with a description of how work in this area should 
progress. 
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Chapter 2.  Mechanisms and Consequences of injury 
 
Mechanisms of injury determine the pathophysiological consequences for the patient.  
This chapter begins with an overview of these mechanisms in order to give context to a 
more detailed examination of blast injury.  Thereafter the chapter turns to the 
physiology of the cardiovascular response to injury, again with emphasis on the 
reaction to blast.  There is then an examination of the linked systems of inflammation 
and coagulation before a description of the disordered coagulation seen after severe 
injury; the role of platelets in these is emphasised. 
 
2.1 Non-Blast Injury 
 
Irrespective of mechanism, tissue injury is caused by the deposition of energy (Hunt, 
Marr and Stuke, 2012).  In thermal and chemical burns, molecular damage is 
generated, often without actually disrupting the tissue.  However, in most cases, 
kinetic energy does work in tissue, disrupting the bonds of cellular and extracellular 
structures.  This is usually due to the interaction between the host and a solid object 
moving relative to it.  Primary blast injuries are the major exception to this.  In any 
case, damage is generated when kinetic energy does work in the tissues to disrupt 
intra- and intermolecular bonds.  The amount of damage done is a function of the 
kinetic energy deposited. 
 
The forces generated in any collision are applied to the materials of the objects 
involved.  The force may be in tension or compression or it may involve shear, where 
forces act in opposing directions on different parts of an object, an example being the 
differential acceleration of tethered and mobile parts of a viscus.  As forces act on a 
material (stress—force per unit area) they deform it (strain—relative size of the 
deformation).  Depending on the material and the type (tensile, compressive or shear) 
and magnitude of the strain, the deformation will either be elastic or plastic.  Elastic 
strain is fully reversed by removal of the stress; plastic is not.  Kinetic energy may still 
be dissipated by elastic deformation due to the generation of heat and noise.  Finally, 
at the point of maximum plastic strain, the material fails and is disrupted.  The tensile, 
compressive or shear strength is the stress at which this occurs.  A special case is fluid 
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filled objects subjected to compression.  Due to Boyle’s law, the reduction in volume 
caused by the compression increases the pressure of the fluid.  This increases the 
tensile stress on the wall of the fluid-filled structure.  If the increase exceeds its tensile 
strength, the wall will rupture. 
 
Penetrating injuries are also caused by collisions.  Sharp objects serve to concentrate 
the force of the collision in a small area, such that the blade or point produces very 
large and very local increases in stress on the material through which it thereby cuts.  
Bullets and other projectiles concentrate the forces less but have more available 
kinetic energy to do work on the material.  Low energy projectiles cause only very local 
damage to material cut and crushed as they pass through.  High energy projectiles, 
such as high velocity military bullets, occasionally pass through tissue with little loss of 
energy.  (The determinants of this are a complex interaction between the nature of the 
materials traversed by the projectile and the material and kinetic properties of the 
latter.)  More commonly, their large available kinetic energy is dissipated by generating 
heat, crushing local tissue, accelerating tissue away from the passage of the projectile 
and deforming the bullet itself.  The consequence is that high velocity projectiles 
generate a larger permanent cavity than low energy ones.  They also generate a much 
larger temporary cavity.  The temporary cavitation does not, in the main, devitalise the 
affected tissue, most of which is only elastically deformed (hence it is temporary).  
However, tissue is a mixed medium and some of the material will have less capacity for 
elastic strain and will either permanently deform or will fail.  In particular, bone is 
weak under tension and temporary cavitation can generate fractures remote from the 
permanent wound track. 
 
The clinical impact of an injury is not just a function of the kinetic energy that was 
dissipated in causing it.  The site of injury is crucial.  Local injury to adipose tissue is of 
far less significance than destruction of central nervous tissue.  Systemically, injuries 
that cause significant bleeding, disrupt the airway or otherwise embarrass the delivery 
of oxygenated blood to the tissues (e.g. cardiac tamponade, pneumothorax, vascular 
occlusion) may be fatal despite relatively minor tissue disruption. 
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2.2 Blast 
 
2.2.1 Physics of Blast 
 
Explosions liberate large amounts of energy in very short spaces of time (Wolf et al., 
2009); e.g. the velocity of detonation (the speed at which the detonation wave 
propagates through the material) of trinitrotoluene is 6,900m/s (Cooper, 1996).  A high 
velocity, high pressure blast wave is produced which moves out quickly through the 
surrounding medium.  Initially, this wave, known as the peak over pressure, is 
contiguous with an expanding cloud of the hot gaseous products of the explosion.  
Since it is moving faster than the speed of sound in the medium, the blast wave soon 
decouples from the slowing expansion of the gases (Figure 2.1) 
 
 
 
Figure 2.1 A large explosion under (broadly) free-field conditions.  The blast wave is clearly visible and 
has moved away from the expanding gases. 
 
The peak overpressure is short-lived since it decays rapidly as it moves away from the 
point of the explosion, particularly where the medium is air rather than water.  The 
passage of the blast waves accelerates the air, producing a blast wind (dynamic 
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overpressure), which carries with it energised fragments of the explosive, its container 
and other nearby objects.  The outward movement of the blast wind eventually 
dissipates, leaving (in air) a volume of rarefied, low pressure gas near the point of 
explosion.  The medium therefore reverses its movement to correct this 
underpressure, oscillating until uniform pressure is restored throughout (Figure 2.2). 
 
 
Figure 2.2  A Frielander curve showing the rapid rise to peak overpressure and subsequent negative 
pressure after an explosion.  In this idealised curve, oscillation is not shown.  (Mediavilla Varas et al., 
2011) 
 
The relative importance of the peak overpressure and the blast wind (and fragments) 
depends upon the environment of the explosion.  In an incompressible liquid medium, 
as with underwater explosions, the blast wave propagates much further than in a gas, 
where the compressibility of the medium allows its energy to accelerate and heat the 
air.  Conversely, dense liquid media reduce the movement of the dynamic 
overpressure and fragments, which consequently have a much reduced radius of 
effect.  Interaction of the blast wave with solid surfaces can cause it to be reflected.  In 
complex environments this can allow reflected and non-reflected blast waves to meet 
at particular points where the peak overpressure will be summed (Wolf et al., 2009).  
Consequently, blast waves can cause damage further from the point of explosion in 
confined spaces and cause more severe injury. 
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2.2.2 Blast Injuries 
 
Injuries from explosions are categorised as primary, secondary, tertiary and quaternary 
(Zuckerman, 1940). 
 Primary blast injuries are those caused by the peak overpressure and are 
unique to explosions.  When the blast wave interacts with the body it causes 
differential acceleration of structures according to their density and other 
characteristics.  Consequently energy is deposited at interfaces between 
materials of different density, as may be found at the internal surface of hollow 
viscera.  The propagation of the blast wave though the different tissues of the 
body generates a high-velocity, low-amplitude stress wave and a low-velocity, 
high-amplitude shear wave.  The stress wave is compressive but when reflected 
at a density interface pulls tissue apart (tension).  This leads to damage at a 
microscopic level (albeit potentially affecting a considerable volume of tissue) 
rather than large lacerations (Figure 2.3).  Shear waves cause gross relative 
movement of tissues, particularly due to the movement of the body wall.  This 
causes tearing of structures from their attachments and disruption of solid 
organs (Horrocks, 2001). 
 Secondary blast injuries are those caused by the impact of fragments 
energised by the blast wind.  Professionally manufactured military munitions 
contain preformed fragments or have casings which are designed to break up 
along lines of weakness producing fragments with predictable ballistic 
properties (Dearden, 2001).  The size, mass and shape of the fragments dictate 
how far and fast they move through the air and how they interact with the 
body.  This allows the manufacturer to control the wounding effects and radius 
of the weapon.  Munitions may be optimised to typically injure rather than kill 
and to produce predictable chances of injury and death at given distances from 
detonation.  Most improvised explosive devices (IEDs) lack this sophistication.  
Their casings fracture randomly and their wounding effects are highly 
unpredictable.  Large fragments may be energised causing severe injuries.  
However, in some cases secondary blast from an IED may be chiefly due to the 
impact of energised soil and sand, in which the device has been disguised, 
which (depending on proximity to the device and the quantity of explosive) 
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may cause a diffuse, shallow destruction of tissue with devitalisation and 
tattooing of tissue beyond. 
 
 Tertiary injuries are caused by the body being moved by the blast wind and 
striking against other objects.   
 
 All other effects, including burns, inhalational injury and psychological sequelae 
are classified as quaternary.  Crush due to building collapse is classified as a 
tertiary or quaternary injury by different authors.  A hyperinflammatory 
response seen in some Israeli victims of improvised explosive devices and 
caused by absorption of pentaerythritol-tetranitrate has been described and 
the term quinary blast injury proposed (Kluger et al., 2007).  The Quaternary 
group is already disparate and the burden of proof to justify the establishment 
of a fifth category of injury must lie on Kluger et al.  No clear reason not to 
include this novel mechanism as part of the quaternary group is given. 
 
 
Figure 2.3 Post mortem image of primary blast injury in a pig.  There is a large area of contusion on the 
side that faced the explosive but no significant laceration. 
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Traumatic amputation after blast injury is an interesting phenomenon.  These injuries 
have been common in Afghanistan: Morrison et al found that 169 of 656 IED casualties 
in a four year period sustained 278 lower extremity amputations (Morrison, Hunt, et 
al., 2012).  Amputations were traditionally thought to be caused by differential 
acceleration of different parts of the limb by the blast wind.  This should cause 
disruption at the joints where those parts interact.  However, Hull et al (1994), 
examining injuries sustained in Northern Ireland, found that the level of bony 
transection was usually in the middle of the shaft of long bones.  Experiments on 
sheep limbs have shown that the bone is in fact fractured by the action of the peak 
overpressure.  The blast wind then accelerates the limb distal to the fracture, tearing it 
off (Hull and Cooper, 1996).  Pure limb flail remains a relevant mechanism: Singleton et 
al (2014) recently found that 17.3% of lower limb amputations were through knee, 
most without a nearby fracture.  They also found no evidence of an association of 
traumatic amputation with primary blast lung injury, a past finding which had 
supported Hull and Cooper’s hypothesis. 
 
2.2.3 Impact and Implications of Primary Blast Injury 
 
Compared with the general population of trauma victims, those injured by explosive 
devices are more severely injured, with worse physiology and more need for surgery 
and critical care.  Mortality is also higher (Frykberg, Tepas and Alexander, 1989; Kluger 
et al., 2004).  The relative contribution of the components of blast injury is the subject 
of some debate.  There is considerable variation by bombing type, but penetrating 
(secondary) injuries undoubtedly predominate (Arnold et al., 2003).  In a large review 
of terrorist incidents in diverse environments, 47% of immediate fatalities were found 
to have evidence of primary lung injury (Frykberg and Tepas, 1988).  Primary blast lung 
injury is unquestionably an important cause of early death.  As may be expected, 
primary blast lung injury is more common after explosions in confined spaces among 
patients admitted to hospital (77.5% confined space v 24.5% open space explosion) 
(Leibovici et al., 1996).  These Israeli experiences compare with the Madrid bombing: 
18.7% of patients who were admitted to the nearest hospital had evidence of blast 
lung injury; these 17 patients made up 63% of the patients admitted to the critical care 
unit (Gutierrez de Ceballos et al., 2005).  On 7 July 2005, 4 suicide bombers killed 52 
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others and injured more than 700 people.  The Royal London Hospital received the 
largest number of casualties.  Seven required intensive care admission, three of whom 
had traumatic amputations.  Despite this, and the enclosed space nature of all the 
incidents, none had primary blast lung injury (Shirley, 2006).  The incidence of primary 
blast lung injury among hospitalised patients varied between 0 and 44% in one review 
of many incidents (Arnold et al., 2003).  This variation may reflect differences in data 
quality and definitions between incidents as well as the realities of the device, 
environment and casualties. 
 
From the civilian clinical perspective, the important lesson is that these injuries occur, 
particularly in the critically ill population.  A different point of view is held by a military 
healthcare system.  It must expect to manage blast-exposed patients, rather than 
simply plan against a low probability, high impact event.  It must design clinical 
facilities and prioritise research efforts on the basis of data about the incidence and 
consequence of primary lung injury.  If this is common and has high immediate 
lethality, there must be a concentration on prevention and protection.  If the 
immediate lethality is lower but the overall morbidity and mortality still high, there 
may be an opportunity for therapeutic intervention.  In that case there must be more 
emphasis on clinical care and research.  The crucial question is: how common is blast 
injury in military patients surviving to reach medical care? 
 
Champion and colleagues have argued that the lethal range of fragments from most 
explosives exceeds that of the primary blast effect (Champion, Holcomb and Young, 
2009).  Many injury models require exposure to large peak overpressures to induce 
primary lung injury.  This is equivalent to close proximity to typical military munitions, 
well within the radius of flight of fragments.  Three factors may allow contemporary 
military casualties to sustain primary blast injury while surviving the effect of 
fragmentation.  First, explosions in complex urban or other environments may involve 
the reflection and summation of blast waves, allowing primary blast effect beyond its 
free-field range, while fragments are impeded by other structures.  Second, the 
lethality of penetrating fragments is related to the structures they traverse.  The 
advent of advanced body armour for servicemen means they are more likely to survive 
explosions, albeit often with multiple amputations (Morrison, Hunt, et al., 2012).  This 
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is due to enhanced protection from secondary injury, which could make it possible to 
be exposed to injurious but sub-lethal primary blast without dying from concomitant 
fragment injury.  Third, improvised explosives do not have the carefully engineered 
preformed fragments seen in military munitions.  Indeed, they may not contain metal 
fragments at all to avoid detection.  Chance variation in fragment behaviour would 
again allow immediate survivors to be blast-exposed. 
 
Data from Iraq and Afghanistan have fuelled this debate.  Ramasamy et al (2009) found 
that 2 (3.7%) of 53 IED injured patients admitted to a British field hospital had 
significant primary blast injury.  Ritenour et al (2010) have since shown that 172 (3.6%) 
of 4765 US patients admitted after becoming victims of explosions in Iraq and 
Afghanistan had evidence of primary blast injury.  Smith (2010) reviewed 1678 British 
cases (immediate deaths and those admitted to hospital) injured by blast and found 
that 113 (6.7%) had evidence of blast injury.  Smith also found that 44% of these 
survived to reach medical care but that 24% of those died of their wounds. 
 
These papers, covering heterogeneous time periods, environments and threats, 
demonstrate that primary blast injury is a significant threat to military patients, 
including a small group of initial survivors (perhaps 1 in 30 of all casualties in recent 
conflict, but a higher proportion of the severely injured).  Preventative research is 
required but blast-injured patients will continue to present.  Since it can be difficult to 
detect initially, military resuscitation practice should be optimised to the needs of 
patients with and without primary blast injury.  Consequently, research must also 
address both patient groups. 
 
2.3 Physiological Response to Injury 
 
The physiological response to injury has several components: the cardiovascular and 
neurohumoral systems, inflammation, coagulation, metabolism and behaviour are all 
affected.  These responses are intimately related to one another, sharing neural and 
molecular pathways, initiators and feedback mechanisms.  The neurohumoral, 
metabolic and behavioural aspects are not relevant to this thesis and will not be 
explored further. 
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2.4 Cardiovascular Response 
 
2.4.1 Cardiovascular Response to Conventional Trauma 
 
The cardiovascular response to isolated haemorrhage involves two phases of 
sympathetically mediated changes (Little et al., 1995). 
 Initially, reduced venous return leads to reduced stroke volume due to 
Starling’s law.  This leads to a reduction in pulse pressure and consequently of 
arterial baroreceptor output.  Through centrally mediated reflex arcs, this 
causes a loss of vagal output to the heart and then sympathetic activation.  The 
former causes tachycardia.  The latter is chronotropic, enhancing the 
tachycardia, and inotropic, increasing cardiac contractility and consequently 
stroke volume.  These serve to ameliorate the fall in cardiac output.  Peripheral 
sympathetic activation increases vascular resistance through arteriolar 
constriction.  Increased total peripheral resistance and the relative preservation 
of cardiac output serve to maintain blood pressure.  Since the arterioles of 
certain vital tissues beds (such as the brain) are not constricted by this process, 
their perfusion is maintained at the expense of others.  Perfusion of local tissue 
beds is also modulated by the production of nitric oxide, its derivatives, carbon 
monoxide and potassium (Atkins, Johnson and Pearce, 2006). 
 In the absence of other stimuli, further haemorrhage will eventually lead to the 
activation of a second, depressor reflex mechanism.  This mechanism 
supersedes the baroreceptor reflex, activating the vagus and inhibiting 
sympathetic flow.  The consequence is profound bradycardia and hypotension.  
This reflex response may be compounded by the production of a large amount 
of the vasodilator nitric oxide by the endothelium.  Slowing the heart increases 
the diastolic interval, which may improve cardiac filling and coronary perfusion.  
Decreased afterload due to the fall in peripheral resistance may reduce cardiac 
work.  The depressor response may therefore be protective.  However, the 
reduced cerebral perfusion leads to depressed consciousness and fluid 
resuscitation is required to restore the blood pressure.  Atropine will correct 
the bradycardia, but may endanger a patient’s life (Little et al., 1995).   
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Tissue injury or ischaemia leads to a quite different response.  Increased sympathetic 
activation leads to increased total peripheral resistance with consequent increased 
blood pressure and redistribution of blood flow towards muscle and away from the gut 
and kidneys (Overman and Wang, 1947).  It also stimulates a tachycardia.  This would 
be opposed by a normal baroreceptor response.  However, within a few hours of injury 
that response is altered, becoming less sensitive to hypotension and recalibrated to 
maintain a higher blood pressure.  One consequence is a persistent tachycardia often 
seen after injury. 
 
When tissue injury coexists with haemorrhage it attenuates the response to the latter.  
The early tachycardia is reduced by 10 to 15% and the late bradycardia abolished 
(Little, Marshall and Kirkman, 1989).  This appears to be due to central inhibition of the 
efferent limb of the response to haemorrhage.  The vasoconstriction caused by injury 
leads to better preservation of blood pressure.  However, this seems to be at the 
expense of cardiac output, and consequently of oxygen delivery (Rady et al., 1993). 
 
Somatic nerve stimulation can simulate much of the modulation of cardiovascular 
response by musculoskeletal injury.  Animals subjected to haemorrhage with nerve 
stimulation have higher mortality than those without stimulation (Overman and Wang, 
1947).  Normally oxygen uptake by the tissues is governed by metabolic demands, the 
supply of oxygen being more than adequate.  In haemorrhage with musculoskeletal 
injury, local blood supply can become inadequate as total body oxygen delivery falls 
(DO2) since blood is diverted away from some vascular beds.  When this occurs, their 
oxygen consumption ceases to be independent of DO2 and this is reflected in a fall in 
total body consumption of O2 (VO2).  The level of DO2 at which VO2 becomes 
dependent on DO2 is called the critical oxygen delivery.  It is higher in haemorrhage 
with brachial nerve stimulation than without (Kirkman et al., 1995). 
 
It is interesting to speculate upon why this modulation is adaptive.  It may be that it 
gives some protection at lesser degrees of blood loss (which were perhaps more 
common than severe haemorrhage in the lives of our ancestors).  The cardiovascular 
effects of musculoskeletal injury mimic the visceral alerting response of the defence 
reaction, which exists to prepare the body for fight or flight and activates in response 
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to fear and other stimuli.  Preparing the body for the muscular work that is required to 
avoid further injury may very well be an adaptive response to musculoskeletal 
damage. 
 
2.4.2 Cardiovascular Response to Blast Injury 
 
Exposure to thoracic blast produces a characteristic cardiovascular response (Kirkman 
and Watts, 2010).  This is characterised by hypotension and bradycardia, which begin 
to develop after 2s and 4s respectively (Ohnishi et al., 2001).  This is consistent with its 
being a reflex response, not due to direct effects on the heart or CNS.  The initial 
bradycardia is profound: in rats, an increase in the mean heart period/beat-to-beat 
interval from 133ms to 489ms.  This recovers after 5 minutes with a more moderate 
bradycardia (heart period around 160ms) persisting for several hours.  Mean blood 
pressure recovers from a nadir of 40mmHg to 70mmHg, also over five minutes, but 
further recovery to 100mmHg takes 1hr and some hypotension persists for 24hrs.  
Blast also causes apnoea, which in this model lasted 28s. 
 
The efferent pathway mediating the bradycardia is the vagus nerve.  Vagotomy 
abolishes the bradycardia but (in the Ohnishi model) only partially corrects the 
hypotension.  Atropine blocks the bradycardia without modulating the hypotension.  
Thus the two are separately mediated: the bradycardia’s afferent and efferent loops 
are vagal; the hypotension has vagal and either non-vagal elements or a non-reflex 
component.  Systemic vascular resistance is reduced for some time after blast (Irwin et 
al., 1999).  The vagally mediated components of these changes are consistent with the 
pulmonary defence reflex mediated by the pulmonary afferent C fibres (Ohnishi et al., 
2001).  The fall in SVR may therefore be due to the sympathoinhibition which is a 
feature of this reflex (Daly and Kirkman, 1988).  In addition, blast is known to induce 
the production of large amounts of NO (Žunić et al., 2000), which causes 
vasodilatation.  Finally, embarrassment of the cardiac musculature by air embolism or 
contusion may be the cause of the hypotension. 
 
Sawdon, Ohnishi et al combined haemorrhage and blast in a rat model (Sawdon et al., 
2002).  Haemorrhage began 10 min after thoracic blast exposure (i.e. after resolution 
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of the initial extreme bradycardia).  Blasted animals had a lower blood pressure at the 
onset of haemorrhage and were unable to maintain it at that level as blood was lost; 
sham blasted animals initially preserved normal MAP.  The bradycardia due to 
haemorrhage appears to have occurred earlier (after less blood loss) in blasted than in 
non-blasted animals.  At the extreme of blood loss, cardiovascular parameters in the 
two groups converged, presumably reflecting a narrower range of possible 
combinations available in the context of marked hypovolaemia.    
 
2.5 Inflammatory Response 
 
Inflammation is fundamental to the pathophysiology of trauma.  While most deaths 
occur early, due to head injury and haemorrhage, (Trunkey, 1983) sepsis causes 3.1-
17% of deaths and organ failure 1.6-9% (Pfeifer et al., 2009).  Perhaps 25% of trauma 
victims develop multiple organ dysfunction syndrome (MODS) (Ciesla et al., 2005).  
Critical illness accounts for 42 to 52% of acute care costs for injured 
patients(Christensen et al., 2008) and has significant long term sequelae (Ulvik et al., 
2007).  Inflammatory processes underlie all of these problems. 
 
The processes described in this section are associated with characteristic clinical 
phenotypes.  Widespread activation of inflammation is recognised in the Systemic 
Inflammatory Response Syndrome (SIRS).  SIRS is not necessarily a pathological state 
and is characterised by (at least two of) pyrexia (or hypothermia), tachycardia, 
tachypnoea and leucocytosis (Bone et al., 1992).  SIRS arises in response to both injury 
and infection, and consequently the manifestation in trauma and sepsis can be 
indistinguishable.  Initial injury, systemic inflammation and subsequent sepsis all 
interact to lead to MODS.  SIRS is accompanied by a simultaneous upregulation of 
immunosuppressive mechanisms which particularly affect the adaptive immune 
system.  The compensatory anti-inflammatory syndrome (CARS) or immunoparalysis, 
leaves the patient vulnerable to subsequent infection (Tschoeke and Ertel, 2007).  
CARS appears to be a misnomer: the immunosuppression was originally thought to be 
a delayed reaction to the initial inflammation but studies that block the latter (Remick 
et al., 1995) or look for genomic correlates of both phenomena (Xiao et al., 2011) 
suggest that this is not the case.  In recent years, the supportive management of MODS 
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and the identification and treatment of sepsis has greatly improved.  However, there 
may be a group of patients in whom this has uncovered a late syndrome of persistent 
inflammation, immunosuppression and catabolism (PICS) (Gentile et al., 2012). 
 
The mechanisms of dysfunction in individual organs, of the failure to terminate 
inflammation and of immune suppression are beyond the scope of this discussion.  
This section will give a “bottom-up” description of the inflammatory response, which 
underlies all of these, describing its initiation and early mediation.  This will allow later 
sections to draw connections between inflammation and coagulation.   
 
The innate immune system is a highly conserved homeostatic mechanism that protects 
the body from injury and infection. Under normal conditions, inflammation is followed 
by resolution and repair.  Components of inflammation are involved in other 
homeostatic mechanisms (e.g. tissue repair, control of metabolism, hormonal 
regulation) which are not discussed.  It is useful to divide the elements of the 
inflammatory response into functional groups (Medzhitov, 2008).  The threat to tissue 
homeostasis, or insult, generates effects at levels ranging from the cell to the whole 
organism.  These in turn generate or reveal molecular signals that are the initiators of 
inflammation.  These are detected by a series of non-cellular and cellular sensors.  The 
sensors then activate the (non-cellular) mediators and (cellular) effectors of 
inflammation (see Figure 2.4).  In order to reach and combat the threat, the principle 
effectors—neutrophils and macrophages—are able to cause local tissue destruction 
through the release of enzymes and reactive oxygen species (ROS) (Nathan, 2002).  
Since many of the mediators and effectors are circulating molecules and cells, the key 
first stage in inflammation is an increase in blood flow (calor, rubor) and an increased, 
selective permeability of the endothelium (tumor).  This allows the mediators and 
effectors to be recruited to the site of the insult.  Swelling and the presence of certain 
initiators and mediators in the tissue leads to activation of nociceptors (dolor).   
 
The inflammatory response uses positive feedback mechanisms to promote quick 
response to threats, and negative feedback to localise and control the response 
(Nathan, 2002; Chen and Nuñez, 2010).  Without microorganisms, damaged tissue 
quickly moves on to repair—the weal from a slapped wrist quickly fades, the 
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inflammation of a surgical wound is mild and resolves if it does not become infected.  
Equally, colonisation by commensal bacteria is not a threat that requires constant 
inflammation of all the skin and gut wall.  These mechanisms of discrimination and 
control can be overstimulated by large insults to which they are not adapted, causing, 
respectively, organ injury and immunosuppression. 
 
2.5.1 Initiators and Sensors in the Activation of Inflammation 
 
Trauma has direct effects at the cellular, tissue, organ and organism levels.  At the 
cellular level, it leads to the disruption of cell membranes, causing necrosis.  Injury to 
tissues can disrupt tissue architecture, expose subendothelial molecules and allow 
toxic substances, such as haem, to enter the interstices.  Injured organs can become 
dysfunctional or disrupted.  This discussion will concentrate on the effect of injury to 
respiratory and circulatory structures.  These lead to hypoxaemia, haemorrhage and 
impaired perfusion which in turn cause local or systemic ischaemia, the latter being 
shock.  Adaptive processes and treatment of local ischaemia or shock leads to 
reperfusion (locally: ischaemia-reperfusion—I/R; systemically: haemorrhagic shock-
resuscitation—HS/R) which can actually worsen the insult.  These in turn lead to 
further cellular stress, which can lead to apoptosis or necrosis.  It is this interplay of 
events that generates the diverse initiators of inflammation seen after severe injury. 
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Figure 2.4  Initiation of inflammation. (Derived from Medzhitov, 2008)  Insults, such as trauma, lead to 
effects at the cellular/extracellular level.  These lead to the production of endogenous initiators.  
(Exogenous initiators [not shown] include molecules produced by microorganisms [PAMPs – see 
Subsection 2.5.3] and others such as allergens.)  Sensors for these initiators may be extracellular 
molecules such as natural antibodies, or cellular receptors, such as TLRs.  Mediators include the 
protease cascades, which are principally initiated by extracellular sensors, and lipid mediators, cytokines 
and chemokines, which are released by effectors stimulated by cellular sensors.  There is then crosstalk 
between mediators and effectors, producing both positive and negative feedback loops depending on 
the situation.  Effectors also communicate directly with one another, e.g. via adhesion molecule 
interactions. 
However, mediators are able to cause damage to cellular and extracellular molecules (i.e. “effects”) by, 
for example, the action of proteases and alterations in oxygen delivery due to coagulation and 
vasoactive mediators (arrow A). This leads to the formation of further initiators, which combines with 
active production by mediators (arrow B, an example would be release of HMGB-1 by macrophages), 
forming positive feedback loops.  Additionally, some effects can imitate mediators, e.g. through the 
peroxidation of lipids to generate PAF-like lipids that can ligate the PAF receptor; arrow C).  (This could 
equally be regarded as an initiator-sensor pathway which is then harnessed to be used by a mediator, 
PAF.) 
The key points are redundancy, which is a reflection of the complexity of the system, and the existence 
of feed-forward and feed-back loops.  The latter include inhibitory mechanisms which regulate 
inflammation and are not shown here. 
PAMP—Pathogen-associated molecular pattern; TLR—Toll-like receptor; HMGB-1—High Mobility 
Growth Box 1; PAF—Platelet-activating factor. 
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2.5.2 Ischaemia/Reperfusion 
 
During ischaemia, low oxygen tension causes dysfunction in the oxygen transport chain 
in mitochondria, leading to the release of highly reactive free radicals: reactive oxygen 
species (ROS) (Fischer, 2006).  As ROS levels rise they overcome cellular defence 
mechanisms to cause damage to functionally vital structures such as membrane 
molecules, which can lead directly to cell dysfunction or lysis.  ATP production falls and 
the existing supply is consumed, producing ADP and then hypoxanthine.  Cell 
membrane ion pumps begin to fail, leading to swelling and membrane dysfunction.  
Mitochondrial contents are released, which can initiate cell death.  While restoration 
of oxygen supply is necessary for cell survival, it also leads to the accumulation of more 
destructive substances: accumulated hypoxanthine reacts with oxygen to produce 
more ROS.  Reactive nitrogen oxygen species (RNOS) derived from nitric oxide (NO) 
also play an important role. 
 
Finally, ischaemic injury causes endothelium to expose a non-muscle myosin heavy 
chain antigen (Zhang, Alicot, et al., 2006).  A natural antibody exists to this antigen, i.e. 
a circulating, specific, monoclonal IgM not produced by prior pathogen exposure 
(Zhang et al., 2004); this activates complement (Zhang, Takahashi, et al., 2006).  Since 
complement deficient animals are protected, this is one of the most important 
mechanisms of I/R injury (Chan et al., 2003). 
 
2.5.3 Products Released by Cellular Disruption and Extracellular Damage 
 
In normal tissue and cells there is extensive compartmentalisation which separates, for 
example, nuclear contents from the cytoplasm and blood from the extracellular matrix 
(Nathan, 2002).  After injury this compartmentalisation is broken down, whether by 
direct trauma, indirectly through I/R or as a result of inflammatory processes.  
Previously separated receptors and their ligands, or enzymes and their activators or 
substrates, can now interact.  This is one of the principle mechanisms which generates 
endogenous initiators and exposes them to their counterpart sensors. 
 
20 
 
Cellular disruption releases many substances including ATP, uric acid, heat shock 
proteins and high-mobility growth box-1 (HMGB-1) (Bianchi, 2007).  These molecules 
are part of a heterogeneous group known as damage-associated molecular patterns 
(DAMPs).  DAMPS are highly conserved cell molecules which are detected by pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs).  TLRs are expressed by 
a variety of innate and adaptive immune cells and by epithelial and parenchymal cells 
(Kaczorowski et al., 2008).  Their activation leads to increased production of 
proinflammatory gene products.  (DAMPs have their exogenous counterparts, 
pathogen-associated molecular patterns [PAMPs]; examples include 
lipopolysaccharide [LPS] and formyl-methionyl-leucyl-phenylalanine [fMLP].)   
 
HMGB1 is a nuclear protein that binds DNA, and is one of the most studied DAMPs.  As 
well as being released by necrotic cells (Scaffidi, Misteli and Bianchi, 2002) it is actively 
secreted by a variety of cells including monocyte/macrophages and endothelial cells 
(Mullins et al., 2004; Qin et al., 2006).  Systemic inflammation is induced in mice by 
bilateral femur fracture (Levy et al., 2007).  This can be almost abolished by blockade 
of TLR-4 or by use of HMGB-1 neutralising antibodies, but there is no synergy between 
the two methods of blockade.  This indicates a profound importance for the HMGB-
1/TLR-4 signalling axis in the pathophysiology of systemic inflammation in this model 
(Levy et al., 2007).  Haemorrhagic shock also induces HMGB-1 mediated systemic 
inflammation (Kim et al., 2005). 
 
Serum levels of HMGB-1 are raised within 30 minutes of severe injury complicated by 
hypoperfusion.  The rise in HMGB-1 correlates with the severity of injury, tissue 
hypoperfusion, early posttraumatic coagulopathy and hyperfibrinolysis as well as with 
systemic inflammatory response and activation of complement (Cohen et al., 2009).  
The relative contribution of active and passive release of HMGB-1 in these situations is 
unclear. 
 
2.5.4 Effectors and mediators of inflammation 
 
Inflammation is driven by the action of effectors (cellular components) and mediators 
(molecular components).  The following subsections briefly describe the principle 
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actions of the most important of these in the initiation of inflammation: complement, 
which responds to signals of I/R injury and leads to mast cell activation and neutrophil 
recruitment; mast cells and macrophages, which respond to complement and directly 
to injury and other stimuli and which serve to activate endothelium and recruit 
neutrophils; and endothelium, which forms the barrier between blood and tissue but 
which, once activated, becomes the means by which neutrophils are summoned and 
guided to the site of injury.  In a subsequent subsection, the key role of neutrophils in 
initiating inflammation will be explored.  Before that, there is a brief discussion of the 
largest class of mediators, cytokines, with emphasis on how they signal for the events 
which lead to neutrophil recruitment. 
 
2.5.5 Complement Activation 
 
Complement is a highly conserved protease cascade and the principle early mediator 
of inflammation after I/R (Arumugam et al., 2004).   Activation leads to mast cell 
stimulation (Metz and Maurer, 2007), the release of anaphylatoxins and the formation 
of the membrane attack complex (MAC), which can lyse both bacteria and host cells.  
The anaphylatoxin C5a is chemotactic to neutrophils and can increase vascular 
permeability and upregulate the expression of endothelial adhesion molecules.  
Complement molecules can also be initiated by other mediators of inflammation such 
as proteases (Huber-Lang et al., 2006) and thrombin (Markiewski et al., 2007).  
Deposition of MAC is seen extensively after I/R (Carden, Smith and Korthuis, 1990; 
Hugo et al., 1990; Weiser et al., 1996) and may be a significant pathway of 
complement-mediated injury.   
 
Systemic complement activation is seen after trauma within half an hour and 
correlates with injury severity and tissue hypoperfusion, and with mortality and 
inflammatory complications (Fosse et al., 1998; Ganter et al., 2007).  While the 
classical/lectin pathway is activated, amplification via the alternate pathway is 
correlated with severity and outcome (Ganter et al., 2007). 
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2.5.6 Mast Cells and Macrophages 
 
Mast cells possess large cytosolic granules that contain histamine, other mediators and 
proteases (Metz and Maurer, 2007).  Degranulation follows seconds after stimulation 
and is accompanied by increased synthesis of TNF- α, of other cytokines and 
chemokines and of the fatty acid derivatives platelet-activating factor (PAF) and the 
leukotrienes.  Mast cell-deficient mice develop significantly less muscle fibre death 
(Bortolotto et al., 2004) and lung injury (Goldman et al., 1992) after limb I/R.   
 
Macrophages are also contain granules and able to release cytokines and proteases to 
induce inflammation.  Their reaction to initiators of inflammation is less florid than 
that of mast cells but it is also more sustained.  Macrophages (Medzhitov, 2008) are 
also able to detect the transition of tissue cells between the discreet states of 
normality, stress, apoptosis and necrosis; they also appear to be able to distinguish 
between different causes of apoptosis, though the mechanism is unclear.  
Macrophages can therefore detect, integrate and report the status of many cells in a 
tissue bed, altering the inflammatory (and other) responses accordingly.* 
 
2.5.7 Endothelium 
 
Mast cell tryptase and other proteases cleave the terminal residues of protease 
activated receptors (PARs) on mast cells, neurones, endothelium and neutrophils.  The 
neoterminal residues of the PARs self-engage, i.e. engage the PAR’s own binding site, 
activating their cytosolic G-proteins.  This leads to further activation of mast cells and 
neurones.  It makes endothelium more adhesive to leukocytes and it causes leukocytes 
to release PAF.  Along with mast cell-derived PAF, this in turn reinforces endothelial 
activation and attracts leukocytes into the tissue.   
 
Endothelial cells can be activated by other cells using a variety of mediators and 
express their own TLRs.  They also transduce mechanical information related to blood 
flow via the glycocalyx, altering cell function, particularly NO and prostacyclin 
                                                 
*
 This description excludes the important role that macrophages later play in the resolution of 
inflammation and the initiation and control of healing. 
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production (see subsection 2.7.5) (Tarbell, Weinbaum and Kamm, 2005).  
Catecholamines have an important role in activating endothelium (Johansson et al., 
2011b).  In the first stage of endothelial activation, cells contract, exposing the 
subendothelial membrane, which allows fluid, mediators and effectors to pass into the 
extracellular space (Hunt and Jurd, 1998).  (When intravascular hydrostatic pressure is 
low, e.g. due to haemorrhage, endothelial activation may conversely allow interstitial 
fluid to pass into the circulation, leading to a form of autoresuscitation.)  The Weibel-
Palade bodies undergo exocytosis, releasing von Willebrand factor (vWF) into the 
blood and bringing P-selectin to the surface.  The second stage of activation requires 
de novo synthesis of cytokines, chemokines, tissue factor and adhesion molecules.  
Activation causes endothelium to lose its normal anticoagulant phenotype. 
 
Activated endothelium therefore promotes traffic of molecules and cells between the 
compartments and promotes coagulation.  These are adaptive changes which facilitate 
the inflammatory response (coagulation helps contain infection as well as limiting 
blood loss).   
 
Activation of large areas of endothelium affects systemic circulation and leads to 
massive fluid shifts.  It also releases inflammatory mediators into the circulation.  In 
sufficient concentration these may prime circulating neutrophils and activate 
endothelium at uninjured sites.  This ectopic activation then opens the door for 
neutrophil infiltration and consequent injury to bystander organs.  Endothelial 
activation should be a quickly reversible state.  However, sufficient damage can render 
endothelium unable to step down to the resting state or it may induce apoptosis 
(Hotchkiss et al., 1999; Guan et al., 2002), with desquamation and loss of vascular 
integrity. 
 
2.5.8 Cytokines 
 
There is a prodigious literature on cytokine signalling that cannot be summarised here.  
Some important molecules will be discussed briefly.  IL-1β and TNF-α are produced by 
monocytes/macrophages, mast cells, epithelium and other immune and non-immune 
cells in response to stimuli that include complement, NO, ROS, TLR ligands and 
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themselves.  Their effects include autocrine induction of other cytokines, priming of 
neutrophils and activation of endothelium.  Both can produce anti-apoptotic effects 
that may be important in sustaining inflammatory response but TNF is also able to 
induce apoptosis in target cells under certain circumstances.   
 
The elaboration of chemokines, a subclass of cytokines, is crucial to the recruitment of 
effector cells, which can migrate up a chemokine concentration gradient to reach the 
point of release.  The particular pattern and effect of this varies according to tissue, 
stimulus and other factors.  Chemokine production in animal models of lung contusion 
(Raghavendran et al., 2005) serves as a good example.  This is not least because 
bronchoalveolar lavage fluid provides a window onto tissue chemokine levels without 
the need for biopsy.  Neutrophil attractant chemokines (CXCL-1 and -2) rises early and 
peaks at 24 hours after contusion.  The monocyte attractant CCL-2 rises by 24 hours 
but peaks at 48 hours.  All return to normal by 7 days.  As one would expect, 
neutrophils infiltration precedes the increase in lung monocyte/macrophages.  
Chemokines can be immobilized on endothelium (McDonald et al., 2010), allowing 
effectors to migrate intravascularly along the gradient so formed until very close to the 
site of inflammation.  While cytokine and chemokine signalling has diverse functions, 
their particular role in this account of the induction of inflammation is the activation 
and recruitment of neutrophils. 
 
2.5.9 Neutrophils and the Two-Hit Hypothesis 
 
Neutrophils are the primary early effector cell in innate immunity (Nathan, 2006).  
After injury there is systemic release of steroids, catecholamines and proinflammatory 
cytokines.  These probably lead to bone marrow neutrophil mobilisation, and (in the 
blood) to activation. 
 
Neutrophils carry a deadly arsenal of cytotoxic substances (Borregaard et al., 1995), 
yet circulating neutrophils must pass through capillaries that are narrower than the 
resting cell without releasing them (Nathan, 2006),  Marginated cells must scout for 
signals indicating injury to local tissue.  Weak adherence between the neutrophil’s 
surface molecules (L-selectin and leucocyte adhesion molecule-1 [LAM-1]) and those of 
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the endothelium (E-selectin, P-selectin and endothelial leucocyte adhesion molecule-1 
[ELAM-1]) allow the former to roll along the vessel wall.  Activated neutrophils and 
endothelium express integrins (CD11a/CD18) and intercellular adhesion molecule-1 
(ICAM-1), respectively.  These allow stable adhesion of the neutrophil to the vessel 
wall.  It subsequently spreads and then passes between endothelial cells by diapedesis 
into the extravascular space.   
 
Neutrophil degranulation is stimulated by a complex interaction of signals that 
integrate information about the cell’s location and the presence of tissue injury and 
microorganisms (Nathan, 2006).  While both of the latter must usually be detected, 
activation may occur after trauma alone because some initiating signals (e.g. HMGB-1 
or fMLP from disrupted nuclei and mitochondria, respectively) may signal via the same 
pathways as foreign material.  Degranulation releases, sequentially, adhesion 
molecules, signals to increase vascular permeability and enzymes which can degrade 
the extracellular matrix (matrix metalloproteases).  Neutrophils may then be guided 
from the point they leave the blood to the site of inflammation by chemokines and 
other signals, including mitochondrial DAMPs (McDonald et al., 2010; Zhang et al., 
2010).  This process takes less than an hour (Nathan, 2006; McDonald et al., 2010) at 
which point the neutrophil will attempt to phagocytose bacteria found at the site of 
inflammation.  In their absence, full activation ensues (Nathan, 1987), leading to a 
respiratory burst and degranulation.  In the respiratory burst, iNOS and NADPH oxidase 
cause a massive production of NO and superoxide, which in turn form other highly 
damaging ROS and RNOS.  The remaining granules release proteinases, other enzymes, 
antibiotic molecules and oxidants.  The latter activate MMPs.  In combination these 
acts give rise to destruction of the extracellular matrix and damage to cells.  
Neutrophils may also undergo a specialised form of cell death (NETosis) in which they 
eject their DNA to form neutrophil extracellular traps (NETs) (Kaplan and Radic, 2012).  
These are coated in many of the cell’s antimicrobial effectors. 
 
These changes make the tissue more accessible to immune cells and inhospitable to 
microorganisms, but at some cost to the structure and function of the tissue.  Natural 
wound healing without these actions, as in immune deficiencies, is prevented by 
infection (Lekstrom-Himes and Gallin, 2000).  However, where micro-organisms are 
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absent, neutrophils slow wound healing (Dovi, Szpaderska and DiPietro, 2004; Shaw 
and Martin, 2009).  Through activation in normal tissue, they also cause injury at 
distant sites.   
 
The neutrophil predominates in early systemic inflammation just as it does locally 
(Weiss, 1989; Baue, 1992).  The importance of the neutrophil is not just as the effector 
of tissue defence and tissue damage but, before that, as the decision-maker of the 
innate immune system.  It integrates different signal types through the multiple 
stimulation required for full activation.  After severe injury, multiple initiators generate 
redundant contributions to that stimulation, leading to widespread and inappropriate 
migration and activation. 
 
The following is a summary of likely events.  There is a marked early neutrophilia 
(Botha et al., 1995) (at about 3 hours post injury).  Subsequently there is a drop in the 
neutrophil count (by 6 to 12 hours).  This is significantly greater in patients who go on 
to develop MOF than in those who do not.  This presumably represents the 
sequestration of activated neutrophils in the tissues.  So it appears the activated cells 
are sequestered and are replaced by immature cells from the marrow (Hietbrink et al., 
2006).  The activation of circulating neutrophils is matched by an increase in their 
response to in vitro stimulation by LPS or fMLP, known as “priming” (Moore et al., 
2005; Hietbrink et al., 2006).  This is also reduced later after injury. 
 
Neutrophil priming has been implicated in the “two-hit” hypothesis of the 
development of post-injury MODS (Moore et al., 2005).  This holds that the initial 
trauma with its associated tissue injury and physiological disturbance constitute a “first 
hit”, leading to neutrophil priming.  The period during which primed neutrophils 
circulate, or even enter the tissues without causing damage (Anderson et al., 1991), is 
then a vulnerable window during which a “second hit” will lead to an excessive and 
systemic inflammatory response by the neutrophils.  Second hits include such 
immunologically potent events as surgery (Lasanianos et al., 2011), blood transfusion 
(Bilgin and Brand, 2008) and infection (Moore et al., 2005).  Importantly, this 
hypothesis suggests that the inflammatory reaction after the second hit is more than 
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simply the addition of the responses which would be expected to the two insults 
separately. 
 
While some individual patients are seen to have a florid inflammatory response to a 
particular second hit, a more usual situation may be a series of priming stimuli and a 
series of activating “second hits”.  This makes confirmation of the two-hit hypothesis 
difficult both because of the heterogeneity of patient studies and the difficulty of 
designing models that reflect the complex interaction between trauma 
pathophysiology and therapy.  Genomic studies have shown no correlation between 
potential second hits and changes in leucocyte gene expression (Xiao et al., 2011).  
(This alone is not a sufficient rebuttal of the hypothesis: the profound initial leucocyte 
genome expression changes after injury may give rise to the “primed” phenotype, 
while subsequent activation may not have a genomic signature.) 
 
In addition, studies of the two-hit hypothesis have concentrated on the ex vivo biology 
of neutrophils (Moore et al., 2005).  However, inflammation has redundant pathways.  
Neutrophil activity and the action of terminal complement elements act independently 
after I/R (Kyriakides et al., 1999).  Blockade of either pathway reduces endothelial 
permeability after hind limb ischaemia by nearly 50%.  Permeability is halved again 
when both are blocked.  Equally, neutrophil injury to bystander organs implies 
activation of the latter’s endothelium in order to attract the neutrophils and permit 
them to enter the tissue.  Modern accounts of the gut hypothesis have begun to make 
these linkages (Clark and Coopersmith, 2007). 
 
2.5.10 The Gut Hypothesis 
 
The mucosa associated lymphoid tissue (MALT) of the gut is the largest lymphoid 
“organ” in the body.  The splanchnic circulation is the first to be sacrificed and the last 
to be restored in low flow states (McNeill, Stark and Greenway, 1970).  Poor perfusion 
of the gut is associated with loss of gut barrier function (Fink, 2003).  Although no 
evidence has been found that gut-derived bacteraemia or endotoxaemia is the cause 
of systemic inflammation after injury (Moore et al., 2005), this does allow altered 
interaction between luminal molecules and microorganisms and the MALT (Clark and 
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Coopersmith, 2007).  Studies have demonstrated that the gut lymph of animals 
subjected to HS/R (but not the portal blood) (Magnotti et al., 1998) contains 
substances that can cause endothelial activation and apoptosis in the lung (the first 
organ to be perfused by blood carrying the lymph deposited in the subclavian vein) 
(Davidson et al., 2004; Deitch et al., 2004) and activate circulating PMNs (Gonzalez et 
al., 2001).  Two components have been identified as being of particular importance: a 
modified albumin and various lipid factors (Kaiser et al., 2005).  Division of the gut 
lymphatics can prevent HS/R induced ALI in the models used and administration of 
HS/R gut lymph to healthy animals can induce ALI (Senthil et al., 2007).  Thus in these 
models, HS/R gut lymph is necessary and sufficient to cause ALI after HS/R.  However, 
isolated limb I/R can cause ALI without systemic hypoperfusion (Kyriakides et al., 
2000). Hindlimb (non-gut) lymph after HS/R can also cause endothelial dysfunction and 
neutrophil priming (Diebel et al., 2008, 2009).  Non-gut lymph may therefore 
contribute to both ALI after both systemic and isolated hypoperfusion.  Additionally, 
most HS/R models do not simulate the tissue injury of major trauma, thus the relative 
importance of the hypoperfused gut and the damaged tissues is not known. 
 
It is clear that the gut has an important role in inflammatory initiation after injury.  
However, the systemic release of DAMPs, complement proteins, cytokines and lipid 
mediators, along with the circulation of activated mediators, generate profoundly 
redundant pathways for the systemic activation of inflammation. 
 
2.6 Normal Coagulation 
 
The two principle components of coagulation are platelets and the clotting factor 
cascade.  Vessel injury reveals tissue molecules that activate both elements.  The 
formation of a clot begins with the formation of a platelet plug.  The clot then matures 
and strengthens as fibrin is laid down and cross linked.  Crucially, platelets are the 
principal site of clotting factor activity. This section describes these principal 
components of coagulation according to the cell-based model of coagulation 
developed by Hoffman (Monroe and Hoffman, 2006).  Assays used to measure platelet 
and clotting function are described in section 6.3. 
2.6.1 Platelets 
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Platelets are discoid cell fragments 2-4μm by 0.5μm which tend to circulate at the 
margins of blood vessels, pushed there by large cells which occupy the fast flowing 
centre (Loscalzo and Schafer, 2003).  They normally contact but, unlike leucocytes, do 
not interact with the intact, unactivated endothelium.  They have complex structures 
(see Figure 2.5) with multiple cytosolic granules (Jurk and Kehrel, 2005).  α-granules 
are the most abundant, containing large adhesive proteins such as vWF, growth factors 
(e.g. platelet-derived and vascular endothelial growth factors), clotting factors (V, VII, 
XI, XIII), and regulators of coagulation (protein C, plasminogen activator inhibitor 1 
[PAI-1], tissue factor pathway inhibitor [TFPI]).  Dense granules contain secondary 
agonists of platelets, which when released will signal for further platelet activation in 
an autocrine and paracrine manner.    They are also a store of calcium, vital to platelet 
activation and coagulation, as is the dense canalicular system 
 
Platelets also have an open canalicular system (OCS), a network of conduits lined with 
cell membrane passing through the body of the platelet (Jurk and Kehrel, 2005).  Since 
the outer membrane itself is inaccessible due to the platelet’s actin cytoskeleton, 
exocytosis actually occurs initially into the OCS, with adhesion molecules then 
redistributing to the exterior.  The OCS also provides a store of cell membrane for use 
when the platelet spreads or divides.  A marginal band of microtubules forms a 
cytoskeleton; associated microfilaments act on this to permit shape change.   
 
Figure 2.5.  Schematic (Mbassa, 2015) (left) and scanning electron micrograph (Semple, Italiano and 
Freedman, 2011) (right) of the structure of a platelet. 
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Platelets have multiple roles in clot formation (Monroe and Hoffman, 2006).  
Coagulation factors are bound to the platelet surface (factors V, VIII and IX) and thus 
this is the site of most thrombin formation.  Vessel wall damage exposes platelets to a 
variety of stimuli including collagen, fixed vWF, ADP and thrombin, which lead to 
activation.  Initially, Glycoprotein Ib (GPIb) interacts with vWF, tethering the platelet to 
the area of damage.  GPVI then interacts with collagen.  Activation of these receptors 
leads to intracellular signals that cause a conformational change in the GPIIa/IIIb 
complex (integrin αIIbβ3, CD41/CD61).
*  The newly exposed binding site can then bind 
to vWF (fixing the platelet in place) or fibrinogen (allowing crosslinking).  ADP and TXA2 
are also released, leading to autocrine stimulation via P2Y12 and TP receptors 
respectively.  ADP serves mostly to potentiate other elements of platelet activation.  
Thrombin generation (see subsection 4.1.2) strongly activates platelets via PAR-1. 
 
Activation leads to changes in platelet morphology: they sphericise, the surface 
becomes blebbed and then the platelet begins to spread out across a surface.    
Granule content is released, bringing P-selectin (CD62P) and platelet-endothelium cell 
adhesion molecule (PECAM, CD31) to the surface.   
 
Platelets’ activation leads to their adherence to damaged vessel wall and their 
aggregation with each other (and other blood cells).  They thereby form a plug which, 
along with contraction of the blood vessel, begins to block the loss of blood from the 
vessel.  Activation also leads to the expression of negatively charged phospholipids on 
the platelet surface and the release of small fragments of platelets less than 2μm 
across known as platelet-derived microvesicles (MVplt) (Martínez et al., 2005).  These 
provide the surface needed for the generation of large amounts of thrombin, which in 
turn leads to stabilisation of the clot with cross-linked fibrin.  The final important role 
of platelets is contraction, which is mediated by the platelet’s actin cytoskeleton, 
which is linked to the CD41/61 complex at the platelet surface and thereby to the 
fibrin network (Loscalzo and Schafer, 2003).  Clot retraction serves to minimise the size 
of the clot, particularly the obstruction it may cause to the flow of blood in the vessel. 
 
                                                 
*
 Platelets are the only blood component that express this complex which is therefore widely used as a 
platelet specific marker.(Macey et al., 1999; Jacoby et al., 2001) 
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2.6.2 Microvesicles 
 
Microvesicles are small cell fragments released by endothelial, circulating and tissue-
resident cells.  Some are produced constitutively and others in response to stressors or 
apoptosis.  Microvesicles can differ in the nature of their cell wall, the surface markers 
they express and their cytosolic makeup.  The nature of microvesicles is determined 
both by the parent cell and the stimulus.  As such, microvesicles can function as 
specific mediators or messengers of the parent cell.  Microvesicles in the circulation 
may be important in the crosstalk between coagulation and inflammation (Morel et al., 
2011). 
 
Microvesicle production is generated by a variety of mechanisms, whose interaction 
and relative importance is not clear (Morel et al., 2011).  In resting cells, 
phosphatidylserine (PS) is preferentially expressed on the internal layer of the cell 
membrane lipid bilayer.  Cell stimulation leads to increased intracellular calcium which 
induces active transport of PS to the external layer.  As already noted, the resultant 
negatively charged membrane is thrombogenic.  This change, along with mechanical 
effects, loss of cytoskeletal anchoring and release of mitochondrial contents, causes 
instability of the membrane which leads to microvesicle formation. 
 
In normal subjects the largest group of circulating microvesicles are directly derived 
from megakaryocytes (Italiano, Mairuhu and Flaumenhaft, 2010).  Platelets shed MVplt 
during activation and these are estimated to have procoagulant activity 50 to 100-
times greater than the parent platelet.  MVplt express large amounts of PS and have a 
high surface-area-to-volume ratio.  MVplt formation takes about 15s and therefore 
follows initial aggregation and adhesion, serving to promote the clotting cascade 
(Italiano, Mairuhu and Flaumenhaft, 2010).  As clot forms, an early predominance of 
leucocyte microvesicles is overtaken by their platelet-derived counterparts.  The 
former, which express a considerable amount of tissue factor, may have an important 
role in clot initiation.  The latter certainly are important: Scott’s syndrome is a bleeding 
diathesis that occurs in patients with impaired platelet microvesicle formation.  In 
summary, MVplt appear to after formation of the initial platelet plug and appear to 
potentiate the formation of fibrin, even outpacing their parent platelets in this regard. 
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Formation of both procoagulant enzyme complexes and the anticoagulant protein C 
complex requires PS expression but the latter may require a 10-fold higher 
concentration (Morel et al., 2011).  MVplt may therefore be important in protein C-
mediated coagulopathy (see section 2.7).  Brain-derived microvesicles have been 
implicated in coagulopathy after head injury (Zhang et al., 2012). 
 
2.6.3 Fibrin Generation 
 
The understanding of the mechanisms of fibrin formation have been revolutionised by 
the introduction of Hoffman’s cell-based model (Monroe and Hoffman, 2006).  This 
replaced the simplistic notion of the intrinsic and extrinsic clotting cascades, which 
took no account of the spatial relationship between the molecules involved and failed 
to explain several aspects of coagulation physiology and pathology.  Clot formation 
proceeds in three stages: initiation, amplification and propagation (Monroe and 
Hoffman, 2006).  These lead to the production of large quantities of thrombin, which in 
turn leads to the formation and crosslinking of fibrin polymers. 
 
Initiation.  Damage to the wall of blood vessels exposes cells that express tissue factor 
(TF).  Factor VII (fVII) binds to the TF and is activated by a variety of proteases to form 
fVIIa.  TF/fVIIa on cell surfaces then activates fX and fXI.  fVa, released from platelets as 
they start to adhere or activated from circulating fV by fXa and other proteases, forms 
a complex with fXa on the cell surface.  This fXa/Va complex then generates a small 
amount of thrombin.  See Figure 2.6.  A small amount of fIXa is also generated. 
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Figure 2.6.  Initiation.  Modified from Monrow and Hoffman 2006. See text. 
 
Amplification.  The thrombin generated during initiation then works in concert with 
tissue collagen to induce platelets adherent to the site of injury to enter their most 
activated phenotype.  They therefore release their granule contents, adhere and 
aggregate and alter their surfaces to provide the arena for the clotting factor activity 
during propagation.  The thrombin also activates fV, fVIII (releasing it from vWF) and 
fXI on the platelet surface. 
 
Propagation.  fXIa activates fIX, which (along with fIXa from initiation) then complexes 
with fVIIIa.  fVIIIa/IXa then cleaves fX and the resultant fXa associates with fVa to form 
the prothrombinase complex.  See Figure 2.7.  This then produces large amounts of 
thrombin, sufficient both to cleave fibrinogen and to sustain a positive feedback loop 
by further activation of upstream factors.  All of these reactions are localised to the 
platelet (or microvesicle) surface.  Platelet activation moves negatively charged 
phospholipids such as phosphatidylserine (PS) to the outer layer of the cell membrane, 
which allows clotting factors to bind and form complexes.  While other cells, such as 
leucocytes, may express PS and develop a prothrombotic phenotype when activated, 
platelets and MVplt are far more important.   
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Figure 2.7.  Propogation.  Modified from Monrow and Hoffman 2006. See text. 
 
Fibrinogen binds to platelet-surface GP IIb/IIIa from where it is cleaved by thrombin to 
form fibrin, which polymerises.  Thrombin, now present in excess of the amount 
required to clot fibrinogen, is incorporated into the growing clot.  It also activates fXIII, 
leading to cross-linking.  Finally, a further stage of platelet activation is initiated by 
high-concentration thrombin cleavage of PAR-1, which may be the stimulus for platelet 
contraction. 
 
The preceding subsections have described the activation of platelets by damaged 
vessel wall, leading to the formation of a plug within which platelets and their 
microvesicles act as the site for the formation of fibrin.  Fibrin then binds the clot 
together.  Small scale vessel injury is commonplace and even large tissue damage 
usually leads only to local coagulation.  What prevents the clotting process spreading? 
 
2.6.4 Natural Anticoagulants and Fibrinolysis. 
 
There are three inhibitory mechanisms: tissue factor pathway inhibitor (TFPI), 
antithrombin (AT) and protein C.  TFPI inhibits fXa once the latter has been released 
from the cell surface.  It is expressed on endothelial surfaces and released by platelets 
(Lwaleed and Bass, 2006).  AT binds to heparin-like glycosaminoglycans, such as 
endothelial membrane syndecans, and inhibits the action of thrombin and fXa.  Thus 
both TFPI and AT serve to localise clotting activity, particularly at the initiation phase, 
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to sites of vascular injury and prevent it occurring on normal endothelium (Monroe 
and Hoffman, 2006). 
 
Protein C is cleaved by the complex of thrombomodulin and thrombin on the 
endothelial surface.  The cleavage of protein C is amplified by binding to the 
endothelial protein C receptor (EPCR).  Activated Protein C (aPC) bound to EPCR can 
then cleave endothelial PAR-1, with the cytoprotective effects mentioned previously.  
Most (60% in one mouse model) of aPC is released from EPCR.  aPC forms a complex 
with Protein S and then degrades fVa and fVIIIa.  Since these are vital factors for 
coagulation, thrombomodulin serves to turn thrombin, the lynchpin of coagulation, 
into an anticoagulant; this is the “thrombin switch”.  Bound thrombin is also 
inactivated 20 times faster than free thrombin, stopping both clotting and the 
production of aPC.  Of note, aPC inactivation of thrombin is inhibited at the platelet 
surface (Oliver et al., 2002)  aPC is therefore formed and exerts its effect chiefly on 
intact endothelium; its physiological role is therefore also to localise clotting at sites of 
injury (Weiler, 2010)  This does not preclude its having a pathological role in 
coagulopathy after trauma (see subsection 2.7.2). 
 
The last major component of coagulation is the fibrinolytic system.  Tissue-type 
plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) both 
cleave plasminogen to form plasmin.  tPA is the dominant actor and is released by 
damaged endothelial cells (Maegele, Schöchl and Cohen, 2014).  It has low affinity for 
circulating plasminogen.  However, plasminogen becomes incorporated into clot 
where the fibrin acts as a co-factor for tPA, increasing its activity 100-fold (Rijken and 
Lijnen, 2009).  Plasmin cleaves fibrin, leading to clot dissolution, but also exposing a 
higher affinity plasminogen-binding site, promoting further fibrinolysis. Plasmin can 
also cleave other proteins, including elements of the extracellular matrix such as 
collagen.   
 
The capacity of plasmin to breakdown clot is enormous and has to be kept in check.  
Thrombin-thrombomodulin complexes cleave thrombin activatable fibrinolysis 
inhibitor (TAFI).  TAFI inhibits thrombolysis by modifying fibrin terminals to remove the 
higher affinity plasminogen-binding site.  Thrombin therefore serves to stabilise clots 
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against thrombolysis, although TAFI activation may be significantly impaired by the 
release of platelet factor 4 by activated platelets (Mosnier, 2011).  However, the effect 
of TAFI may be exceeded by thrombin-induced activation of protein C.  Excess aPC 
enhances fibrinolysis by degrading PAI-1.  Since aPC generation is also thrombin-
dependent, it can be seen that the predominant action of thrombin, pro- or anti-
fibrinolytic, will depend on circumstances. 
 
2.6.5 Coagulation-Inflammation Cross-Talk 
 
Having established the normal physiology of inflammation and coagulation (and before 
moving on to the pathophysiology seen in trauma), this subsection examines the ways 
in which the two are related, while the next subsection looks at the role of platelets in 
that interaction. 
 
The mechanism of blood clotting is inextricably bound up with inflammation (Esmon, 
2005; Levi and van der Poll, 2010).  Its components have evolved alongside those of 
inflammation and many of them are shared between the two processes (Levi, 2004).  
Platelets and leucocytes have both evolved from haemocytes found in invertebrate 
haemolymph.  Many of the molecular components, such as the serine proteases of the 
coagulation and complement systems, also have common antecedents.   
 
However, the linkage is adaptive and not merely vestigial.  There is crosstalk between 
the two processes at many levels.  FXa, thrombin and fibrin can stimulate mononuclear 
and endothelial cells to produce IL-6 and IL-8 (Sower et al., 1995; van der Poll, de Jonge 
and Levi, 2001).  Cleavage of PARs is the key mechanism for the action of the 
coagulation proteases on inflammation.  Thrombin and aPC both cleave PAR-1.  
However, the resultant signalling is modulated such that they have antagonistic 
downstream effects on the inflammatory phenotype of endothelial cells: thrombin 
enhances permeability and cell death while aPC opposes these (Weiler, 2010).  In 
animal models of the therapeutic use of aPC in sepsis, this signalling function has been 
demonstrated to contribute more to its efficacy than the antithrombotic function.  
FXa, plasmin and thrombin and can also cleave C3 and C5, thus activating the 
complement system (Amara et al., 2010).  Fibrin also appears to have a direct 
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proinflammatory effect, stimulating release of cytokines (Perez and Roman, 1995) and 
chemokines (Harley and Powell, 1999). 
 
2.6.6 Platelets as Immune Cells 
 
Classically considered only to have a role in clotting, the inflammatory role of platelets 
is now increasingly recognised (Semple, Italiano and Freedman, 2011).  Platelet 
activation leads to the release of a host of substances from its granules and cytoplasm, 
including cytokines.  Platelet production is stimulated by cytokines, especially IL-6.  
Cytokines also increase the expression and stability of very large vWF multimers 
released from endothelium, which in turn activate platelets.  Calcium ionophores 
(released from dying cells) and complement, i.e. products of inflammation, are among 
the most potent stimulators of negative phospholipid expression by platelets (Zwaal 
and Schroit, 1997). 
 
Platelet selectins cause tethering of neutrophils (Semple, Italiano and Freedman, 2011; 
Engelmann and Massberg, 2012).  Platelets express CD154, the ligand of CD40, by 
which they can activate neutrophils (and also dendritic cells, thereby promoting 
activation of the adaptive immune system).  NETs (see subsection 2.5.9) are released 
by neutrophils exposed to TRAP-activated platelets and platelet-induced NETosis has 
been shown to be important in a mouse model of transfusion-related acute lung 
injury, a clinical entity that presents similarly to lung injury seen after trauma 
(Caudrillier et al., 2012).  NETs activate coagulation via tissue factor and fXII and recruit 
platelets by binding vWF.  PAMPs and DAMPs can stimulate leucocytes to express 
tissue factor, thus initiating coagulation.  By these and other pathways there is a 
feedback between coagulation and leucocyte activation that can lead to thrombus 
formation in response to pathogens, which are thereby trapped—this is 
immunothrombosis (Engelmann and Massberg, 2012).  Platelets express TLR-4 and 
signalling via this pathway is important to platelet sequestration and cytokine release 
in sepsis models (Aslam et al., 2006; Cognasse et al., 2006).  These interactions are also 
implicated in thrombotic disease associated with inflammation (e.g. deep vein 
thrombosis) (Engelmann and Massberg, 2012).  There is clearly potential for platelets 
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to be important mediators of inflammatory activation after trauma, but this requires 
further study. 
 
2.7 Coagulopathy and Endotheliopathy of Trauma 
 
Disordered coagulation after trauma is well described.  It is multifactorial (Hess et al., 
2008).  Resuscitative dilution of clotting factors, acidosis and hypothermia all play 
significant roles.  However, up to 34% of severely injured patients have been shown to 
be hypocoagulopathic very early after trauma, before these factors develop (Brohi et 
al., 2003, 2007; MacLeod et al., 2003; Maegele et al., 2007; Rugeri et al., 2007).  This 
section details the mechanisms producing these changes.  Trauma patients also 
develop a later hypercoagulopathy with a predisposition to thromboembolism (Cap 
and Hunt, 2014) but this will not be examined here. 
 
2.7.1 Mechanisms of coagulopathy 
 
Hypothermia is common after serious injury, reflecting not just heat loss due to 
exposure and treatment but, more significantly, reduced heat production due to 
inactivity and shock.  Hypothermia is therefore linked to outcome independent of 
bleeding (Shafi, Elliott and Gentilello, 2005).  Very low temperature (<30C) interferes 
with clotting function, but this is probably of little significance at commonly 
encountered levels of hypothermia (33 to 36C) (Hess et al., 2008).  Acidosis can directly 
affect clotting function (Martini and Holcomb, 2007; Darlington et al., 2011).  Acidosis 
both interferes with clotting protease function and promotes degradation of 
fibrinogen.  Correction does not fully correct the coagulopathy, regardless of whether 
the acidosis was endogenous (due to shock) or exogenous (due to acid administration).  
Large volume fluid therapy was formerly standard in managing trauma patients, as was 
red blood cell transfusion without plasma.  Both are capable of diluting clotting factors 
below their critical concentrations (Faringer et al., 1993; Hiippala, Myllyla and Vahtera, 
1995; Hirshberg et al., 2003). 
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2.7.2 Acute Traumatic Coagulopathy 
 
In 2003, Brohi described Acute Traumatic Coagulopathy (ATC; also called Acute 
Coagulopathy of Trauma Shock [ACoTS]) affecting 24.4% of trauma patients admitted 
to the Royal London Hospital via the Helicopter Emergency Medical Service (Brohi et 
al., 2003).  These patients had received very little prehospital fluid therapy (median 
800mL).  Severely injured patients (ISS ≥ 16) were coagulopathic in 33.1% of cases 
whereas only 10.8% when not severely injured.  Macleod independently presented 
similar data from Florida that year (MacLeod et al., 2003).  Other papers have 
subsequently confirmed the existence of this abnormality. 
 
Brohi and Macleod both suggested that ATC is driven by a combination of shock and 
tissue trauma.  In a subsequent international collaboration they confirmed this 
interaction (Frith et al., 2010).  Patients with a low ISS were unlikely to develop ATC, 
regardless of base deficit (BD) on admission.  Conversely, patients with a low BD were 
unlikely to develop ATC, regardless of ISS.  The extreme groups (ISS<16, BD>12 or 
ISS>35, BD<0.1) were, unsurprisingly, relatively small (each 1% of the total).  However, 
with n=3646, they still represent modest cohorts.  Other studies have confirmed the 
effect of an interaction between injury severity and shock on the incidence of ATC 
(Wafaisade et al., 2010). 
 
The aetiology of this has been hotly debated.  Brohi, collaborating with Cohen’s group 
in San Francisco, has advanced a mechanism based upon aPC.  A fall in circulating 
protein C was shown in patients with ATC, presumed to represent its activation and 
consumption (Brohi et al., 2007).  A subsequent study with measurement of aPC 
showed that increases were correlated with coagulopathy and increased fibrinolysis 
(Cohen et al., 2012).  This mechanism was subsequently supported by a mouse model 
of trauma-shock (Chesebro et al., 2009).  The model developed an apparently aPC-
driven coagulopathy in response to a combination of trauma and shock.  This was 
abolished by antibody-inhibition of the anticoagulant action of aPC.  Of note, blocking 
aPC’s cytoprotective function led to rapid death in all subject, associated with 
pulmonary thrombosis and perivascular haemorrhage.  In contrast to this evidence 
supporting the role of aPC, a recent study has shown that adding aPC to plasma does 
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not interfere with clotting except at concentrations far above those seen in ATC 
(Campbell, Meledeo and Cap, 2014); this may undermine the role of aPC or may mean 
that the action of aPC is dependent on co-factors and spatial relationships not fully 
present in the studied assay.  A large multi-centre US study has demonstrated a five-
fold rise in aPC among trauma patients with evidence of ATC (Cohen et al., 2013). 
 
A paper (Rizoli, Scarpelini, et al., 2011) examining clotting factor deficiency noted that 
a close association existed between ATC and reduced factor V activity.  This would be 
expected in a coagulopathy driven by aPC or by consumption.  Reduced activity of the 
other clotting factors was unusual, making it very unlikely that they had been 
consumed.  More recently Kutcher et al (2014) found reduced clotting factor levels 
when comparing transfused trauma patients with non-transfused ones.  However, 
there was no reduction in fibrinogen on admission.  More recently, an international 
study (Hagemo et al., 2014) has demonstrated that hypofibrinogenaemia at admission 
is more common than previously thought: 8.2% had plasma levels below 1.5g/L.  Low 
fibrinogen was strongly linked to mortality.  This joins other evidence to point towards 
factor consumption as an important component of ATC (Cap and Hunt, 2014). 
 
2.7.3 Disseminated Intravascular Coagulation 
 
These findings are relevant to the major alternative explanation, advanced by the 
Japanese group led by Gando (2009).  They see nothing novel in Brohi and Macleod’s 
findings (despite the crucial early time point) and assert that ATC is simply 
disseminated intravascular coagulation (DIC) with fibrinolysis.  DIC is a consumptive 
coagulopathy, most familiar in sepsis, where a massive dysregulation of coagulation is 
linked to endothelial dysfunction.  ATC cases tend to meet the two international sets of 
diagnostic criteria for DIC (Oshiro et al., 2014).  However, these detect the 
consequences of DIC (evidence of thrombin generation, platelet consumption, 
fibrinolysis and coagulopathy) and the systemic inflammatory response syndrome 
rather than addressing the underlying cause.  Indeed, it is a widespread failure of the 
Protein C system leading to consumption of clotting factors, not its overactivity, that is 
usually advanced as the cause of DIC (Gando, Sawamura and Hayakawa, 2011).  Thus, 
while the DIC criteria may be have some predictive value in trauma (Sawamura et al., 
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2009), the underlying theory of causation is at odds with the evidence presented by 
Brohi and others.  It is therefore no surprise that histopathological examination of 
tissue from trauma patients who fulfil the DIC criteria shows no evidence of 
microthrombi and other markers of DIC (Rizoli, Nascimento, et al., 2011).  Of note, DIC 
implies an uncontrolled consumption of factors due to a specific pathophysiological 
mechanism.  The mere consumption of factors, which in a severely traumatised patient 
may be fulfilling their proper role of stemming haemorrhage, does not itself imply DIC 
 
2.7.4 Fibrinolysis 
 
If DIC is not the mechanism, then low fibrinogen levels after injury may be due to 
consumption in clot formation at sites of injury or be due to fibrinogenolysis, although 
this remains unclear (Davenport, 2013).  The latter may be a side-effect of pathways 
contributing to fibrinolysis, which is another major component of ATC.  Once again, 
Brohi and collaborators are responsible for some of the key papers on this subject 
(Brohi et al., 2008; Raza et al., 2013).  Fibrinolysis is activated in most trauma patients; 
the degree of activation is correlated with the severity of injury and shock; plasmin-
antiplasmin levels on admission, a measure of fibrinolytic activation, are independently 
correlated with clinical outcome.  It may be that the mechanism involves consumption 
of PAI-1 by aPC, although some authors have argued against this (Cap and Hunt, 2014).  
There is controversy as to what level of fibrinolysis is pathological; a question 
complicated by parallel arguments about the use of thromboelastography (TE) in its 
detection.  (TE is discussed in subsection 5.1.2.)  In a very large study (n=1,996), Cotton 
et al (2012) defined hyperfibrinolysis (HF) as a 7.5% reduction in r-TEG amplitude 30 
minutes after maximum amplitude (LY30>7.5%).  HF was present in 2% of patients but 
was associated with 76% mortality (v 10% in those without HF).  The paper by Raxa et 
al (2013) demonstrated that fibrinolysis activation was detectable in patients without 
severe lysis on TE.  Whether all clinically important lysis can be detected by setting a 
very low threshold for TE detection (LY30>3%) has not been established (Hunt, Raza 
and Brohi, 2013; Ramos et al., 2013). 
 
This dispute plays into the clinical debate about the treatment of fibrinolysis.  
Tranexamic acid (TXA) is a lysine derivative which prevents the binding of 
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plasminogen/plasmin to fibrin and thus inhibits fibrinolysis.  The CRASH-2 study 
(CRASH-2 trial collaborators, 2010) was a large (n=20,211), pragmatic study of TXA use 
in trauma patients and its use was associated with a 9% reduction in all-cause 
mortality (relative risk [RR],0.91; 95% confidence interval [CI], 0.85-0.97;p= 0.0035).   
This was due to a reduction in deaths due to bleeding (Roberts et al., 2011) and 
occurred despite no significant reduction in blood transfusion.  Blood products were 
not available at many participating sites in this global trial, which might obscure a 
reduced need.  TXA use has been widely adopted, particularly in military practice, 
(Morrison, Dubose, et al., 2012) but many objections to the trial have been raised, 
leading to poorer uptake in US civilian practice (Napolitano et al., 2013).  An Australian 
trial may resolve this by assessing the drug’s efficacy specifically in the setting of fully 
resourced Western medicine (Mitra et al., 2014).  Of note, TXA also has anti-
inflammatory effects which may contribute to its efficacy (Jimenez et al., 2007). 
 
2.7.5 Endotheliopathy of Trauma 
 
The preceding discussion has concentrated on the changes in blood after injury, which 
are characterised by consumption, fibrinolysis and a possible amplifying and unifying 
action of aPC.  Coagulation is also heavily influenced by the endothelium.  Aspects of 
endothelial dysfunction after trauma were discussed in subsection 2.5.7.  This 
subsection explores recent findings which implicate the endothelium in the 
coagulopathy of trauma.   
 
While activation leads to the endothelium becoming locally procoagulant, substances 
released during activation may promote systemic hypocoagulopathy.  The 
endothelium is coated by the glycocalyx, a glycoprotein/proteoglycan layer which 
sequesters up to a quarter of the plasma volume and modulates the interaction of 
platelets and leucocytes with the vessel wall.  It also contains heparin-like substances.  
Johansson’s group in Copenhagen have produced a series of papers which show the 
importance of the glycoclayx (Johansson et al., 2011a, 2011b; Ostrowski and 
Johansson, 2012) and which can be construed to support Brohi’s proposed mechanism 
of coagulopathy (Holcomb, 2011).  It has already been noted that ATC occurs when 
there is a combination of tissue injury and shock and that it is tissue injury, not shock 
43 
 
that leads to sympathetic activation (subsection 2.4.1).  High circulating 
catecholamines after trauma were associated with markers of glycocalyx degradation, 
endothelial activation, tissue injury  and fibrinolysis; they were an independent 
predictor of death (Johansson et al., 2011b).  Syndecan-1 is a major glycocalyx 
component; circulating levels correlated with catecholamines, protein C degradation 
and a similar group of markers and, again, predicted mortality (Johansson et al., 
2011a).  Crucially, patients without a raised Syndecan-1 did not exhibit a correlation 
between injury severity and catecholamines, inflammation and coagulopathy.  Finally, 
autoheparinisation was detectable in a small proportion of trauma patients, and was 
associated with high syndecan-1 (Ostrowski and Johansson, 2012).  These papers 
studied a small cohort (75-77 patients) and require verification.  In addition, 
endothelial activation/injury leads to the degranulation of the Weibel-Palade bodies, 
releasing (inter alia) tPA (Maegele, Schöchl and Cohen, 2014). 
 
The implication of these findings is that tissue injury contributes to ATC in several 
ways: tissue factor exposure activates coagulation, leading to thrombin production; 
catecholamine release (and presumably direct mechanical effects also) damages 
endothelial glycocalycx; this releases heparin-like substances; more significantly, it 
exposes the cell surface molecules that are implicated in ATC (thrombomodulin, EPCR).  
The low flow state of shock also leads to endothelial damage (Kozar et al., 2011) and 
may then facilitate the interactions needed to produce the thrombin switch and the 
activation of protein C.  Finally, aPC, as well as deactivating coagulation proteases, may 
end the inhibition of tPA (which itself has been released as part of endothelial 
changes). 
 
2.7.6 The Role of Platelets in Coagulopathy 
 
The role of platelets in the coagulopathy of trauma has not been clearly delineated.  
This subsection reviews the limited number of human studies that are available.  These 
assess platelets using diverse means, which are explored in more detail in Chapter 5.  
Ogura et al (2001) studied a small mixed population of critically ill patients, half of 
whom had been injured.  They demonstrated platelet activation by flow cytometry, 
reflected in increased CD62P expression, platelet microvesicles and platelet-leucocyte 
44 
 
aggregates compared with blood from normal controls.  Jacoby et al (2001) studied 
platelet function in 100 trauma patients.  In blood collected on admission, flow 
cytometry demonstrated increased platelet microvesicles, CD62P expression and 
binding of PAC-1, a measure of the activation-induced change in GPIIb/IIIa.  They also 
used a PFA-100.*  Admission blood showed shorter closing time in trauma patients 
than controls.  Repeat testing at 24, 48 and 72 hours showed the loss of platelet 
microvesicles and persistent activation.  However, there was a marked difference in 
closing times between survivors and the six non-survivors.  The former essentially 
normalised whereas the latter, which showed a trend to being higher on admission, 
became notably extended at the later time points.  On admission there was a weak 
inverse correlation between activation and closing time but in non-survivors the 
activation was associated with prolonged closing time.  This would seem to indicate 
either that platelets have been stimulated to the point of becoming effete or are being 
inhibited. The PFA-100 is sensitive to haematocrit.  While this is an acknowledged 
limitation of the Jacoby paper (2001), preventing isolated assessment of platelet 
function, it may actually be a reflection of the contribution of red cells to coagulation 
in vivo (Spoerke et al., 2010). 
 
Solomon et al (2011) used multiplate electrode aggregometry to demonstrate a 
decreased platelet response to ADP and TRAP in non-survivors when compared to 
survivors along with a reduced platelet contribution to clot strength on ROTEM.  While 
detectable, these deficits were modest.  However, there was considerable variability in 
the results of these tests among survivors, with many exhibiting a phenotype 
responsive to stimulation.  Kutcher et al also used multiplate in a more severely injured 
cohort, finding more hyporesponsiveness at admission than the previous study (below 
normal response to at least one agonist in 45% of patients) (Kutcher et al., 2012).  They 
followed the time course of platelet hyporesponsiveness, which became nearly 
universal after 6 hours, with (generally) a slow increase in response up to 120 hours 
after admission.  Wohlauer et al used platelet mapping to show a significant fall in 
ADP-and arachidonic acid-stimulated platelet function after trauma.  This was found to 
be common in a much less severely injured cohort than the two preceding studies, 
with severely injured patients all exhibiting the deficit (Wohlauer et al., 2012).  Time 
                                                 
*
 The PFA-100 and related nomenclature is discussed in subsection 5.1.3. 
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from injury to admission was not stated in the paper but the trauma centres involved 
served rural populations; delayed admission may partly explain the higher rate of 
platelet dysfunction.  Carroll et al showed that a reduced clot strength after initiation 
with ADP correlates with the need for transfusion; unfortunately they did not report 
the proportion and characteristics of patients with this abnormality (Carroll et al., 
2009).  Windeløv et al (2014) showed no clear relationship between injury severity and 
platelet function.  In a related paper they assessed the contribution of MVplt to 
coagulopathy (Windeløv, Johansson, et al., 2014).  They demonstrated that trauma 
patients with impaired clot formation had low levels of PS-expressing MVplt. 
 
These papers are heterogenous in methodology and results, but some consistent 
messages emerge.  Platelets from traumatised patients show evidence of activation, 
e.g. surface marker or MVplt expression.  There is evidence of a divergence in platelet 
function between non-survivors and survivors; there seems to be reduced function 
and response to stimulation in the non-survivors.  There is mixed evidence as to 
whether such a functional deficit is associated with severity of injury, although most 
relevant papers support this proposition, and its detection may be sensitive to the 
timing of assessment.  
 
A low platelet count (<150x109/L) is uncommon after trauma, occurring in less than 
10% of those with ISS<45 (Hess et al., 2009).  However, low admission platelet count is 
correlated with transfusion requirement and outcome, independent of ISS (Hess et al., 
2009; Brown et al., 2011).  Kutcher et al found that platelet responsiveness correlated 
with platelet count (Kutcher et al., 2012). 
 
A preliminary study using ROTEM in British military casualties showed that 40% of 
seriously injured patients had significant evidence of hypocoagulopathy (Woolley et 
al., 2013).  Comparison of EXTEM (ROTEM stimulated by thromboplastin) and FIBTEM 
(EXTEM with cytochalasin D) traces for these patients revealed relative preservation of 
the FIBTEM trace, indicating that platelet dysfunction plays a significant role.  (See 
sections 5.2 and 5.3 for further explanation of these terms). 
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In summary, studies with varied patient groups and methods of platelet analysis have 
produced divergent findings.  It is difficult to determine the true incidence of platelet 
dysfunction, its severity or its contribution to coagulopathy.  However, dysfunction 
certainly occurs, it is linked to the platelet count, it develops over several hours and 
may persist for days.  
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3 Resuscitation after Trauma 
 
3.1 Damage Control 
 
There has been an extensive debate about the best fluid regime for the resuscitation 
of trauma victims.  The endpoints of resuscitation, the choice of fluids and the timing 
and volume of fluid administered have all been the subject of controversy.  Until 
recently, the practice of high volume crystalloid infusion before the use of blood and 
blood products was an accepted standard of care; the aim was to restore 
normotension.  Studies in animals and humans have led to a re-evaluation of this 
practice.  Small volume, hypotensive resuscitation is now commonplace, as is a greater 
emphasis on the use of blood and blood products, especially the latter.  Resuscitation 
is now aimed at preventing or relieving the lethal triad of coagulopathy, acidosis and 
hypothermia.  As part of this, surgery is now integrated into the practice of what has 
become known as Damage Control Resuscitation (DCR) 
 
Damage Control Surgery (DCS) was a term introduced by Rotondo et al in 1993, based 
on naval practice in the preservation of the fighting capacity of warships (Rotondo et 
al., 1993),  although the concept is in fact much older.  DCS involves abbreviated 
surgery to stop haemorrhage and contamination followed by a period of intensive care 
to restore physiology and later, planned reoperation for definitive management.  
Initially described for abdominal trauma it has now been implemented for other 
injuries (Pape et al., 2002) and is widely practiced and endorsed in guidelines.   
 
The move to DCR came in the last decade (Holcomb et al., 2007; Jansen et al., 2009; 
Duchesne et al., 2010).  It combines DCS techniques with simultaneous medical 
therapy to correct physiology. The principle components are: 
 DCS 
 Hypotensive resuscitation 
 Limited use of crystalloid fluids 
 “Balanced” or “haemostatic” resuscitation, using a high ratio of plasma and 
platelets relative to red blood cells. 
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These are practiced concurrently.  DCS is thus now considered just one part of the DCR 
process and the former, staged concept has been abandoned.  After considering some 
of the basic physiology of resuscitation, this discussion will examine the three non-
surgical elements of DCR.  The process of the development of evidence and practice in 
this area has also influenced the development of the animal model used in this thesis, 
and will be explored in some detail. 
 
3.2 Physiological Considerations 
 
Fundamentally, resuscitation is intended to restore tissue oxygen delivery without 
deleterious effects such as increased bleeding or inflammation.  Global oxygen delivery 
(DO2) is governed by the arterial oxygen content (CaO2) and the cardiac output (CO) 
(Marino, 2013): 
 
DO2 = CaO2 x CO 
 
CaO2 is governed by the haemoglobin concentration ([Hb]) and the oxygen saturation 
SaO2, with a negligible contribution from dissolved oxygen. 
 
CaO2 ≈ [Hb] x SaO2 x 1.34 
 
Fluid therapy will predominantly affect CO and [Hb] (although changes in lung 
perfusion may alter SaO2).  Fluid therapy increases CO by increasing the venous return 
to the heart, and consequently the filling pressure and end diastolic volume of the 
heart, leading to an increase in the stroke volume.  PRBCs can combine this effect with 
an increase in [Hb].  It would seem to follow that PRBCs are the ideal resuscitation 
fluid.  However, blood is a non-Newtonian viscous liquid, i.e. one that reduces its 
viscosity under shear stress, including flow through vessels (Merrill, 1969).  (The 
phenomenon is familiar to anyone who has been the victim of the sudden exit of 
previously unmoving ketchup from its bottle.)  The viscosity is related to the 
haematocrit.  Consequently, dilutional therapy can raise CO by reducing viscosity.  The 
effect is exaggerated by the fact that the blood will become even less viscous at it 
flows, creating a diminishing positive feedback effect.  In consequence, a 38% 
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reduction in haematocrit in a polycythaemic patient can cause a 225% increase in CO 
(LeVeen et al., 1980).  PRBCs have a very poor ability to increase CO when compared 
with whole blood, crystalloids and colloids (Shoemaker, 1987).  More viscous blood 
may also be less able to perfuse the microcirculation, leading to alterations in the 
distribution of flow. 
 
3.3 Evidence for Normotensive and Hypotensive Resuscitation 
 
Evidence in this area is complicated by the fact that some investigators have compared 
early fluid resuscitation with late, some have looked at different volumes and infusion 
rates of fluids (from none to slow infusion to large boluses) and some have compared 
resuscitation to different blood pressure endpoints.  In clinical practice, fluid 
administration will be tailored to an individual patient’s needs which may make the 
practical difference between these concepts small.  However, in human trials this leads 
to protocol violations.  Animal studies are more likely to keep to protocol, but the 
difference between, for example, the blood pressure profile in the large volume 
infusion arm of one study and that in the normotensive arm of another may be small. 
 
3.3.1 Origins of Conventional Resuscitation Practice 
 
The orthodoxy of normotensive resuscitation was established in the American College 
of Surgeons’ Advanced Trauma Life Support (ATLS) guidelines.  These guidelines and 
the didactic course that promoted them were established by an orthopaedic surgeon 
horrified by the poor care received by his family after an aircraft crash.  They quickly 
became the mainstay of trauma care training in the USA and throughout the world.  
Their methodical approach to the care of the injured has unquestionably saved many 
lives. 
 
Until the ninth edition, the ATLS recommendations on fluid resuscitation for patients 
with signs of hypovolaemia called for the rapid infusion of 2l of warmed Ringer’s 
lactate solution, followed by an assessment of cardiovascular response and further 
infusion as indicated to normalise blood pressure (American College of Surgeons, 
2008).  These recommendations derived chiefly for the work of scientists using a 
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model of haemorrhage developed by CJ Wiggers (1950).  The Wiggers model was 
designed to investigate the phenomenon of irreversible shock, a state after 
haemorrhage in which the subject will die regardless of any resuscitation.  In this 
model, blood was withdrawn from experimental animals through an intravascular 
cannula to achieve a desired level of hypotension and this was then maintained for 
many hours by withdrawing or infusing blood to compensate for any change in blood 
pressure.  Other investigators modified this model, with less profound and more short-
lived hypotension, to make the insult potentially survivable.  These investigators then 
found that resuscitation with crystalloid fluid required three times the volume of shed 
blood in order to restore normotension or prevent death (Shires T et al., 1964; Dillon 
et al., 1966). 
 
3:1 resuscitation became widespread, with the explicit intention of filling a depleted 
extracellular space with fluid.  This it did, causing massive pulmonary oedema in 
patients with non-thoracic injury during the Vietnam War, known as “Da Nang lung” 
(Dutton, 2007).  Fluid resuscitation was a lifesaving intervention in Vietnam but the 
idea that there may be reason for caution had been born. 
 
A potentially significant fault can be identified in the Wiggers model.  Since the tap on 
the cannula is closed when not in active use, there is no possibility of the animal 
bleeding.  In contrast, an injured patient depends upon maintaining the integrity of a 
clot to prevent the reactivation of haemorrhage.  An increase in blood pressure could 
disturb a clot, leading to further blood loss. 
 
Despite this, modified Wiggers model experiments continued into the 1980s, 
confirming the status quo.  In parallel with this, a debate began between those who, in 
accordance with this paradigm, detected a benefit from prehospital fluid 
administration and those who found it to be pointless, often because it seemed to take 
longer to gain the necessary intravenous access than it would to take the patient 
directly to hospital.  It is noteworthy that prehospital and in-hospital high volume fluid 
resuscitation were adopted without any clinical trials.  This is despite the existence of 
clinical evidence against them dating back to the First and Second World Wars 
(Cannon, 1918; Beecher, 1949).  There were even early animal experiments using 
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uncontrolled haemorrhage: in 1965 a study by Shaftan and colleagues using femoral 
artery transection showed that elevation of blood pressure by infusion of blood or 
crystalloid or by vasopressors caused haemorrhage to restart.   
 
3.3.2 Uncontrolled Haemorrhage 
 
From the late 1980s, reports have increasingly been published on animal trials 
including an element of uncontrolled haemorrhage.  The first (Gross et al., 1988) was a 
study comparing resuscitation after controlled haemorrhage and after haemorrhage 
from division of three branches of the ileocolic artery.  Animals received no treatment 
or one of two regimes of fluid resuscitation.  As one would expect, aggressive 
resuscitation benefitted the controlled haemorrhage group.  However, it caused 
intraabdominal bleeding and death in the uncontrolled haemorrhage animals.  The 
same group from Haifa found similar results using rat tail transection to model the 
uncontrolled haemorrhage (Gross et al., 1989). 
 
William Bickell and his colleagues made one of the most significant contributions to 
this debate with a series of experiments and, importantly, the major randomised trial 
of delayed resuscitation (see subsection 5.3.3).  Their pig model involved open 
splenectomy (to prevent autotransfusion) followed by placement of a steel wire in the 
aorta such that when pulled it would produce a 5mm longitudinal aortotomy.  The 
abdomen was closed with the wire ends exteriorised.  In an early study, aortotomy did 
not lead to exsanguination in unresuscitated animals.  The nadir of cardiac physiology 
was reached at 5 minutes, after which animals began to recover.  At post mortem the 
aortotomies were sealed with a dense adherent clot (Bickell, Bruttig and Wade, 1989).  
In a subsequent study (Bickell et al., 1991), animals were randomly assigned to receive 
either no fluid or crystalloid at three times the calculated rate of blood loss, beginning 
6 min after aortotomy.  At 2 hours, all the former group were alive and all the latter 
group dead (p<0.05).  The resuscitated group had significantly more intra-abdominal 
haemorrhage.  Initially they exhibited a high blood pressure, but this putative 
advantage had disappeared after 30min, by which time they were significantly more 
acidotic than the unresuscitated animals.  The resuscitated group had soft, gelatinous, 
nonadherent clot at post mortem.  Bickell suggested that as well as increased pressure 
52 
 
dislodging the thrombus (what is now widely termed “popping the clot”), dilution of 
clotting factors and altered rheology also add to the degree of haemorrhage. 
 
Stern’s group published two important papers in the early 90s which involved a more 
significant haemorrhage.  Immature swine were bled through a cannula to a mean 
arterial pressure (MAP) of 30mmHg before pulling of the aortotomy wire (Kowalenko 
et al., 1992; Stern et al., 1993).  This was considered to better simulate a potentially 
lethal haemorrhage.  Animals were then resuscitated to a MAP of 40, 60 (in the latter 
study) or 80mmHg (using a limited volume of crystaloid then reinfusion of shed blood).  
Animals in the 80mmHg group died significantly more often and earlier than the others 
in both studies.  Volume of haemorrhage into the abdomen was related to the 
resuscitation endpoint and, congruently, the volume of resuscitation fluid given.  The 
mildly under-resuscitated group (60mmHg) had the best biochemical profile.  Stern 
noted that an effect of the less aggressive resuscitation regimes was a delay before 
reaching maximal pulse pressure (80mmHg—10min, 60mmHg—35min, 40mmHg—
45min).  Allowing the clot to mature before increasing blood pressure may be 
beneficial. 
 
Marshall (1997) modelled uncontrolled haemorrhage by using a cannula to bleed rats 
at a constant rate for 15 min and then transected their tails at 30 min.  Simulated 
prehospital resuscitation was performed until 90min, when the tail bleed was stopped 
surgically and resuscitation then continued to a MAP of 80 mmHg and a Hct of 30% 
using Ringer’s lactate and shed blood.  The animals were allowed to recover from 
anaesthesia and monitored for three days.  Animals were randomised to receive 
different prehospital regimes in the period from 30 to 60 min.  A group resuscitated to 
a MAP of 80 mmHg with Ringer’s lactate all died before 60 min (group I), whereas 75% 
of animals survived when the endpoint was 40 mmHg (group III).  There were two 
other groups where shed blood and Ringer’s lactate were used in a 1:5 ratio as the 
prehopital fluid, with the same two MAP endpoints (groups II—80 mmHg, group IV—
40 mmHg).  These groups had similar survival, base deficit and arterial pH to group III 
throughout the experiment.  Prehospital volume requirements were (means): group I, 
151 mL; group II, 69 mL; group III, 29 mL; group IV 20 mL.  Group I’s needs were 
significantly greater than the other groups and group II’s were significantly greater 
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than the two groups resuscitated to 40mmHg.  Multivariate analysis suggested that 
MAP, Hct and the interaction between them were significant predictors of mortality.  
As well as confirming the deleterious effect of a high MAP endpoint in uncontrolled 
haemorrhage (in the context of surgical control being exercised soon after), this study 
suggested additional benefit from early blood transfusion and revealed the marked 
reduction in volume required when even a small proportion of blood is used. 
 
David Burris and colleagues from the Uniformed Services University of the Health 
Sciences used a rat model with two puncture wounds to the abdominal aorta to 
investigate the outcome of hypotensive resuscitation in situations where surgery is 
very delayed, as may occur in battle or after a disaster.(Burris et al., 1999)  Animals 
were resuscitated for two hours after injury and monitored up to 72 hours.  At 2 hours, 
3 of 11 unresuscitated animals were alive and all died within 4 hours.  All resuscitated 
groups had better survival at 2 hours, but this advantage only persisted to 72 hours in 
two groups: one given Ringer’s lactate to a MAP of 80mmHg and one given hypertonic 
saline in hetastarch (HH) to a MAP of 40mmHg.  Ringer’s lactate to a MAP of 100 or 
40mmHg and HH to a MAP of 80mmHg had poorer survival.  The authors concluded 
that moderate resuscitation was required in these circumstances. 
 
These models have concentrated on injury to major vascular structures, rather than to 
the viscera, which is more common in patients.  Matsuoka and colleagues addressed 
this with a model involving sharp removal of part of the liver in rats.  (This is a visceral 
injury, but not a blunt injury.)  They concluded that visceral injuries behave differently 
and that massive fluid infusion is safe after injury to the abdominal viscera (Matsuoka, 
Hildreth and Wisner, 1995, 1996).  However, their studies either used low MAP 
endpoints, which would not properly reveal the disadvantage of high volume 
resuscitation, or were confounded by the use of hypertonic solutions, which make it 
difficult to interpret the implications for pressure endpoints alone.  Krausz’s group 
reported studies involving one (“moderate”) or two (“severe”) incisions to the spleen 
of rats (Abu-Hatum, Y. Bashenko, et al., 2002; Abu-Hatum, Yulia Bashenko, et al., 
2002).  In both studies, large volume Ringer’s lactate infusion increased bleeding 
compared to untreated animals; in the severe model, it also worsened survival.  These 
studies used a single bolus fluid infusion.  
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Krausz’s group then investigated fluid infusion at different rates, for the period 15 to 
60min after massive splenic injury.  Even the fastest infusion of Ringer’s lactate used 
had little effect on MAP.  Despite this, increasing rate of infusion was associated with 
increasing blood loss, although not worsening survival (Abu-Hatum, Yulia Bashenko, et 
al., 2002).  However, in a similar study with the addition of splenectomy at 45min, they 
did find a shorter mean survival time after operation in the large volume Ringer’s 
lactate group (Krausz and Hirsh, 2003).  This could imply that this group had already 
bled enough by 45 min that splenectomy could not salvage them, whereas more 
conservative resuscitation delivered the “patient” to the “surgeon” in a better state to 
be able to benefit from control of haemorrhage.  While sharp incision of the spleen 
may not fully reproduce a laceration, Krausz’s group are to be particularly commended 
for investigating these injuries with variations in severity and management. 
 
This is a necessarily incomplete account of animal trials in this area.  In 2003, 
Mapstone and colleagues published a systematic review of these (Mapstone, Roberts 
and Evans, 2003).  They identified 44 trials comparing fluids with no fluid and 9 
comparing hypotensive with normotensive resuscitation.  They found that fluids were 
beneficial in animals with severe haemorrhage but detrimental in those with moderate 
haemorrhage.  Hypotensive resuscitation was beneficial with a pooled relative risk of 
death 0.37 (95% CI, 0.27–0.50).   
 
Animal work has continued in this area with concordant results.  In an interesting 
paper in 2011, Li et al looked to determine the optimum hypotensive resuscitation 
regime (Li et al., 2011).  Using a rat model with a mixed splenic and vascular injury with 
later surgical haemostasis they evaluated the targeting of several MAP endpoints in 
the hour before surgery. The found that 50mmHg gave the best outcome, both for 
mortality at 4 hours post-surgery and for measures of tissue function.  They then 
performed a second evaluation, varying the time for which the 50mmHg MAP was 
maintained.  They found a sharp drop in survival between groups given the 
hypotensive regime for 90 and 120 minutes.  The body’s capacity to tolerate 
hypotensive resuscitation is therefore a function of both its depth and duration. 
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3.3.3 Human Data 
This extensive investigation in animal models has been highly influential on clinical 
practice since there has been only poor quality human data.  The most important 
human trial in this area is that of Bickell and colleagues (1994).  They assigned patients 
with penetrating injury to receive standard care (i.e. prehospital fluid infusion) or no 
fluids until reaching the operating theatre.  Bickell reported a statistically significant 
improvement in survival to hospital discharge in the delayed resuscitation group (70% 
v 62% survival, p=0.04, Chi Square).  The trial had several flaws.  “Randomisation” was 
by day of the week and as such there was no allocation concealment, which can have a 
large effect on trial outcome in either direction.(Higgins et al., 2011)  There was also 
no reported blinding of hospital staff or data collectors.  8% of patients in the delayed 
arm received prehospital fluids, which was a protocol violation.  However, it is unclear 
whether this was inadvertent or a desperate measure in the face of profound 
hypotension—an action that might usefully have been permitted in the protocol.  The 
study took place in an urban environment with short prehospital times and excluded 
patients with blunt injury.  Consequently, its general applicability in a mixed trauma 
population or in the context of prolonged prehospital times (as in rural, military and 
disaster situations) is moot. 
 
The other major trial comparing fluids with no fluids (Turner et al., 2000) showed no 
benefit but had so many protocol violations that the proportion of patients actually 
being given fluids in the two arms of the trial was nearly the same.  Three trials 
comparing large and small volume resuscitation showed no mortality benefit and there 
have been no completed trials comparing hypotensive and normotensive strategies.  A 
trial comparing two different low MAP endpoints during surgery for trauma has 
published preliminary data (Morrison et al., 2011).  In preparing for this trial the 
investigators have established that an intraoperative MAP endpoint of 65mmHg 
represents a consensus of current practice among US trauma surgeons. 
 
A Cochrane Review concluded that there was no reliable evidence to support either a 
liberal or restricted resuscitation strategy (Kwan et al., 2014).  They eschewed meta-
analysis because of the heterogeneity of the trials.  Wang and colleagues did perform 
meta-analysis, both of trials and observational studies, and concluded that there was 
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strong evidence of benefit for a restricted resuscitation strategy (Wang et al., 2014).  
The Cochrane review’s position is more rigorous.  Clinicians should regard the benefit 
of hypotensive resuscitation as supported but not definitively proven by the available 
evidence. 
 
In parallel with these investigations of the amount and timing of fluid resuscitation 
there has been extensive examination of which clear fluid (colloids or crystalloids, 
isotonic or hypertonic) should be used.  These lie beyond the scope of this discussion.  
It should be noted that clinical trials have not realised the promise of these alternative 
fluid types (Bulger et al., 2010, 2011), that the preponderance of evidence favours 
isotonic crystalloids (Perel, Roberts and Ker, 2013), that colloids may induce 
coagulopathy (Kozek-Langenecker, 2015) and that crystalloids predominate in UK 
civilian practise.  While the US military makes extensive use of colloids, the UK Armed 
Forces have largely abandoned them. 
 
3.3.4 Resuscitation Research at Dstl Porton Down 
 
In the context of these findings about hypotensive resuscitation, which was the UK 
military standard of care, Kirkman and colleagues at DSTL, Porton Down have sought 
to examine the effects of different fluid regimes in models of military injury, including 
prolonged resuscitation and blast injury.  In these experiments, blast injury was 
induced using a bare charge with the subject protected by a Kevlar blanket.  
Accordingly, blast exposure caused only primary blast injury, allowing the effect of this 
phenomenon to be studied in detail and preventing wide discrepancies in injury 
pattern between subjects in the same group, as would occur with exposure to 
fragmentation injury.  They first used a controlled haemorrhage model combined with 
blast or sham blast to compare extended periods (up to 8 hours) of hypotensive and 
normotensive resuscitation (Garner et al., 2010).  In blast exposed animals, survival 
times were significantly reduced in the hypotensive groups, with evidence of 
hypoxaemia induced by the primary blast lung injury combining with poor tissue 
perfusion to produce inadequate oxygen delivery.  In the sham blasted groups, 
prolonged hypotensive resuscitation produced considerable physiological 
derangement, including a high base deficit, compared with normotensive 
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resuscitation.  There was a trend towards greater mortality in the hypotensive group 
but this was not significant.  However, given the ethically appropriate constraint on the 
size of the study, this may represent a type II error.  This study clearly demonstrated 
the possible deleterious effects of prolonged hypotensive resuscitation.  However, it 
did not account for the possibility of rebleeding. 
 
Kirkman and colleagues then developed a model that included the possibility of 
rebleeding (Kirkman, Watts and Cooper, 2010).  To do this they added a grade IV liver 
injury, which was induced by a surgically preplaced wire which was pulled after 
controlled haemorrhage and blast or sham blast.  Liver injury followed haemorrhage to 
ensure that the known cardiovascular effects of blast would not have a differential 
effect on the degree of blood loss from the liver—after 30% blood volume 
haemorrhage, cardiovascular physiology should be similar between blast and sham 
blast groups, as already discussed in subsection 2.4.2. 
 
Having demonstrated that hypotensive resuscitation causes problems through poor 
tissue perfusion and oxygenation, they studied strategies to improve these through 
fluid therapy and supplemental oxygen.  For one trial they designed a novel hybrid 
resuscitation regime involving one hour of hypotensive resuscitation followed by 
normotensive resuscitation (Doran et al., 2012).  This was designed to allow any clot to 
gain 80% of its strength during the hour before the increase in perfusion pressure 
(Shaftan et al., 1965).  Thereafter, the improved cardiac output, potentially combined 
with improved microvascular flow due to decreased blood viscosity, would restore 
oxygen delivery to the tissue.  Hypotensive resuscitation, being the UK military practice 
at the time, remained the comparator. 
 
In blast exposed animals, the novel hybrid strategy was associated with a significant 
fall in mortality compared with hypotensive resuscitation (from 5 out of 6 to 2 out of 6, 
p=0.02, Kaplan-Meier analysis, Peto’s log rank test).  No difference in mortality was 
seen in the two sham blasted groups.  In all groups, the oxygen extraction ratio (OER), 
which reflects the adequacy of oxygen delivery, rose from the normal of 25% to the 
physiological maximum of 80%.  All groups also developed a significant acidosis.  
Restoration of perfusion in the novel hybrid groups associated with an improvement in 
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the acidosis and a fall in the OER.  OER remained maximal in the two hypotensive 
groups.  In the blast-hypotensive group acidosis worsened until the animals 
succumbed.  In the sham blast-hypotensive group, oxygen delivery appears to have 
been adequate to sustain life but, despite continued maximal oxygen extraction, not to 
correct the acidosis.  There was no evidence of increased bleeding in the novel hybrid 
groups. 
 
In a separate trial, blast exposed animals were treated with hypotensive resuscitation 
and either oxygen supplementation titrated to maintain SaO2 of 95% or air.  Oxygen 
therapy successfully improved the SaO2, improved delivery of oxygen and markedly 
improved mortality (6/6 v 2/6, p=0.014) (Kirkman, Watts and Cooper, 2010). 
 
Following a review of all available evidence, novel hybrid resuscitation has been 
adopted as standard British military practice.  Logistical and tactical considerations 
make supplemental oxygen therapy impractical in many military settings.  Nonetheless 
oxygen is made available and used wherever practicable. 
 
3.3 Haemostatic Resuscitation 
 
The description by Brohi and then others of a hypocoagulopathy that affects a 
significant proportion of trauma patients (Brohi et al., 2003; MacLeod et al., 2003) and 
predicts adverse outcome coincided with the large-scale military engagements of the 
USA and her allies in Iraq and Afghanistan.  In-hospital resuscitation practice in the US 
Armed Forces developed over the subsequent decade in an attempt to find better 
ways to address the physiological derangements of injured servicemen.  Military 
reports proved highly influential on civilian practice.  Two trends were particularly 
noteworthy: the use of recombinant activated factor VII (rFVIIa) and the use of high 
ratios of fresh frozen plasma and platelets to red blood cells.  rFVIIa was developed for 
the treatment of bleeding in patients who have a genetic deficiency for the clotting 
factor.  Case reports of its use in traumatic bleeding began in Israel (Kenet et al., 1999), 
and the practice became widespread in the US military (Spinella et al., 2008).  Two 
civilian randomised control trials failed to provide convincing evidence of its safety and 
efficacy (Boffard et al., 2005; Hauser et al., 2010).  This potent drug has the potential 
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to cause significant thromboembolic complications (O’Connell et al., 2006).  The drug 
is most effective when given to patients without hypothermia or acidosis (Meng et al., 
2003).  Defining the correct circumstances for its use therefore remains problematic.  
Following initial enthusiasm there has been a decrease in its use in the British military 
(Smith, 2013). 
 
3.3.1 Plasma Therapy in Resuscitation with Blood Components 
 
Blood component therapy replaced whole blood transfusion in the decades after the 
Second World War as it became technically feasible and was perceived to offer more 
efficient use of donated blood and rational, targeted use of components to treat 
specific problems.  In the context of trauma and haemorrhage, the practice developed 
of giving FFP only once a coagulopathy had been documented or a certain amount of 
PRBC had been transfused (Holcomb and Pati, 2013).  Recognising the incidence of 
coagulopathy early after injury clearly undermines this practice.  A series of cohort 
studies of both military and civilian patients has appeared to show decreased mortality 
in trauma patients who receive a high ratio of FFP to PRBC during massive transfusion. 
 
The first was the study by Borgmann et al (2007).  They demonstrated much lower (65 
v 19%) mortality in patients receiving high (mean 1:1.4, p<0.001) ratios of FFP to PRBC 
compared to those receiving low ratios (1:8).  By 2011, a systematic review included 
eleven retrospective studies, nine of which found evidence of benefit for high or 1:1 
FFP:PRBC ratios (Rajasekhar et al., 2011).  More recently, Bhangu et al  (2013) analysed 
six studies where the ISS did not differ between low- and high-ratio groups (OR 0.56, 
95% CI 0.40–0.78, p < 0.001 where high was defined as >1:2) but no additional benefit 
of 1:1 resuscitation. 
 
However, all these studies are potentially confounded by survival bias.  It has been 
typical practice for PRBC to be immediately (in the ED) or quickly (in the laboratory) 
available for transfusion to trauma patients.  PRBC is kept refrigerated and delivered 
through a warming circuit to enter the patient at an appropriate temperature.  FFP has 
not been kept thawed and ready because of its short shelf life when not frozen. The 
current vogue for early, high-dose FFP may mean that some high volume units, 
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including military hospitals, may have changed this policy.  However, in the period 
covered by these studies, it meant that there was a delay before administration of FFP 
could begin.  Accordingly, patients requiring the largest amount/highest rate of PRBC 
transfusion will quickly develop a low FFP:PRBC ratio.  These patients are those with 
active haemorrhage and consequently the highest risk of death.  It follows that 
patients who require the highest PRBC volumes will have the lowest FFP:PRBC ratios 
unless they survive long enough to “catch up”.  Early death, the outcome measure, can 
therefore govern FFP:PRBC ratio, the treatment measure, confounding the analysis 
(Snyder et al., 2009; del Junco, Fox, et al., 2013). 
 
There is other evidence in support of high ratio resuscitation, in the form of studies 
comparing similar patient cohorts before and after the instigation of high ratio policies.  
For example, the group at Vanderbilt (Cotton et al., 2008) demonstrated improved 
mortality after the introduction of such a policy.  However, their study had very 
different cohorts before and after the policy change and such studies are easily 
confounded by other changes in management.  They also claimed to demonstrate a 
reduction in blood product usage. However, the treatment group was defined by 
protocol activation (a clinical judgement) and many appear to have received less than 
10 units, but the latter was an inclusion criterion for the control cohort.  No such 
reduction was seen in a similar study from Copenhagen which did not have this design 
flaw.  This group confirmed the apparent mortality benefit (Johansson and Stensballe, 
2009). 
 
Despite these evidential shortcomings, clinicians have to respond to the reality of early 
coagulopathy in a substantial proportion of the most severely injured patients.  Is high 
ratio FFP the answer?  A careful study by Brohi’s group in London has recently 
demonstrated this (Davenport, Curry, et al., 2011).  They examined coagulation status 
in patients before and after receiving PRBC and FFP, recording the ratio received for 
each 4 units of PRBC transfused.  In coagulopathic patients, FFP transfusion improved 
coagulation parameters.  Interestingly, this effect was maximal at an FFP:PRBC ratio 
between 1:2 and 3:4.  This accords with the maximal mortality benefit seen in some 
studies (Kashuk et al., 2008; Teixeira et al., 2009).  However, this was described as a 
preliminary report of an ongoing study; multivariate and subgroup analysis on a larger 
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cohort should yield more information on whether this is an independent effect of the 
ratio or is confounded by other factors, such as injury severity, physiology, timing and 
other treatments. Thus it is sensible to predict some benefit from giving early FFP, at 
least in this range of ratios.  As a practical matter, some authors have suggested that, 
given the logistic constraints of FFP readiness, aiming for a 1:1 ratio may have the 
effect of achieving a 1:2 ratio (Holcomb et al., 2008). 
 
Others retain an emphasis on achieving 1:1 transfusion.  Is there any reason to believe 
FFP may be harmful?  At a mechanistic level, FFP is about as “dirty” as a drug could be 
(Pandey and Vyas, 2012).  FFP contains a multitude of biologically active molecules 
ranging from pro- and anticoagulant factors to immunoglobulins and cytokines.  Any 
blood transfusion risks infection and other complications, despite donor screening, 
leucodepletion and other measures.  The study of FFP:PRBC ratio in the German 
Trauma Registry indicated that high ratios may be associated with increased septic 
complications and multiple organ failure (Maegele et al., 2008). Johnson and 
colleagues in Denver demonstrated in a retrospective study that volume of FFP 
transfusion is an independent predictor of multiple organ failure and that this effect is 
greater when the patient has required more than 6u of PRBC (Johnson JL et al., 2010).  
However, all such studies suffer from the possibility of selection bias.  This works in the 
opposite direction to survival bias: receiving high doses of FFP may indicate more 
severe pathology, not measured or accounted for in the multivariate analysis; these 
patients may be more likely to develop MOF because of these underlying changes 
rather than the FFP. 
 
Holcomb and colleagues completed a large (n=905) multi-centre prospective study of 
transfusion ratios which was specifically designed to address the problems seen in 
previous observational studies (PROMMTT) (Holcomb JB et al., 2013).  By using 
appropriate inclusion criteria, collecting detailed data on the timing as well as amount 
of blood products given and using time-dependent statistical modelling they sought to 
remove the influence of survival bias.  They concluded that achieving a high ratio of 
FFP to PRBC during the first 6 hours of resuscitation was associated with a much 
reduced mortality during the first 6 hours.  They demonstrated that received ratios 
changed over time with most patients initially receiving a low ratio (i.e. PRBCs first) 
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and then reaching a high ratio over time (as FFP is administered).  Subgroup analysis 
suggested that mortality benefit may have been confined to those patients who were 
given a high ratio initially (del Junco, Holcomb, et al., 2013).  This group then 
conducted a large randomised control trial (Holcomb et al., 2015) comparing 
PRBC:FFP:Plt ratios of 1:1:1* to 2:1:1.  No difference in the primary endpoints 
(mortality at 24 hours and 30 days) was found, but this may have been a type 2 error.  
1:1:1 appeared to be superior in the analysis of secondary endpoints including 
exsanguination and achievement of haemostasis and was not associated with an 
increase in adverse events. 
 
More recently, there has been considerable interest in the role of plasma products in 
addressing the endotheliopathy of trauma.  In vitro studies demonstrate that plasma, 
unlike crystalloid, can reduce the permeability of endothelial cells induced by hypoxia 
and other insults (Pati et al., 2010; Wataha et al., 2013).  Plasma also restored the 
glycocalyx in rat models (Kozar et al., 2011; Torres et al., 2013).  Clinical confirmation 
of these effects has not yet been demonstrated. 
 
3.3.2 Platelet Therapy in Resuscitation with Blood Components 
 
Evidence and practice relating to the administration of platelets has followed a parallel 
course to that for plasma over the last decade.    Initial military reports of benefit of 
high platelet:PRBC ratios (Perkins et al., 2009) were followed by civilian retrospective 
studies (Holcomb et al., 2008).  A systematic review of studies of platelet:PRBC ratio 
found seven studies that used regression or propensity scoring to address confounders 
(Hallet et al., 2013).  Those reporting on massively transfused patients found a survival 
benefit for high ratios, those studying all transfused patients did not.  Two studies used 
a before and after design (either side of the introduction a high ratio policy) to avoid 
survival bias; one found a benefit.  PROMMTT also considered platelet therapy and 
similarly found a survival benefit associated with achieving a high ratio during the first 
6 hours (Holcomb JB et al., 2013). 
 
                                                 
*
 1:1:1 implies one unit PRBC, one unit FFP and a volume of platelets equivalent to a single donor’s 
contribution to a pool of platelets.  In UK practice, this would equate to one pool for every six units of 
PRBC and of FFP.(Lowes, 2014)  This combination is referred to as reconstituted blood. 
63 
 
The use of platelets in military resuscitation practice carries considerable difficulties.  
Platelet pools are generated by combining the Buffy coat (the platelet-rich layer 
between cells and plasma in centrifuged blood) from several donated units of blood.  A 
pool must contain >240x109 platelets (UK Blood Transfusion & Tissue Transplantation 
Services, 2013) and this is achieved by combining platelets from six donors.  A pool of 
platelets must be mechanically agitated during storage and maintained at a 
temperature of 22 +/- 2°C, presenting logistical challenges in transporting pools to 
remote parts of the world.  A pool must be used by the end of the fifth (exceptionally 
the seventh) day after collection.  Given the time necessary to collect, pool and 
transport platelets to Afghanistan, their shelf life after arriving at the point of use 
during the recent operation there was very short.  Pools generated in the USA were 
even more severely affected by this constraint. 
 
An alternative source of platelets is apheresis in which platelets are removed from 
donor blood which is return to the bloodstream.  Platelets were in this way harvested 
from pre-screened volunteers at Camp BASTION and other bases with military 
hospitals (Jansen et al., 2014).  Generation of platelets for transfusion in this way may 
take 4 hours, so is not a complete substitute for stored pools (Lowes, 2014).  Apheresis 
platelets were used when stored pools were unavailable in the UK hospital but were 
the mainstay of platelet component therapy in US units (Perkins et al., 2009). 
 
3.3.3 Fresh Whole Blood 
 
The drivers of the adoption of component therapy were touched on in subsection 
5.4.1.  However, operations in Iraq and Afghanistan have seen a return to the use of 
fresh whole blood (FWB), chiefly in US practice.  FWB can also be collected from local 
donors, and is available much quicker than apheresis platelets.  It is therefore a useful 
supply in emergencies and a means of ameliorating the logistical problems alluded to 
above.  However, use of emergency FWB precludes virology testing, leucocyte 
depletion and other safety measures.  Reconstituted blood (see footnote to subsection 
5.4.1) is not equivalent to FWB.  The storage media used in the components mean that 
(using US products) reconstituted blood has a haematocrit of 29%, with low platelet 
and clotting factor concentrations (Kauvar et al., 2006).  FWB may have other potential 
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benefits; e.g. leucocyte microvesicles, which express TF, are preserved and may 
support clot initiation (see subsection 2.6.2).  Use of freshly donated blood prevents 
any storage lesion. 
 
Extensive US military experience of FWB usage has raised few safety issues: viral 
contamination rates may be slightly higher than in domestic component therapy but 
this is considered to be offset by the life-saving indications for which FWB is used.  
There is some retrospective evidence that FWB usage has been associated with 
improved outcome relative to those managed with component therapy alone.  In 
particular, Spinella et al showed that FWB was associated with less total transfusion 
and improved mortality when compared with component therapy in an unmatched 
retrospective study of experience in Iraq and Afghanistan (Spinella et al., 2009).  A 
civilian pilot study with a randomised design showed no reduction in transfusion with 
FWB use but may have been confounded by uneven distribution of head inured 
patients between treatment arms: further studies are planned (Cotton et al., 2013). 
 
3.4 Prehospital Use of Blood Products. 
 
3.4.1 Background to Prehospital Transfusion 
 
Blood transfusion became a safe treatment with the development of storage solutions 
and the understanding of blood groups, work led by Peyton Rous in the US (Hess and 
Thomas, 2003).  Rous’s student Robertson developed a practical method and 
apparatus for collecting, storing and administering blood.  He described 44 successful 
transfusions given in a casualty clearing station on the Western Front (Robertson, 
1918).  Thus, transfusion has been used to sustain patients forward of surgical care 
since the earliest days of the treatment.  During the Spanish Civil War (1936-1939), 
Canadian surgeon Norman Bethune revolutionised the use of blood in prehospital care 
by organising mobile transfusion services and advocating his concept of  'taking the 
blood to the wounded and not the wounded to the blood' (Franco et al., 1996).  
Subsequent military prehospital use of blood transfusion has been highly variable.  
Some civilian experience also exists, including in the context of air ambulances (Dalton, 
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1993; Berns and Zietlow, 1998; Green et al., 2013; Lockey, Weaver and Davies, 2013) 
but these accounts do not include a rigorous examination of efficacy. 
 
The decade of conflict in the Middle East and Central Asia has driven a significant 
number of improvements in the medical care of military casualties (Penn-Barwell et 
al., 2015).  Since exsanguination remains a potentially preventable cause of battlefield 
mortality (Kelly et al., 2008), the treatment of hemorrhage has been a significant focus 
of trauma care innovation. The last decade has seen the rehabilitation of tourniquets 
(Kragh et al., 2009), the development of hemostatic dressings (Lawton, Granville-
Chapman and Parker, 2009), improvements in paramedical training and the 
development of deployed trauma systems (Blackbourne et al., 2012). 
 
There has also been an attempt to move the perceived benefits of damage control 
resuscitation into the prehospital arena.  The UK Defence Medical Services have, for 
some time, projected advanced resuscitation capability forward of the hospital 
(O’Reilly, König and Tai, 2008), with demonstrable improvements in mortality 
(Morrison, Oh, et al., 2013). The UK Medical Emergency Response Team  (MERT) is an 
Advanced Medical Retrieval platform (Morrison, Oh, et al., 2013).  In addition to 
standard en route care, the physician-led team can administer resuscitation fluids 
using the intraosseous and central or peripheral intravenous routes, perform chest 
decompression (thoracotomy, tube or open or needle decompression) and drug-
assisted airway management.  The capability was further enhanced by carrying four 
units of PRBC and thawed FFP, for prehospital transfusion. 
 
Patients who might benefit from prehospital blood transfusion (PHBTx) include those 
who would not reach hospital alive without support to cardiac output and oxygen 
transport.  Other patients may reach hospital alive but with profound shock, which is 
associated with adverse effects on coagulation, inflammation and survival.  Earlier 
transfusion may ameliorate these.  Detrimental effects may occur in patients in whom 
the treatment is given unnecessarily but the current clinical consensus is that these are 
outweighed by the benefits in others. 
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3.4.2 Evidence for prehospital transfusion 
 
Chapter 4 of this thesis includes the first comparative analysis of the benefits of this 
strategy in the context of armed conflict.  Two recent US civilian papers are worth 
noting.  Brown et al (2015) on behalf of the Glue Grant group demonstrated a reduced 
24-hour mortality among patients who received blood transfusion prior to admission 
to a Trauma Centre.  There were 50 of these in a cohort of 1415 trauma patients.  
However, 24 of these received blood after admission to a peripheral hospital.  There 
was no explanation of the circumstances or indications for transfusion among the 
remaining 26 patients so the findings of this study are hard to generalise.  Holcomb et 
al (2014) have published a comparison of outcomes between patients admitted via 
two helicopter services, one of which had deployed PRBC and FFP for prehospital 
admission.  Early outcomes such as admission base deficit and transfusion 
requirements were better in patients for whom PHBTx had been available.  However, 
no mortality benefit was seen at 24 hours or 30 days.  Multivariate analysis suggested 
a trend to lower mortality (e.g. at 6 hours OR 0.23, p=0.088).  However, there was 
considerable risk of error due to multiple testing and the analysis had included 
variables that were confounded by the treatment, such as admission coagulation 
assays.  These two studies have not established an evidence base for the practice of 
PHBTx.  An animal study that should be mentioned is that by Sondeen et al (2011).  
They used a swine model of uncontrolled splenic bleeding to demonstrate increased 
blood loss after resuscitation with Hextend (a colloid) when compared with blood 
products.  However, animals resuscitated with Ringer’s lactate did not develop a 
coagulopathy (as the Hextend subjects did) or the (statistically significant) increased 
blood loss, so the model may have simply demonstrated the deleterious effects of 
colloids on coagulation.(Kozek-Langenecker, 2015) 
 
3.4.3 British Military Indications for and Practice of Prehospital Transfusion 
 
Prehospital transfusion is considered for patients without a palpable radial pulse or 
who have a non-invasive systolic blood pressure of less than 80mmHg. The aim is to 
restore these parameters, rather than to resuscitate to normotension, unless a 
traumatic brain injury is suspected, or time to definitive care is anticipated to exceed 
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one hour (Doran et al., 2012).  If more than one unit of PBRC is required, plasma is co-
administered, to achieve a ratio of 1:1. A loading dose of 1g of tranexamic is given to 
all transfused patients.  Platelets are not normally used in prehospital practice. 
 
Blood products are carried in sealed containers consisting of a fabric outer case and a 
vacuum insulated chamber with an inner, removable thermal isolation compartment. 
These devices are capable of maintaining storage temperatures of 2-8°C for up to 24 
hours, in external temperatures of 45°C. The storage temperature is monitored using a 
temperature indicator tag together with single-use time-temperature indicators 
(WarmMark® and ColdMark®, ShockWatch, Dallas, Tx).  Blood products are only 
administered if the tag indicates a green light. Components are warmed during 
administration, using a portable battery operated fluid warming system (enFLow™, GE 
Healthcare, Waukesha, WI).  The hospital is informed during flight if a transfusion 
occurs so that the blood container may be promptly exchanged for a new one with a 
full supply of products.  This process has the clinical benefit of alerting clinical teams to 
the likely arrival of a hemodynamically compromised casualty. 
 
UK guidelines allow red cells stored in saline, adenine, glucose and mannitol to be used 
for up to 35 days (UK Blood Transfusion & Tissue Transplantation Services, 2013).  
There is evidence that as red cell age increases, a storage lesion develops which is 
associated with adverse outcomes in transfused trauma patients (Weinberg, Barnum 
and Patel, 2011).  Consequently, current UK military trauma transfusion practice is to 
use units less than 14 days old, which has the effect of increasing overall wastage at 
times of low usage.  Plasma is newly thawed for prehospital use following which 
unused units are available for use in the base hospital for up to five days.  The 
approach provides non labile clotting factors and reduces wastage (Evans et al., 2013).  
The logistic challenges of maintaining a blood supply to austere settings, and the 
impact of shortage, necessitates a much greater degree of redundancy than in civilian 
systems.  Despite the challenges, wastage of blood products in the UK system has been 
managed, with 65% of PRBC and 80% of FFP units sent to Afghanistan used, which 
compares favorably with US experience (Rentas et al., 2012). 
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Blood directives mandate haemovigilance and the traceability of all blood 
components. The documentation of prehospital transfusion is as per the UK military 
hospital protocol and consists of a double labelling system. One label remains in the 
patients’ records, the other is returned to the pathology laboratory. The exigencies of 
administering a transfusion in a cramped aircraft, sometimes under attack, can make 
this challenging, especially if there are multiple casualties. Nonetheless, the MERT 
prehospital transfusion program achieved 100% traceability. Furthermore, no serious 
side effects or complications of transfusion attributable to units transfused in the 
prehospital setting have been reported.  
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Chapter 4.  Prehospital Transfusion Outcomes 
 
4.1 Introduction 
 
Section 3.4 outlined the introduction of PHBTx into UK military resuscitation practice.  
As already suggested, the purpose was to sustain the lives of exsanguinating patients 
and to draw the practice of DCR into the prehospital arena (O’Reilly et al., 2014).  It 
was intended principally to reduce mortality among injured servicemen but it was also 
suggested that it might reduce morbidity, blood product usage and length of stay in 
ITU.  However, there were concerns that PHBTx could be deleterious under certain 
conditions (e.g. unnecessary transfusions with immune sequelae or efficient volume 
expansion leading to “popping the clot”) and that it was logistically burdensome. 
 
The Flight Intervention and Resuscitation in the Military (FIRM) project was initiated by 
the author under the authority of the Defence Professor of Surgery to assess whether 
routinely collected clinical data could be used to retrospectively assess the impact of 
PHBTx on mortality and other outcomes.  This chapter sets out the process and main 
findings of the original FIRM project. 
 
The introduction of PHBTx usage by the UK MERT coincided with the increasing 
presence of US troops in Helmand province that began in 2008 and was extended by 
an 11,000 troop surge in 2009.  Consequently, there were three main groups of 
patients treated in Camp Bastion: local nationals, UK servicemen and US servicemen.  
The project was intended to assess mortality, morbidity and ITU length of stay but this 
information was not likely to be always available for local nationals as they are moved 
to local facilities once this is clinically suitable and then lost to follow up.  Since UK and 
US servicemen were routinely evacuated while still intubated and ventilated, it was 
essential to have full follow up data for these patients.  The project therefore required 
a unique US-UK data sharing collaboration if it was to proceed.  This was set up as a 
joint project between the Royal Centre for Defence Medicine, Birmingham and the US 
Army Institute of Surgical Research (USAISR), San Antonio, Tx. 
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Other projects based on this data collaboration were quickly established (Morrison, 
Oh, et al., 2013) but do not form part of this thesis.  The author initiated the FIRM 
project and created the initial study design.  The author collaborated with others in 
obtaining the necessary ethical approvals and data access.  The author is particularly 
indebted to Maj J Morrison for his work with colleagues at USAISR to match records 
from the three source databases to produce the FIRM dataset.  Preliminary analysis 
carried out by the author with statistical staff at USAISR revealed that deficiencies in 
the available data would mandate a novel study design to achieve the desired matched 
cohorts of PHBTx recipients and controls.  The author produced the initial version of 
this which was then modified on advice from the project statistician.  The matched 
cohorts were produced according to this new methodology (for which credit is due to 
Dr A Apodaca-Morrison) and the author then carried out the statistical analysis.  In 
order to properly differentiate the author’s contribution to the work being reported, 
the methods section of this chapter will detail the author’s proposals and the ways 
these were altered. 
 
4.2 Aim and Hypothesis 
 
The purpose of this work was to assess what information about the clinical benefits (or 
risks) of PHBTx could be gleaned from the available human data.  To facilitate this, the 
study was designed to evaluate the hypothesis that the provision of PHBTx to injured 
personnel led to a reduction in mortality when compared with similarly injured 
patients who did not receive PHBTx 
 
4.3 Methodology 
 
4.3.1 Sources of Data 
 
This study was approved by the Royal Centre for Defence Medicine Academic Unit and 
the US Army Medical Research and Materiel Command.  Data was obtained from three 
sources: the UK Joint Theatre Trauma Registry (JTTR), the US Department of Defence 
Trauma Registry (DoDTR) and the UK prehospital MERT database.  The JTTR includes 
demographic, injury, treatment and outcome data on all UK personnel hospitalised 
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due to injury while deployed and on all non-UK personnel treated in UK facilities.  
Injuries are coded using the Abbreviated Injury Score (AIS) system.  (See the Appendix 
for further discussion of injury coding.)  The DoDTR has a similar remit for US 
personnel and facilities.  In both cases, data collection on foreign nationals ceases at 
the point that they leave the national treatment facility or evacuation chain, whereas 
data on own-nation personnel is continually updated (and corrected) until after the 
serviceman has been discharged from medical care.  As such, DoDTR data about US 
servicemen will be more accurate than JTTR data, as it will capture late mortality and 
morbidity, length of stay and corrections to injury data in the light of fuller evaluation.  
JTTR and DoDTR records were completed by dedicated trauma nurse co-ordinators 
(TNCs); at Camp BASTION the UK and US TNCs shared an office but used separate 
systems.  The MERT database covers all patients treated by the MERT, including those 
evacuated to sites other than BASTION.  It was completed by MERT personnel and 
includes mission data (e.g. flight times) and treatment details. 
 
Each database used its own patient identifiers, albeit with some inconsistent cross-
referencing.  To resolve this, an algorithm was used to match patients’ time and date 
of injury, demographics and injuries.  (The author is grateful to Dr J Jones, USAISR for 
this work.)  This produced a single FIRM dataset. 
 
4.3.2 Initial Study Design 
 
The initial proposal was to use a propensity score-based matching process to establish 
matched cohorts of PHBTx recipients and non-recipients.  Propensity scoring is used 
when a study population includes a mixture of persons who were and were not 
exposed to a treatment (or other factor of interest).  The concept is that exposed cases 
are matched with similar non-exposed cases such that known confounders of the 
outcome of interest may be evenly distributed.  This is intended to mimic the benefits 
of using randomisation in prospective studies (albeit the latter can also distribute 
unknown confounders).  A multivariate logistic regression is used to build a model that 
calculates the chance that any given subject would receive the treatment if it were 
available; this is the propensity score.  A propensity score is calculated for each 
treatment recipient and a control case is selected with a similar propensity score.  This 
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produces pairs of recipients and controls, necessitating the use of appropriate 
statistical tests (Austin, 2008). 
 
The important data fields in the FIRM dataset were: 
 Demographics (age, sex, national status) 
 Mechanism of injury 
 Injury details (AIS codes of all identified injuries) 
 Initial prehospital observations (HR, RR, GCS, SpO2) recorded by 
MERT/PEDRO/DUSTOFF personnel 
 Prehospital treatment (PHBTs, airway, vascular access, chest decompression) 
 Timings (Time and date of incident, helicopter arrival and departure, arrival at 
hospital, start of surgery) 
 Observations on arrival at hospital  (HR, RR, GCS, SpO2, BP) 
 In-hospital treatment (blood products, rFVIIa, TXA and others) 
 Hospital (i.e. BASTION) length of stay 
 Disposal (e.g. local national patients transferred to host nation facilities) 
 Mortality outcome 
 
The patients were divided into three groups:  Those brought in by MERT before PHBTx 
was available (pre-PHB), those brought in by MERT after PHBTx was available (post-
PHB) and those brought in by platforms that were never equipped with PHBTx.  The 
latter group will not be considered further until the discussion.  Only those data fields 
that could not be affected by the intervention could be used in generating the 
propensity score.  This includes demographic and injury data and prehospital 
observations.  It excludes observations on admission to hospital.  Many severely 
injured patients in both groups, including several PHBTx recipients had incomplete or 
non-existent prehospital observations.  Indeed there appeared to be a relationship 
between the severity of injury and the likelihood of prehospital observations being 
absent and a change in the chance of their being recorded over time.  This is 
understandable: the constrained, dark, moving and sometimes dangerous 
environment aboard a helicopter in a combat area makes observations difficult.  The 
more severely injured a patient is, the more important it is to concentrate on 
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immediately life-saving interventions rather than on accurate data recording.  
Recording may have become more common as familiarity with the environment grew 
and training improved.  However, this potentially created a confounding relationship 
between the recording of these data and outcome.  To use the prehospital 
observations might therefore have introduced bias into the results.  It was concluded 
that prehospital observations could not be used as a basis of the propensity score. 
 
Logistic regression on the dependent variable of PHBTx usage in the Post-PHB group 
was carried out.  ISS was used as a summary statistic for the AIS codes.  The other 
independent variables were the patient demographics, the mechanism of injury and 
the time from injury to arrival at hospital.  Given the lack of direct data about 
transfusion triggers (i.e. prehospital observations), the model generated was heavily 
dominated by the ISS.  Given the limitations of ISS laid out in the Appendix, it was 
thought likely the model would generate pairs that were well matched for ISS but not 
necessarily well matched for the underlying factor of interest, i.e. their injury pattern.  
Ideally, prehospital observations would have compensated for this by matching 
patients according to their physiological response to injury, but these were 
unavailable.  An alternative method of generating matches was therefore required. 
 
4.3.3 Proposed revised methodology 
 
The author proposed a novel matching methodology designed to produce close 
matching of injury profile.  The three most severe AIS codes for each patient were to 
be used, regardless of body region (following a convention derived from the method of 
calculating NISS).  Since age and sex were somewhat consistent among US and UK 
recipients (i.e. mostly young men), the analysis would exclude local nationals and 
ignore these demographic factors.  Each recipient would then be matched with a 
control from the pre-PHB group with the same: 
 Mechanism of injury 
 Three most severe injuries as defined by their severity and body region 
o e.g. matching AIS4 lower limb, AIS3 lower limb and AIS3 abdomen 
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Where such an exact match was not possible, an algorithm would be required to select 
close matches, ranking these and setting a minimum acceptable level of matching.  The 
algorithm would also need to ensure that each potential control was only selected 
once and attempt to maximise the closeness of matching overall.  This outline was 
submitted to the project’s statistical advisors who then worked on generating a usable 
methodology.  Discussions led to agreement that it would be desirable to include local 
nationals and account for demographic factors.  This led to the development of the 
final methodology set out below.* 
 
4.3.4 Final Matching Methodology 
 
Patients who were administered prehospital blood products (recipients) were paired 
with patients transported before 1 July 2008 who would have been expected to 
receive prehospital transfusion if it had been available.  A logistic regression was 
conducted in the Post-PHB cohort with receipt of PHBTx as the dependant variable 
using the variables sex, age, patient category (i.e. national status), mechanism of 
injury, and detailed injury data.  This was used to provide a propensity score for the 
second stage of the matching process laid out below.  The three most severe 
Abbreviated Injury Scale (AIS) codes for each patient, irrespective of body region, were 
included as variables in the regression model.  An algorithm was then created to parse 
the first three digits of the AIS code for each injury to determine the fundamental 
injury descriptors: (1) body region of injury (head, face, neck, thorax, abdomen, spine, 
upper extremity, lower extremity, and other), (2) anatomic region (whole area, vessels, 
nerves, organs/muscles, skeletal/joints, and loss of consciousness), and (3) specific 
forms of injury (abrasions, lacerations, contusions, amputations, burns, etc). 
 
Matching proceeded in two stages.  First, Recipients patients were matched with one 
or more Pre-PHB patients with similar detailed injury data.  Preference was given to 
exact injury code matches for all three injuries.  Where this was not possible an 
algorithm was used to progressively expand the range of acceptable AIS matches.  
Second order matches were based on severity and descriptors 1-3 above, third order 
                                                 
* The author was responsible for the proposed methodology as set out in the preceding paragraph.  The 
changes made to produce the final methodology are largely credited to Dr Apodaca-Morrison. 
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matches were based on severity and descriptors 1 and 2 above, and so on.  The 
algorithm stopped when a selection of potential matches was available with equivalent 
goodness-of-fit, e.g. two potential matches with a single first-order AIS match and two 
second order AIS matches.  Greedy matching20 was then used to select the potential 
control with the most closely matched propensity score (as calculated based on the 
described logistic regression). Once a match was made it was not reconsidered; in the 
event that more than one unmatched control fitted to a case with equal propensity 
score, the control chosen for pairing was selected at random by the algorithm.  This 
process is illustrated in Figure 4.1.*  
 
This process produced groups of patients, matched recipients and matched non-
recipients, consisting of matched pairs (Austin, 2008),  Consequently, categorical data 
were analysed using McNemar’s test, non-parametric data using Wilcoxon’s signed-
rank test.†  The primary outcome was mortality.  Admission observations and total 
PRBC and FFP use were secondary outcomes.  P<0.05 on two-tailed testing was 
determined to be significant. 
 
Mortality for UK and US personnel was defined as death within 30 days of wounding. 
For other patients, follow-up was limited to the in-hospital stay in Afghanistan.  This 
approach is pragmatic, and has been employed previously (Morrison, Oh, et al., 2013), 
as it is impossible to track the progress of casualties from other countries through their 
respective evacuation chains.  The chance of this introducing bias should be small since 
patients were only transferred to local facilities once their clinical progress was such 
that they were thought no longer to need the advanced facilities at BASTION.  
Transfusion volumes pertain to the first 24 hours. 
 
                                                 
*
 This process was conducted by Dr Apodaca-Morrison; all other steps of the analysis were conducted by 
the author. 
† Inspection and graphing of the data showed a great deal of skewed data, so non-parametric tests were 
used throughout. 
76 
 
 
 
Figure 4.1  Matching process.  Each cartouche represents a patient.  On the left, a PHBTx patient’s injury complex is broken down and the 1st, 2nd and 
3rd most severe AIS codes are used for matching.  Each AIS code is broken down to its four principle components A to D: A—Severity; B—Body 
region, C—Organ, D—Form of injury.  On the right, four patients from the period before PHBTx became available are selected as possible matches.  
In this case, the potential matches have two exactly matching injuries but the third injury is only matched for severity and body region.  Each potential 
match has been labelled with its propensity score, i.e. the probability that the patient would have been administered PHBTx had it been available.  The 
potential match with the closest propensity score match is chosen to become the matched non-recipient. 
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4.4 Results 
 
A total of 1592 patients were included: 439 before 1 July 2008 (Pre-PHB) and 1153 
thereafter (Post-PHB).  Table 4.1 compares the two cohorts.  The rate of severe injury 
(ISS 16 or greater) rose from 28% to 42.5% (p<0.001, Chi-square) between the two 
cohorts.  Mortality was higher in the Post-PHB group.  However, mortality among 
severely injured Post-PHB patients was 134/485 (27.6%) whereas it was 39/122 
(32.0%) in the Pre-PHB cohort (p=0.343, Chi-square). 310 of the later group (26.9%) 
received a prehospital blood transfusion during transfer.  Table 4.2 shows the 
characteristics of the 310 PHBTx recipients.  Prehospital transfusion was given to 48% 
of severely injured patients (ISS of 16 or more).  76.7% of recipients were severely 
injured, mostly as a result of explosions. Almost one-half of patients required intra-
osseous circulatory access and/or advanced airway management. The median 
(interquartile range [IQR]) number of units of PRBC and FFP transfused prehospital was 
2 (1-2).  The median (IQR) total transfusion volume at 24 hours was 8u (range 3-18) 
PRBC and 7u (range 2-16) FFP.  Nearly one-half of patients required a massive 
transfusion (>10 units while at Camp Bastion), although one-fifth required no further 
transfusion after admission. 
 
Ninety seven of the 310 patients who received PHBTx were paired with patients from 
the Pre-PHB cohort (Figure 4.2).  Table 4.3 shows the matched characteristics.  The 
groups had excellent matching of injury profiles with 89 in each group being severely 
injured.  Table 4.4 shows the treatments received and outcomes for both groups.  The 
mortality rate in the pre-hospital transfusion recipients was half that of non-recipients 
(8.2% v 19.6%; p=0.013, McNemar).  There was also a small improvement in admission 
heart rate though not in other observations.  However, matched recipients received 
more prehospital airway interventions and reached hospital more quickly than non-
recipients.  Matched recipients patients received more blood products overall (Figure 
4.3) and in higher FFP:PRBC ratios. 
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Figure 4.2.  Study population flow chart.  Pre-PHB/Post-PHB: Study cohorts before and after, 
respectively, the introduction of prehospital blood transfusion (PHBTx). 
Matched recipients:  PHBTx recipients successfully paired with patients from the Pre-PHB cohort with 
similar injury profiles and high propensity scores for receiving PHBTx, had it been available to them. 
MERT Medical Emergency Response Team; JTTR Joint Theatre Trauma Registry; DoDTR Department of 
Defence Trauma Registry 
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Figure 4.3  Units of PRBC and FFP transfused in the first 24 hours in hospital to matched recipients and 
non-recipients of prehospital transfusion. 
Boxes show interquartile range with median.  Whiskers show range.  Groups compared with Wilcoxon 
signed rank test: PRBC Packed red blood cells, FFP Fresh frozen plasma. 
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  Pre-PHB Post-PHB P values  
N  439 1592  
Age  23 (21-28) 23 (20-27) 0.277† 
Patient 
Category 
UK Military 214 (48.7) 642 (55.7) <0.001* 
Coalition 
Military 
129 (29.4) 288 (25.0)  
Afghan  96 (21.9) 223 (19.3)  
Sex Male 425 (96.8) 1116 (96.8) 1* 
Mechanism of 
Injury 
Blunt 25 (5.7) 43 (3.7) <0.001* 
Burn 4 (0.9) 8 (0.7)  
Explosive 246 (56.0) 809 (70.2)  
GSW 163 (37.1) 286 (24.8)  
Other 1 (0.2) 7 (0.6)  
Military ISS  5 (2-16) [1-75] 9 (4-25) [1-75] <0.001† 
Military NISS  8 (3-20) [1-75] 14(5-34) [1-75] <0.001† 
AIS≥3 Head and Neck 43 (9.8) 119 (10.3) 0.853* 
 Face 1 (0.2) 10 (0.9) 0.308* 
 Chest 50 (11.4) 151 (13.1) 0.399* 
 Abdomen 29 (6.6) 141 (12.2) 0.001* 
 Extremity 95 (21.6) 421 (36.5) <0.001* 
 External 7 (1.6) 15 (1.3) 0.636* 
 
Table 4.1.  Comparison of patients admitted before the introduction of PHBTx (Pre-PHB), those admitted 
afterwards (Post-PHB).  P values are shown for significant results in the comparison of Pre-PHB and Post-
PHB. Categorical data are shown as n (%) and compared using Fisher’s exact test (*).  Ordinal and scale 
data are shown as median (IQR) with [range] added where relevant and compared using the Mann-
Whitney U test (†).  Significant results shown in bold. 
  
81 
 
  PHBTx recipients 
Age  24 (21-27) 
Patient Category UK Military 131 (42.3)  
Coalition Military 94 (30.3) 
Afghan  85 (27.4) 
Sex Male 302 (97.4) 
Mechanism of Injury Blunt 3 (1.0)  
Burn 1 (0.3) 
Explosive 226 (72.9) 
GSW 80 (25.8) 
Other 0 (0) 
Military ISS  20 (16-29) [1-75] 
Military NISS  29 (18-48) [1-75]  
AIS 3 or greater Head and Neck 26 (8.4) 
 Face 3 (1.0) 
 Chest 65 (21.0) 
 Abdomen 68 (22.0) 
 Extremity 215 (69.6) 
 External 4 (1.3) 
Prehospital interventions Intraosseous access 140 (45.2)  
 Advanced airway 130 (41.9)  
 Chest decompression 38 (12.3)  
Prehospital time (min)  61 (47-90) [25-1034]  
Admission observations Prehospital arrest 7 (2.7)* 
Systolic BP 122 (92-142)  
Respiratory rate 18 (12-20) 
Heart rate 105(80-125)  
Prehospital transfusion PRBC 2 (1-2) [0-4]  
FFP 2 (1-2) [0-4]  
In hospital transfusion PRBC 7 (1-15) [0-82]  
FFP 6 (1-14) [0-70]  
Cryoprecipitate 0 (0-1) [0-20]  
Platelets 0 (0-3) [0-18]  
Total PRBC  8 (3-18) [0-85]  
Total FFP  7 (2-16) [0-74]  
Any hospital PRBC transfusion 248 (80)  
Massive transfusion 146 (47.1) 
Tranexamic acid  119 (38.4) 
rFVIIa  33 (10.6)  
Mortality  62 (20)  
 
Table 4.2.  Injury profile of all patients who received prehospital blood transfusion.  Data are displayed 
as n (%) or median (IQR) with [range] in some cases.  Hospital blood product usage shown for the first 24 
hours.  Massive transfusion defined as 10 or more units PRBC in 24 hours.  PHBTx Prehospital Blood 
Transfusion; ISS Injury Severity Score; NISS New Injury Severity Score; AIS Abbreviated Injury Scale; PRBC 
Packed Red Blood Cells; FFP Fresh Frozen Plasma; TXA Tranexamic Acid;  rFVIIA Recombinant Activated 
Factor VII.  *Excludes 16 patients with no recorded admission observations.  
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    Recipients Non-Recipients P value 
N  97 97  
Age   24 (20-28) 23 (21-28) 0.975 
Patient 
Category 
UK Military 45 (46.4) 38 (39.2) 0.248 
Coalition Military 31 (32) 45 (46.4) 
 
Afghan Civilian 21 (21.6) 14 (14.4) 
 
Sex Male 95 (97.9) 97 (100) u/t 
Mechanism 
of Injury 
Blunt 1 (1) 3 (3.1) u/t 
Burn 0 (0) 0 (0) 
 
Explosive 50 (51.5) 48 (49.5) 
 
GSW 46 (47.4) 46 (47.4) 
 
Other 0 (0) 0 (0)   
Military ISS   16 (9-25) 16 (9-24.5) 0.686 
Military NISS  22 (15-33) 21 (14-34) 1 
AIS 3 or 
greater 
Head/Neck 0 1 (1) 1 
Face 0 1 (1) 1 
Chest 24 (24.7) 25 (25.8)  1 
Abdomen 18 (18.6) 18 (18.6) 1 
Extremity 67 (69.1) 65 (67) 0.727 
External 2 (2) 3 (2) 1 
 
Table 4.3.  Matched characteristics of paired groups of patients who did and did not receive PHBTx. 
Categorical data are shown as n (%) and compared using McNemar’s test.  Ordinal and scale data are 
shown as median (IQR) and compared using the Wilcoxon signed-rank test.   
u/t – Untestable due to limitations of McNemar’s test (due to zero value or multiple categories; Patient 
category was dichotomised to coalition/Afghan to allow testing)  
ISS Injury Severity Score; NISS New Injury Severity Score. 
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    Recipients Non-Recipients P value 
N  97 97  
Prehospital 
interventions 
Intraosseous access 14 (14.4) 16 (16.5) 0.824 
Advanced airway 19 (19.6) 9 (9.3) 0.041 
Chest 
decompression 
19 (19.6) 22 (22.6) 0.629 
Prehospital time (min) 68 (50-100) 109.5 (70 – 171) 0.008 
Admission 
observations 
Cardiac arrest 7 (7.2) 9 (9.3) 1 
Systolic BP 132 (111-145) 131 (114-150) 0.145 
Respiratory rate 19 (15-24) 20 (16-26) 0.173 
Heart rate 92 (74-115) 105(82-128) 0.041 
TXA 
 
22 (22.6)  0 (0) u/t 
rFVIIa   2 (2)* 10 (10.3) 0.033 
Prehospital 
transfusion 
PRBC 1 (1-2) [0-4] n/a 
 
FFP 2 (1-2) [0-4] n/a 
 
In hospital 
transfusion 
PRBC 2 (1-8.5) [0-49] 0 (0-3.5) [0-26] <0.001 
FFP 2 (0-7.5) [0-44] 0 (0-1) [0-20] <0.001 
Cryoprecipitate 0 (0-0) [0-4] 0 (0-0) [0-3] 0.068 
Platelets 0 (0-0) [0-7] 0 (0-0) [0-6] <0.007 
Total PRBC 
 
4 (2-10) [0-53] 0 (0-3.5) [0-26] <0.001 
Total FFP   2 (2-9) [1-44] 0 (0-1) [0-20] <0.001 
Any in-hospital PRBC transfusion 75 (77) 38 (39) <0.001 
Massive transfusion 12 (12) 8 (8) 0.388 
FFP:PRBC 
ratio 
  1 (0.83-1.23) 0.46 (0-0.72) <0.001 
Mortality   8 (8.2) 19 (19.6) 0.013 
 
Table 4.4.  Treatment and outcomes of matched groups of patients who did and did not receive PHBTx.  
Categorical data are shown as n (%) and compared using McNemar’s test.  Ordinal and scale data are 
shown as median (IQR) with [range] added where relevant and compared using the Wilcoxon signed-
rank test.   
Significant results shown in bold. 
u/t – Untestable due to limitations of McNemar’s test. (due to zero value) 
PRBC Packed Red Blood Cells; FFP Fresh Frozen Plasma; TXA Tranexamic acid; rFVIIa Recombinant 
Activated Factor VII 
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4.5 Discussion 
 
4.5.1 Methodological Validity 
 
A matched cohort design was employed, using an effective novel matching technique 
that produced similar injury complexes within each pair.  Thus it minimised the effect 
of the confounding variables that are included in the process.  (The substantial effect 
of unmeasured confounders is discussed below.)  The lack of prehospital observations 
was undesirable.  Close matching of injuries was intended to compensate for this.  ISS 
and NISS have been criticised on many grounds (see the appendix for a more in depth 
treatment of injury coding) (Lefering, 2002).  In particular, they conflate injury 
patterns, which both loses information about particular injuries and makes very 
different injuries (e.g. severe head injury and proximal limb amputation) essentially 
interchangeable (Russell et al., 2004).  This method therefore sought to match patients 
much more closely, making fuller use of the information contained in the AIS coding of 
the patient’s injuries by using the approach described.  This is a novel application of 
established techniques which may have wider applicability in the analysis of injury 
data, particularly if combined with physiological data.  The group of potential historical 
controls was considerably smaller than the equivalent group after the introduction of 
PHBTx (439 v 1153).  As such, it was inevitable that only a minority of PHBTx recipients 
would be matched to suitable controls.  It is possible that this could introduce some 
element of selection bias.  However, it is inevitable that matching recipients to 
patients from a cohort with less severe injuries selects for less severely injured 
recipients.  It is conceivable that the recorded effect would have been larger if more 
severely injured recipients and non-recipients had been included in the comparison.  In 
a related analysis looking at the effect of different medical retrieval platforms, a 
benefit of the MERT platform (including PHBTx) over others was only demonstrated in 
the ISS range 16-50, so this may not be the case (Morrison, Oh, et al., 2013). 
 
It is impossible to test in this dataset whether the methodology succeeded in 
compensating for the missing prehospital observations.  Since paired tests were used, 
significant results could have been generated by either between-group difference due 
to treatment effects or by poor matching of physiological response to injury within the 
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pairs.  The latter was not seen in the available data: admission observations were 
similar in the two groups. 
 
A facet of propensity score methodology deserves comment.  The conventional 
practice of selecting the potential control with the propensity score most closely 
matched to that of the recipient was implemented.  This is intended to give controls 
with similar characteristics to the recipients, thereby reducing the effect of measured 
confounders in the outcome analysis.  It is possible for the predictors of exposure 
(receiving PHBTx) and of outcome (mortality) to be orthogonal to one another.  At the 
extreme, if exposure were determined by hair colour and outcome by age then a 
propensity score methodology would match on the former alone, potentially leaving 
differences between the groups and, crucially, within pairs on the latter.  More 
realistically, factors may be very differently weighted in how they contribute to the 
propensity score and to outcome.  Thus, a similar propensity score may be arrived at 
based on many differing combinations of underlying characteristics, and the predicted 
outcome of these may vary wildly.  An example in this context might be severe head 
injury: it would have a profound effect on mortality but may have little correlation 
with whether a patient would receive PHBTx.  The present methodology goes some 
way to ameliorating this problem.  A more usual approach is to use multivariate 
analysis of the matched cohorts, employing generalised estimating equation 
methodology (Austin, 2008).  The number of matched cases was insufficient to allow 
this in the present study. 
 
4.5.2 Implications of the Results 
 
There was a large increase in total blood product usage between the two matched 
groups with median PRBC usage increasing from 0 to 4 (p<0.001, Wilcoxon) and from 2 
to 7 among those with ISS 16 or more (p<0.001).  This was despite the fact there was 
no increase in the proportion requiring massive transfusion (over 90% of pairs were 
concordant as to whether they received 10 or more units PRBC).  It is known that there 
has been a steady increase in blood product usage in recent years (Jansen et al., 2014).  
There was a significant difference in usage between the pre- and post-PHB time 
periods (Table 4.1).  Severely injured pre-PHB patients who were transfused received a 
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median (IQR) of 6 (3-12) units PRBC.  Equivalent post-PHB patients who did not receive 
PHBTx received 10.5 (4.5-22) units, a significant increase (p=0.003, Mann-Whitney), 
see Figure 4.4.  The PRBC usage in severely injured post-PHB patients who did receive 
PHBTx was 12 (4-19) units, which is not significantly higher than the latter group 
(p=0.9, ISS and NISS were also similar).  In addition, the FFP:PRBC ratio differed 
markedly between the matched groups.  The 11 excess survivors in the intervention 
group are inadequate for survivorship bias to fully explain the increased total volumes 
and ratios.  Therefore there was a large secular change in resuscitation practice 
between the two groups beyond the provision of a pre-hospital transfusion capability.   
 
 
 
Figure 4.4  Total units of PRBC transfused in the first 24 hours to severely injured (ISS>15) patients who 
received any PRBC or FFP and: 
 Were admitted before PHBTx was available (Pre-PHBTx), 
 Were admitted after PHBTx was available but did not receive PHBTx (No-PHBTx), 
 Received PHBTx (PHBTx). 
Boxes show interquartile range with median.  Whiskers show range.  Groups compared with Mann-
Whitney U test. 
ISS Injury severity score, PRBC Packed red blood cells, FFP Fresh frozen plasma, PHBTx Prehospital blood 
transfusion. 
 
Other factors which may confound the analysis of mortality were identified.  The fall in 
prehospital times probably reflects changes in the deployment of forces in Helmand 
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Province during the study period, with the arrival of US Marine Corps units 
accompanied by US aeromedical assets.  “Intelligent tasking” of aeromedical assets 
was implemented, whereby a combination of clinical, operational and logistic 
considerations drove the choice of which US (Army DUSTOFF or Air Force PEDRO) or 
UK (MERT) capability was deployed to a given casualty incident.  While quick 
transportation to hospital is no doubt beneficial to the casualty, selection of the larger, 
more clinically capable MERT platform during the post-PHB period may be an indicator 
of enhanced casualty burden.  This could be individual (i.e. the casualty’s injuries and 
condition) or collective (i.e. the number of casualties).  MERT can transport 8 casualties 
as opposed to 2 for DUSTOFF and PEDRO.  Thus the effect of the time from injury to 
admission is very difficult to assess.  The increased rate of prehospital procedures 
could represent increased need but, anecdotally, there seems to have been a lowered 
threshold for intervention in combination with the evolution and routine 
implementation of Standard Operating Procedures.  For example, rapid sequence 
induction is now used more as a definitive form of analgesia or where the requirement 
for general anaesthesia to facilitate surgery is anticipated (“expected clinical course”).  
The routine use of TXA and decreased rFVIIa use represent the effects of opposing 
trends in the evidence base for the two drugs (CRASH-2 trial collaborators, 2010; 
Hauser et al., 2010; Morrison, Dubose, et al., 2012). 
 
Therefore, no clear assessment of the hypothesis, which relates to the isolated benefit 
of PHBTx, can be made.  However, the data provide evidence that DCR in combination 
with intensive prehospital intervention including PHBTx is associated with substantial 
improvements in mortality (although the contributions of the various components 
cannot be determined and the prehospital time remains a confounding factor).   
 
Haemostatic resuscitation was introduced in the Post-PHB period, in that blood 
products were used frequently, early and in high FFP:PRBC ratios (Jansen et al., 2014). 
Rotational thromboelastrometry was deployed to guide coagulopathy management 
(Doran, Woolley and Midwinter, 2010).  Transfusion volumes are often interpreted as 
a proxy for blood loss.  Counter-intuitively, the “haemostatic” regime involved much 
larger total transfusion volumes.  This practice has been demonstrated to be able to 
correct physiological derangement in very severely injured combat casualties 
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(Morrison, Ross, et al., 2013).  These patients often need extensive debridement 
which, in the context of normotension with euvolaemia, may require considerable 
transfusion support.  It contrasts with DCR practice as described by others where 
conservation of blood products has been reported as one of the advantages of 
haemostatic resuscitation (Cotton et al., 2011). 
 
4.5.3 Policy Response 
 
 The data shown here were presented as a preliminary analysis at a meeting chaired by 
the Medical Director of the UK Joint Medical Command, the senior officer responsible 
for clinical research.  Prior to this, exploratory examination of scanned copies of 
patients’ notes and of the hospital laboratory information system and data available 
from the deployed ROTEM consoles indicated that it would not be possible to develop 
adequate coagulation or blood gas data to allow analysis.  Critical care follow up data 
was available for UK patients but would be difficult to obtain for US patients (since it is 
not held in any central database).  In any case, such further outcome analyses would 
suffer the same confounders as the mortality comparison.  The meeting directed that 
these should not be pursued. 
 
There was considerable debate as to whether a further analysis should be conducted 
using patients transported by non-MERT platforms as the potential controls.  The 
advantage of this would be that these patients were contemporary with the PHBTx 
recipients and therefore the analysis would not be confounded by differences in 
hospital management.  However, this analysis would involve differences in prehospital 
care much more significant than those seen in the present analysis.  Given the 
additional sensitivity of comparison of different national prehospital platforms and 
practices, the meeting also directed that this analysis should not proceed. 
 
4.5.4 Implications for Further Research 
 
There is very little evidence to support the use of PHBTx.  Neither the recent papers by 
Brown et al (2015) or Holcomb et a l(2014) nor this analysis establish strong evidence 
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in its favour.  In a separate analysis of UK military data, using a different methodology, 
Smith et al have also found no evidence of benefit (Smith et al., 2014). 
 
Concerns about its safety and logistic implications must therefore remain.  While the 
present analysis may show some support for PHBTx in military practice, it does not 
follow that this can be transferred into civilian usage.  The relative infrequency of 
severe injury in civilian practice could mean that its carriage by civilian prehospital 
services would lead to its use among a very different patient population where the 
risks and benefits may be differently balanced.  Where a patient is apparently 
exsanguinating, there can be little doubt that PHBTx is an appropriate treatment 
(though secondary to stanching the flow).  In all other circumstances, there cannot be 
certainty as to its usefulness.  Accordingly, it should be possible to define a population 
in which a sufficient degree of equipoise exists to support the randomisation of 
patients.  Randomised control trials are already proposed in the civilian setting: 
RePHILL (Prof M Midwinter, personal communication) and PAMPer (Brown, Guyette, 
et al., 2015), and these should be supported. 
 
Randomised research faces additional barriers in military practice, although 
randomised therapeutic trials have been conducted recently (Fries et al., 2014).  
However, the withdrawal of UK and US forces from Afghanistan represents the end of 
the opportunity to carry out such research, which unhappily was not pursued earlier in 
recent conflicts.  Additionally, the perception of the efficacy of PHBTx among military 
prehospital practitioners is so strong as to make randomisation impossible even if it 
was a practical option for several years. 
 
This work established that there was insufficient human data to demonstrate a benefit 
of PHBTx.  Given this, and the lack of information about the physiological and 
coagulation effects, the only option to explore the impact of this treatment in the 
context of military trauma at present is the use of an animal model. 
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5 Methodological Background to Work in the Animal Model 
 
The preceding chapter established the need for an animal model to study prehospital 
transfusion.  The remainder of this thesis concerns work carried out in that animal 
model of severe military trauma, which was designed for the evaluation of 
haemostatic resuscitation regimes.  The model was developed with a view to carrying 
out a randomised control trial comparing simulated prehospital transfusion with 
conventional resuscitation.  As discussed in Chapters 2 and 3 the roles of platelets in 
traumatic coagulopathy and of platelet in trauma resuscitation have not been fully 
elucidated.  Consequently, means of evaluating platelet function were required so 
these could be studied in the proposed RCT and in later work.  Therefore, in parallel 
with the model development, a flow cytometry assay of platelet activation and 
response to agonist was developed.  This became the focus of the author’s work and is 
detailed in the next two chapters. 
 
This chapter begins with a discussion of the coagulation assays, including those that 
address platelets, which were used in the model.  It then focuses on an exploration of 
the technique of flow cytometry, which is fundamental to understanding the 
development and assessment of the platelet assay laid out in the next two chapters.  
Although the development of the animal model is outside the scope of this report, this 
chapter ends with comments about the role of animal models and about the necessary 
modifications to the previously discussed Dstl animal model of combat injury. 
 
5.1 Coagulation Assays 
 
The design and validation of the platelet assay was part of the wider selection of 
assays of the coagulation system.  These included standard laboratory tests and 
thromboelastography (TE). 
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5.1.1 Laboratory Clotting Assays 
 
Standard laboratory assessments of coagulation, prothrombin time (PT) and activated 
partial thromboplastin time (APTT), were used.  PT (or its derivative, INR) and APTT 
have been shown to correlate with outcomes after trauma (MacLeod et al., 2003; Dirks 
et al., 2010; Johansson et al., 2011b).  However, these tests were designed to detect 
deficiencies of procoagulant factors and therefore do not reflect abnormalities of 
natural anticoagulants (Tripodi, Chantarangkul and Mannucci, 2009).  They are also 
unaffected by platelet number and function.  These facts, and the clinical advantages 
of near patient testing, have led to increased interest in assessment by rotational TE. 
 
5.1.2 Thromboelastometry 
 
Two commercial systems are available, each involving the stimulated clotting of blood 
in a cup while assessing the forces applied by the clot on a wire suspended centrally 
within it: 
 ROTEM—the wire (in fact a pin) rotates within the cup. 
 TEG—the cup rotates around the wire. 
The force is recorded as a deflection in the TE trace (see Figure 5.1).  Compared with 
laboratory tests, TE is more clinically convenient, rapid and informative: Table 5.1 
shows how different components of a TEG trace are thought to correlate with 
components of the coagulation system. 
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Figure 5.1  Viscoelastic haemostatic assays terminology and parameters 
α, alpha angle; AUC, area under the curve; CFT, clot formation time; CL (t), clot lysis (at time t); CT, clot 
time; k, rate of clot formation; LY (t), lysis (at time t); MA, maximum amplitude; MAXV, maximum 
velocity; MAXV-t, time to maximum velocity; MCF, maximum clot firmness; MCF-t, time to maximum 
clot firmness; ML, maximum lysis; r, time to clot initiation; ROTEM, Rotational Thromboelastogram; RT, 
reaction time; TEG, Thromboelastograph; TMA, time to maximum amplitude; '-'; no equivalent 
parameter. 
Reproduced by kind permission of Dr Roger Luddington, Addenbrooke's Hospital, UK.  See Table 5.1 for 
explanation of those elements used in this thesis. 
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Table 5.1  Key TEG and ROTEM terms used in this thesis, with attention to the contribution of platelets 
to these. 
 
TEG 
term 
ROTEM 
term 
Physiological correlate Platelet contribution 
R CT Time from activation until the 
formation of thrombin 
adequate to lyse fibrinogen, 
i.e. this represents the action 
of clotting factors upstream of 
thombin and is related to the 
processes of initiation and 
amplification. 
Platelets provide the site on 
which clotting factors come 
together, many of them being 
bound to the platelet surface 
during physiological clotting. 
Α α Predominantly the speed of 
generation of fibrin which, 
except in profound 
hypofibrinogenaemia, is 
usually determined by the 
quantity of thrombin 
generated. 
In viscoelastic tests, clotting 
factor activation precedes 
and causes platelet 
activation, which then 
contributes to clot strength 
through platelet aggregation, 
as the site of fibrin formation 
and polymerisation, and by 
binding (anchoring) fibrin 
polymers.  Since it 
contributes to the overall 
strength, it also effects the 
rate of clot formation. 
MA MCF Maximum strength of the clot 
is determined by the amount 
of fibrin generated (and its 
polymerisation and 
crosslinking) and by platelet 
aggregation.  The FIBTEM 
assay gives an MCF due only 
to the contribution of fibrin 
(although see text for further 
discussion). 
As above.  The difference 
between EXTEM and FIBTEM 
trace MCFs is held to 
represent the platelet 
contribution. 
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The use of TE-guided coagulation therapy has been explored in detail in cardiac and 
liver surgery, including using randomised control trials (Craig et al., 2008; Johansson et 
al., 2009).  The transfusion protocols in these studies typically use TE to detect clot 
abnormalities and respond by giving procoagulants (FFP, platelets) or antifibrinolytics 
(Shore-Lesserson et al., 1999).  The possible contribution of endogenous 
anticoagulants, which may be particularly important after trauma (Brohi et al., 2007), 
is not addressed.   
 
In recent years there has been much attention to TE’s applicability in trauma and 
ROTEM is now in routine clinical use in the British armed forces (Doran, Woolley and 
Midwinter, 2010).  Kauffman et al (1997) demonstrated that TEG detected a 
hypercoagulable state in mildly injured patients on admission but that severely injured 
patients were hypocoagulopathic.  TEG, unlike laboratory tests, was an independent 
predictor of transfusion requirement after blunt injury.  Plotkin et al (2008) found that 
low clot strength was associated with increased transfusion in combat casualties 
sustaining penetrating injury.  Again, TEG was superior to laboratory tests at predicting 
blood product use.  Carroll et al (2009) found that TE parameters on admission 
predicted fatality while Leeman et al demonstrated the use of TE to predict massive 
transfusion (Leemann et al., 2010).  Brohi’s group published a series (Davenport, 
Manson, et al., 2011), confirming the superior predictive value of TE over laboratory 
tests, now confirmed in a large international collaboration (n=808) (Hagemo et al., 
2015).  Johansson and Stensballe (2009) successfully implemented a haemostatic 
resuscitation regime using TEG to guide therapy with FFP and other blood products.  
Schöchl et al (2010, 2011) had similar results using factor concentrates.  TEG was the 
established technique in the Dstl laboratory and was therefore used in this study. 
 
5.1.3 Platelet Assays 
 
Having selected TE as the basis of the assessment of coagulation, it was necessary to 
select a means for assessing platelet function.  The assessment of platelet activity is 
complex because of the variety of functions that can be measured and the multitude 
of devices available to do this.  This variety reflects the fact that none is ideal. 
 
95 
 
Components of platelet function include activation (i.e. the expression of stored 
adhesion molecules), microvesicle formation, adhesion, and aggregation.  The latter 
can be static (how many platelet or platelet-leukocyte aggregates are there in the 
sample with or without in vitro stimulation) or dynamic (real time assessment of 
aggregate formation in response to a stimulus).  In addition, it is possible to determine 
the responsiveness of platelets to a variety of stimulants at different concentrations, 
which may be termed activatability.  No single platform provides for testing all of 
these.  In addition, the focus of many commercially available devices is the monitoring 
of antiplatelet therapy (Harrison et al., 2007). 
 
Platelets contribute to the TE trace in three principal ways (Table 5.1): as the site of 
rapid thrombin formation during propagation, by incorporation in the clot through 
binding to fibrin and by binding to one another (aggregation).  Cytochalasin D inhibits 
the conformational changes of the actin cytoskeleton that are crucial to platelet 
activation.  Use of cytochalasin D abolishes most of the contribution of platelets to clot 
strength.  This assay (FIBTEM in ROTEM nomenclature) isolates the contribution of 
fibrin to the clot, allowing detection of fibrinogen deficiency.  Comparison with the 
uninhibited assays gives a crude measure of the platelet contribution to clot strength.  
A poor EXTEM with a normal or near-normal FIBTEM implies inadequate platelet 
function.  When the FIBTEM is also abnormal, it is difficult to distinguish coexistent 
platelet dysfunction.  The functional fibrinogen TEG (FF TEG) removes the contribution 
of platelets using a GPIIa/IIIb antagonist and can be interpreted in a similar way.  In 
fact, these two methods of platelet inhibition (via the cytoskeleton and GPIIa/IIIb) have 
different and additive effects on the TE trace (Lang et al., 2004).  TE can also be 
modified to examine platelet function by using platelet agonists (ADP, arachidonic 
acid) as initiators alongside an exogenous thrombin mimetic and FXIIIa (to remove the 
influence of all clotting factors upstream of fibrinogen) (Craft et al., 2004).  This is 
known as platelet mapping. 
 
Flow cytometry allows measurement of MVplt, of the expression of activation markers, 
and of platelet and platelet-leukocyte aggregates.  These can be assessed with and 
without stimulation.  The technique can be used to study platelets in enriched 
samples: platelet-rich plasma (PRP) can be produced by a variety of techniques.  
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However, Shattil et al (1987) introduced whole blood flow cytometry, in which the 
platelets remain in the physiological milieu of whole blood and artefacts due to 
agitation during processing are minimised.  Platelet flow cytometry has the facility to 
detect multiple activation markers and to change between them easily (Michelson, 
1996).  Thus flow cytometry is a versatile technique allowing assessment of several 
aspects of platelet function.   
 
 A variety of other methods are available (Harrison et al., 2007).  The bleeding time, 
the time taken for a standardised wound to stop bleeding, has declined in popularity 
(Harker and Slichter, 1972).  However, given its insensitivity and poor reproducibility 
(Lind, 1991), this is a greater loss to comedy (Thomas, 1955) than haematology.  Light 
transmission aggregometry and its more user-friendly successor, impedance whole 
blood aggregometry, measure platelet aggregation under low shear in response to 
various agonists.  While the older systems require time and skill to operate, newer 
models have largely automated the process.  Since they are designed to monitor 
antiplatelet therapy, they do not allow an assessment of aggregation without in vitro 
stimulation, as might be seen in blood taken from patients after injury.  The PFA-100 
(Dade International Inc., Miami, FL) tests platelet aggregation and adhesion in 
conditions of shear intended to simulate blood flow (Kundu et al., 1996).  Platelets are 
activated by either collagen/epinephrine or collagen/ADP and the time taken to 
occlude a micropore in the wall of a simulated capillary is measured (closing time).   
 
Flow cytometry was chosen because of its inherent versatility and the facts that the 
equipment was available and the technique was already being employed to assess 
leukocytes.   
 
5.2 Flow Cytometry 
 
5.2.1 Principles of Flow Cytometry 
 
Having selected flow cytometry for measuring platelet function, a new assay had to be 
designed and validated.  An understanding of the principles of flow cytometry is 
necessary to discuss this process.  Flow cytometry measures characteristics of 
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individual cells by passing them through a laser beam past a set of sensors (Shapiro, 
2003; Macey, 2007).  The cells scatter the light.  The amount of light scattered forward 
(FSC) at low angles (0.5-10°) is a function of the size of the particle.  As light is reflected 
and refracted by structures within the cell it is scattered at larger angles.  The amount 
of side scattered light (SSC) is therefore a measure of the internal complexity of the 
cell.  These basic principles were set out by Coulter (1956) and Kamentsky et al  (1965) 
in the 1950s and 60s and allowed for cell counting and sorting devices to be 
developed.  However, in the 1990s, the availability of monoclonal antibodies (mAb) 
conjugated to fluorophores allowed flow cytometers to detect much more detailed 
information about cells.  mAb bind to cell surface epitopes.  When excited by the laser, 
the fluorophores emit characteristic wavelengths of light.  Alternatively, membrane, 
cytosolic and nuclear dyes may be employed. 
 
The cells must pass through the sensing area one at a time.  To achieve this most 
cytometers use a sheath flow technique.  Sample containing the cells enters the 
chamber through a small aperture.  This is surrounded by sheath fluid which is under 
pressure and flowing.  Sample fluid is drawn out and focused by hydrodynamic effects 
which arise from the shaping of the chamber.  This moves cells to the centre of the 
stream.  Pressure adjustment allows cells to be drawn out singly, which allows 
individual examination and prevents clumping.  Flow cytometers can process many 
thousands of detection events (cells, fragments and artefacts) per second.  The speed 
at which the stream passes the sensing area is fixed.  Consequently, the event rate is 
determined by the concentration of cells in the sample fluid and the width of the 
stream.  The laser beam has an oval cross-section.  Consequently, it is wider at the 
centre of the stream than at the edges.  If the sample stream is wide, small events 
passing through the edge of the stream are exposed to the laser for a shorter period at 
a lower intensity.  In consequence they scatter and fluoresce less light.  Conversely, the 
stream may be wide enough to accommodate more than one event passing 
simultaneously, their total scatter and fluorescence being summed.  When the 
cytometer senses an event it detects all light scattered or fluoresced by the contents of 
the sensing area.  Unbound dyes, for example, can contribute to the light detected. 
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5.2.2 Platelet Flow Cytometry 
 
The preparation of platelet samples for flow cytometry is a multiple-step process 
which requires careful standardisation.  Steps such as preparing platelet-rich plasma 
and fixation can affect the detection of surface antigen and attention must be paid to 
the necessity and ordering of these steps during the design of an assay (Cahill, Macey 
and Newland, 1993; Michelson, 1996; Shapiro, 2003).  The choice of anticoagulant is 
important as this can also cause activation.  Citrate, as used in this case, is 
recommended over alternatives such as lithium/heparin and EDTA for this reason 
(Michelson, 1996).  Markers must be selected for the detection of platelets and of 
platelet activation.  Platelet populations can be detected by light scatter characteristics 
alone but under certain circumstances other particles may fall in the platelet area of 
the scatter plot and not bind platelet-specific mAb (Michelson, 1996).  Such an mAb is 
normally included to allow positive identification.  Several markers are available.  CD61 
was selected because it is a widely used platelet-specific marker (Macey et al., 1999; 
Jacoby et al., 2001) and a porcine mAb was commercially available. 
 
There are multiple ways of detecting platelet activation.  PAC-1 mAb are specific for 
the binding site exposed by the activation-dependant conformational change in 
GPIIa/IIIb.  CD61 is part of GPIIa/IIb, so use of PAC-1 and anti-CD61 in the same assay 
could lead to interference at the binding sites.  While there is considerable species 
cross-reactivity, no PAC-1 mAb had been validated for use in pigs so this conflict was 
avoided.  The surface expression of the GPIb-IX-V complex falls during activation as the 
epitopes relocate within the OCS (Figure 2.5).  While this fall can be used as a marker 
of activation by measuring the fluorescence intensity of the platelets as a whole, it is 
not possible to define activated and unactivated populations.  CD62P and CD31 are 
widely used activation markers and validated mAb for porcine use were available.  
CD62P has been shown (in baboons) to be lost from the surface of activated platelets 
within 2 hours (Michelson et al., 1996).  These platelets continue to circulate and 
function in other respects.  For many applications this has the disadvantage that 
platelets must be drawn soon after any stimulus and processed quickly.  However, in 
this study, serial measurement of CD62P expression allows the detection of ongoing 
activation: one would expect a single activating stimulus to be associated with a rise 
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and fall in CD62P expression, whereas sustained expression (subject to assuming 
constant behaviour between baboon and pig platelets) would imply further 
recruitment of platelets to the CD62P+ population.  Measurement of platelet-
neutrophil aggregates (for which the assay could in future be adapted) would enhance 
this since platelets that have lost their CD62P following initial activation can still form 
aggregates (Michelson et al., 1996) and these circulate only for short periods (less than 
30min) (Michelson et al., 2001).  CD62P and CD31 were examined during the design of 
the assay. 
 
The stimulated activation of platelets in a flow cytometry assay can be used to provide 
a positive control, i.e. platelet activation may be stimulated and detected, allowing the 
experimenter to be confident that a failure to detect activation in platelets which have 
not been exposed to an exogenous agonist reflects a physiological reality.  
Additionally, it can be used to detect platelets that are inhibited or effete.  Several 
substances are used to stimulate the activation of platelets in vitro. 
 Thrombin activates platelets by cleaving the free terminal of a protease-
activated receptor (PAR).  The neoterminal then ligates the receptor’s bonding 
site (Grand, Turnell and Grabham, 1996).  While thrombin cannot be used 
alone in vitro due to clot formation, Thrombin Receptor Activating Peptide 
(TRAP), a short peptide consisting of the same residues as the PAR’s 
neoterminal, is a potent activator. 
 ADP has a more selective effect, causing partial degranulation but not 
aggregation of unstimulated platelets (Janes et al., 1994).  Impaired platelet 
response to ADP after injury is well documented (Kutcher et al., 2012; 
Wohlauer et al., 2012). 
 Collagen is a much weaker agonist unless used in combination. 
 Other agonists including epinephrine have been used. 
However, human studies indicate that, while there is considerable variation between 
individuals in their in vitro response to these substances, any given individual has 
broadly equivalent response to all of them (Panzer, Höcker and Koren, 2005).  TRAP 
and ADP were assessed during assay design (see Section 6.4). 
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5.2.3 Technical issues in flow cytometry 
 
There are a number of further technical issues relating to flow cytometry which 
underlie the work described in this chapter: compensation, Fc blockade and the use of 
isotype controls. 
 
Compensation.  First, excited fluorophores do not emit light at discreet wavelengths 
but rather over a range with a prominent peak at the wavelength used to describe 
them.  Hence flourescein has a peak within the range of the green passband (light 
filter).  However, flourescein also emits a small amount of light in the range of the 
yellow passband.  Consequently, any flourescein-conjugated mAb bound to an event 
will contribute to the phycoeytherin (yellow) signal.  Compensation for this 
phenomenon can be achieved by establishing the contribution of each fluorophore to 
the other channels of interest and using simultaneous equations to remove this from 
the reported fluorescence.  This process is automated in modern cytometers. 
 
Fc blockade.  Second, mAb are used for their ability to bind specifically to the epitope 
of interest.  However, non-specific binding also occurs.  Partly, this is due to the Fc 
domain (a major part of the structure of mAb which is constant and allows interaction 
with leucocytes) binding to Fc receptors.  These are expressed on many cell types but 
on leukocytes particularly and, to a lesser extent, platelets.  To prevent this, samples 
can be incubated with unconjugated, non-specific serum, which will saturate the Fc 
receptors.   
 
Isotype controls.  Some non-specific binding will still occur and this leads to the third 
aspect, the use of controls.  No stain controls (assays using vehicle without antibody) 
are used to detect the small amount of autofluorescence which cells exhibit.  It is then 
necessary to appreciate how much fluorescence will be caused by the binding of 
conjugated mAb to molecules other than the epitope of interest.  This is determined 
by running parallel assays using antibodies specific for irrelevant epitopes (i.e. ones 
that will not be present; this is achieved by raising the antibodies against a different 
species) and the same characteristics as the test Ab, i.e. of the same source species, 
the same isotype (light and heavy chain combination) and same fluorophore.  The 
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highest intensity of fluorescence emitted by isotype-bound events can be used to set a 
threshold.  Events in the test assay which fluoresce above this level are then taken to 
be positive for expression of the epitope.  This is the standard approach for 
discriminating positive from negative events in most applications of flow cytometry 
(O’Gorman and Thomas, 1999). 
 
5.3 Animal Models 
 
Chapter 4 of this thesis outlines the findings of the first comparative study of the 
effectiveness of PHBTx in a military context.  Although associated with a survival 
benefit, confounding changes in other aspects of treatment make it impossible to 
determine how much of this is attributable to PHBTx.  Since PHBTx was not a standard 
part of UK military practice and is associated with a considerable logistic burden 
(O’Reilly et al., 2014), further study was warranted to determine its efficacy.  There 
was no prospect of establishing clinical equipoise to allow a randomised trial of PHBTx 
in the current military environment.  Also, it would be extremely difficult to obtain 
suitably and consistently timed samples and the diversity of injuries would obscure 
much of the effect.  Despite this, understanding how, when and to what extent PHBTx 
is useful is highly important.  An animal model was the only means of achieving this.  
Use of an animal model had the additional benefit of allowing far more detailed 
monitoring and analysis of response to injury and treatment than would be possible in 
a human trial.  A suitable model would mimic the response to trauma seen in patients 
injured in contemporary conflict. 
 
This section will briefly consider some general issues surrounding the use of animal 
models, examine some of the relevant available models of trauma and describe the 
development of the existing large animal model of military trauma at Dstl.  Finally, it 
will introduce the process of developing a new model which took place in parallel with 
the work presented in this thesis. 
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5.3.1 Use of Animals in Research 
 
The use of animal models remains controversial (Rawstorne, 2010).  Animal models are 
useful because they allow subjects to be monitored and treated in ways that are not 
possible in human subjects.  Information about disease at its earliest stages or about 
treatment in the absence of the confounding influence of other therapy is gained.  
Objections range from absolute ethical ones, i.e. that there can be no justification for 
using animals (sometimes in ways that make them suffer) as the means to furthering 
man’s goals, to practical ones, i.e. that the information gathered is flawed and not 
helpful.  Interspecies differences can undermine the applicability of findings to human 
disease as can poor modelling of the disease of interest (Frith, Cohen and Brohi, 2012).  
Animal trials may be poorly designed or reported (Kilkenny et al., 2009).  Animal trials 
suffer from the same potential sources of bias as human studies, both internally (need 
for randomisation, blinding and allocation concealment) (Bebarta, Luyten and Heard, 
2003) and externally (need to assess all available evidence and avoid publication bias) 
(Roberts et al., 2002). 
 
The three principles of “replacement, reduction, and refinement” are intended to 
address these issues (Russell and Burch, 1956):  Replacement means using other 
means where possible; reduction means minimising the number of animals used; 
refinement means ensuring the highest scientific standards so that the use of each 
animal contributes as much as possible.  However, as Roberts has pointed out, these 
principles may conflict.  For example, using inbred, single-sex animals which all have 
disease induced in the same way with the intent of achieving the same severity and 
which then receive the same treatment (save for the item of interest) reduces within- 
and between-group variability, allowing smaller numbers to be used.  However, it also 
reduces the applicability of the results to the varied and dynamic reality of human 
disease (Roberts et al., 2002).  Small group sizes also increase the risk of type 2 errors 
in animal research. 
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5.3.2 Models of ATC 
 
Chapter 3 contains a partial description of some of the models which have been used 
in research about haemorrhagic shock and resuscitation.  Controlled haemorrhage can 
be induced by removal of a set volume of blood or by removing blood so as to reach a 
predetermined blood pressure.  Uncontrolled haemorrhage can be induced by a 
variety of injuries, including tail transection, aortotomy and liver injury.  However, a 
model of military injury to investigate the effectiveness of prehospital use of 
haemostatic resuscitation needs to include other aspects of injury and reproduce the 
pathophysiological response to injury. 
 
Brohi’s group recently reviewed available animal models used to investigate trauma 
induced coagulopathy (Frith, Cohen and Brohi, 2012).  They identified 23 models using 
5 species.  Pigs were the predominant large animal used.  Porcine models are held to 
recapitulate the human cardiovascular responses to injury and haemorrhage 
(Tsukamoto and Pape, 2009), which was the basis of their selection for the research 
programme at Dstl.  However, it should be noted that porcine inflammatory response 
has not been well characterised.  Pigs are hypercoagulable relative to humans and 
have less protein C (Siller-Matula et al., 2008).  Several models therefore use measures 
such as haemodilution to “knock down” the pig coagulation system, but it is unclear 
whether this is a valid manoeuvre.   The lack of protein C has clear implications if 
investigating a coagulopathy that appears dependent on this pathway.  None of the 
large animal models studied developed an endogenous coagulopathy due to combined 
injury and shock alone, as humans do. 
 
5.3.3 The Dstl Model 
 
The original Dstl pig model (i.e. before the developments explained in subsection 
3.3.4) was developed to test the effect of resuscitation on mortality and physiological 
parameters, such as blood gases, rather than to assess coagulation (Garner et al., 
2009; Kirkman, Watts and Cooper, 2010).  It was particularly concerned with two 
aspects of military practice not assessed in other models: blast injury and prolonged 
evacuation times (Place, Rush and Arrington, 2003).  The model therefore contains 
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both blast and sham blast arms and is designed so that there is potential salvageable 
mortality among subjects, which can be sustained for several hours with adequate 
resuscitation. 
 
Terminally anaesthetised large white pigs are surgically prepared, including 
splenectomy to prevent autotransfusion (Hannon, Bossone and Rodkey, 1985).  An 
adrenaline solution is applied to the spleen before removal, causing it to contract; the 
intention is to reduce variation by ensuring that the circulation has been similarly 
bolstered with spleen-sequestered red cells before the organ is removed.  The animals 
are wrapped in a Kevlar blanket before exposure to an explosive charge with no casing; 
again, these measures reduce variability by preventing secondary and tertiary blast 
injury.  Shock was induced by removing a fixed volume of blood through a preplaced 
cannula and this was then converted to an uncontrolled haemorrhage.  A Grade IV 
liver injury (i.e. involving disruption of 25-75% of the liver parenchyma) (Moore et al., 
1995) was later added to allow an element of uncontrolled bleeding with the 
possibility of rebleeding.  This was induced by placing a heavy suture through the 
substance of one lobe of the liver during preparation and looping such that it cut 
through when pulled from outside the closed abdomen.  In both cases the controlled 
haemorrhage was intended to reduce variability in the amount of blood that would be 
lost, especially between the blast and sham blast groups (see subsection 2.4.2). 
 
The success of these models has been touched on in earlier sections.  Several 
modifications to this original model were required for the proposed study of PHBTx.   
 Injury and haemorrhage were to be adjusted to induce a coagulopathy at a 
time point corresponding to hospital admission. 
 The endpoints of the trials were to be based on coagulation parameters rather 
than mortality.  As such, it was necessary for the animals to survive until the 
end of the experiment. 
 The liver injury had face validity as a potentially survivable wound, had a 
mixture of arterial and venous branches involved and was capable of 
rebleeding.  However, since the liver was cut rather than injured bluntly, there 
was relatively little damage to tissue that was not amputated.  Since tissue 
injury can alter the response to haemorrhage (Rady et al., 1993) and is crucial 
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to ATC (Frith et al., 2010), a limb injury (intended to mimic a fragmentation 
injury) was substituted. 
 Changes in the operational scenario in Afghanistan meant that evacuation 
times were now much shorter (Morrison, Oh, et al., 2013), and the timing of 
interventions in the model needed to reflect this. 
 
The next chapter focuses on the development of the flow cytometry assay.  The details 
of animal injury that occurred were largely irrelevant at this stage.  Consequently, a full 
description of the model after the modifications mentioned above is reserved for 
Chapter 7.  
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Chapter 6.  Platelet Flow Cytometry Assay Development 
 
This chapter describes the establishment of a porcine platelet assay designed to detect 
the expression of an activation marker and the response to an agonist.  Development 
of the platelet assay proceeded in four stages:   
1. An initial protocol was designed to allow the detection of platelets using 
specific markers and FSC/SSC characteristics. 
2. This assay was altered to optimise the detection of platelets. 
3. Measurements were made of platelet activation and response to agonist. 
4. Some simplifications were made to facilitate use of the assay in the context of 
the complex trial and animal model detailed in Chapter 7. 
 
6.1 Standard Conditions 
 
Animals mentioned in this discussion have been assigned a sequential code (PA1, PA2 
etc) in order to simplify the description.  Blood used in the development of the assay 
was drawn from terminally anaesthetised animals being used in the preparation of the 
model to be used in trials of haemostatic resuscitation.  The materials and methods 
used in animal preparation, injury and sampling were as set out in section 7.1 except 
that during development variations were made in the degree of blast loading, the 
volume of haemorrhage and the details of musculoskeletal injury.  The combination of 
these factors peculiar to each animal was not germane to the development of the 
FACS assay and will not be detailed in this chapter. 
 
All flow cytometry assays were performed on whole blood collected via the femoral 
arterial line and immediately aliquoted into citrated tubes.  These were placed on a 
roller for 5 minutes.  All antibodies were obtained from AbD Serotec (Oxford, UK), see 
Table 6.1.  The initial antibody mixture contained 10µL CD61 mAb, 10µL CD62P mAb 
and 20µL buffer (or equivalent isotypes, as appropriate).  10µL buffer was later 
replaced with 10µL CD45 mAb, as noted below, and this mixture was used throughout 
the remainder of the experiment unless otherwise noted. 
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Table 6.1—AbD Serotec mAb used during the development of the platelet flow cytometry assay. 
Antibody Target Isotype Flurophore 
MCA1222APC CD45 IgG1 APC 
MCA2263F CD61 IgG1 FITC 
MCA2418PE CD62P IgG1 PE 
MCA1746PE CD31 IgG1 PE 
MCA928F Control IgG1 FITC 
MCA928APC Control IgG1 APC 
MCA928PE Control IgG1 PE 
 
All incubation, lysis and fixation steps described below took place at 25°C, with the 
specimens protected from light.  Where appropriate, for red blood cell lysis whole 
blood was incubated for 15min in BD Pharm Lyse solution (BD bioscience, Oxford, UK).  
Where detailed, samples were washed or resuspended in FACS wash buffer (Delbecos 
Phosphate Buffer Solution pH 7.4, 0.01% sodium azide, 4% newborn calf serum).  
Where stated, samples were blocked in Fc blocking serum prior to staining (6µL mouse 
serum and 4µL FACS wash buffer).  Except where specified, samples were refrigerated 
after preparation and analysed the next day.  A no-stain control was performed for 
each animal (and, where appropriate, each protocol).  Isotype controls were 
performed for every assay. 
 
All samples were analysed on a BD FACS Cantotm II and analysed using BD FACSDivatm 
software.  Positive populations were gated using the relevant isotype control, the gate 
being set with less than 5% positive events in the isotype population. 
 
6.2 Initial Protocol Design 
 
A porcine FACS leucocyte assay had previously been developed at Dstl Porton Down 
(Carter, unpublished).  Development of the platelet assay began with modifications to 
this protocol.  The initial considerations were the ability to identify the platelet 
population using FCS, SCC and a platelet-specific marker and secondly to ensure that 
processing the samples 24hrs after initial fixation would not inadvertently change the 
platelet population.  
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The initial protocol, used for analysing the first samples, is detailed in Figure 6.1.  Note 
that no red cell lysis step was included (one had been used in the earlier leucocyte 
assay) as it was anticipated that this step would lead to artefactual platelet activation 
(Michelson, 1996).  Furthermore it was anticipated that these events (i.e. red cells) 
could be gated out on FSC/SSC criteria more easily than in the leukocyte assay due to 
the physical characteristics of the RBCs relative to the platelets.   
 
 
 
Fig 6.1  Initial (left) and final (right) porcine platelet flow cytometry assay protocols 
 
Samples were single stained for CD61 (Macey et al., 1999; Jacoby et al., 2001) in order 
to locate the platelet population using fluorescence. The forward and side scatter 
Whole blood sample 
collected into citrate 
vacutainer and placed on 
roller for 5 min 
40µl antibody mixture added 
and incubated for 15 min 
50µl blood added to 10µl 
blocking serum mixture and 
incubated for 10 min 
100µl 2% formaldehyde 
added and incubated for 
10min 
500µl buffer to stop fixation 
Whole blood sample 
collected into citrate 
vacutainer and placed on 
roller for 5 min 
50µl blood added to 10µl 
ADP (at various 
concentrations) or buffer 
and incubated for 10 min 
100µl 2% formaldehyde 
added and incubated for 
10min 
500µl buffer to stop fixation 
Sample split 
in two 
Sample analysed without 
further dilution Sample analysed  after 
addition of further 1ml of 
FACS running buffer 
Sample  sent to 
collaborators for analysis 
using Imagestream device 
40µl antibody mixture added 
and incubated for 15 min 
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parameters were adjusted until the putative platelet population, tagged with CD61, 
were fully visible in the FCS and SCC scatter plots. Figure 6.2 shows the first scatter plot 
detecting the CD61+ population.   
 
 
Figure 6.2. PA1. First plt scatterplot 
Initial plt assay set up scatter plot. CD 61+ events are in dark red.  The large population of low FSC and 
low SSC events is referred to as the “platelet area”.  The presumed identities of the other events are 
also shown.  The leukocytes also appear to be CD61+; the likely explanation is that there are platelet-
leucocyte aggregates: the flow cytometry equipment was set up to display red data points over black 
ones in this image. 
Representative of a total of 7 samples from 2 animals at 4 time points. 
 
In addition to success in finding this population, which exists below the FSC detection 
minimum set for previous leucocyte studies, a set of pairwise comparisons of same-
day versus next-day analysis on the FACS machine was performed.  This revealed no 
significant changes in FSC, SSC or fluorescence of the population of interest (Figure 
6.3).  Compensation (see subsection 5.2.3) was also calculated and subsequent 
experiments used dual staining for CD61 and CD62P. 
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Figure 6.3.  PA1.  Representative histograms of CD61 FITC and CD62P PE fluorescence processed on the 
day of preparation (top histograms) and 24 hours later (bottom histograms). 
Representative of paired samples from 4 time points in 1 animal. 
 
The next five trials demonstrated consistent flow cytometry findings:  Figure 6.4 shows 
a representative scatter plot from one of these animals (designated PA2) and a 
diagram labelling the populations seen.  It was observed that two populations were 
present in the scatter plots where the platelets had been identified. The staining of 
these two populations were not consistent with the expected staining patterns of 
platelets.  The smaller cluster of the two putative platelet populations (Population A) is 
shifted up and to the left of the larger cluster (population B). The relative complexity of 
the putative platelets appeared to be greater in population A as compared to 
population B (as shown by the differences in the SCC of the two populations).  CD61+ 
events occurred in population B.  The overall CD61 positivity of the events in the 
platelet area (i.e. A and B together) was usually 30 to 60%, normally at the lower end.  
Hence A appears to be a population of more internally complex and more numerous 
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events than the platelets with a size distribution in the lower part of the CD61+ events.  
It was not immediately clear what such a population would be. 
 
 
Figure 6.4. PA2 Scatterplot 
Only events inside the “platelet area” are coloured. 
CD61-/CD62P- Blue 
CD61+/CD62P- Yellow 
CD61+/CD62P+ Magenta 
Representative of 14 samples at 7 time points in 1 animal. 
 
Compounding this, the ratio of CD61+ to CD61- events increased over the course of 
most experiments.  Figure 6.5 shows histograms of CD61 fluorescence of a typical 
study at two time points.  At first there is a distinct positive group that is small 
compared to the negative one; subsequently, the peaks are more equal.  Note that 
there is not a blending together of the two peaks.  The latter might have indicated a 
lack of saturation of the epitope by antibody, i.e. some events were recorded as 
negative because not all (or enough) of their surface epitopes had been marked by the 
antibody, perhaps due to an insufficient concentration. 
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Figure 6.5  PA2 CD61 histograms.  Histograms showing FITC-A fluorescence of events in the platelet area 
at baseline (left) and R105 (right).  The gate was set using a 0.1% threshold on the isotype control for the 
B2 time point. 
CD61+ as % of parent: B2—23.7% 
   R105—51.6% 
Representative of the pattern of change seen in duplicate samples from 7 time points in this animal and 
in 4 other animals. 
 
Thus the initial assay appeared to detect events with the size and complexity of 
platelets but with poor uptake of the platelet marker, the presence of a second, 
distinct population of events and a dynamic shift between the two over the course of 
the experiments.  It was now necessary to optimise the detection of platelets and to 
identify population A. 
 
6.3 Protocol Optimisation 
 
A series of experiments were then conducted to examine all the alterable aspects of 
the sample preparation process to determine their impact on the results.  The 
following steps were examined: 
 
1. The effect of Fc receptor blockade using mouse serum (which was originally 
included in the leukocyte assay to prevent non-specific binding). 
2. The effect of a red cell lysis step. 
3. Comparison of whole blood platelet staining with platelet-rich plasma (PRP) 
preparation. 
4. Antibody and sample titration. 
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5. The concentration of fixative during the fixation step. 
6. The concentration of fixative during storage overnight. 
7. The degree of dilution of the sample during analysis on the FACS machine. 
 
A series of pairwise or higher-order comparisons of the first three changes mentioned 
was conducted during study PA3, a sham blasted animal.  The remaining aspects are 
examined in the next subsection. 
 
Fc receptor blockade and red cell lysis were elements of the original leucocyte assay.  
Fc receptor blockade with mouse serum interfered with CD61 detection in the platelet 
area (see Figure 6.6).  Use of red cell lysis produced no usable data (Figure 6.7).  These 
steps were removed from the protocol. 
 
 
Figure 6.6. PA3 CD61 FITC histograms at B2. 
Left—with Fc receptor blockade.  Right—without Fc receptor blockade. 
No increase in fluorescence was observed with the isotype controls. This implied that the improvement 
in CD61 positivity was due to improved specific binding to CD61, not non-specific binding to any Fc 
receptors expressed within the population. 
Representative of paired samples at 3 time points in 1 animal. 
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Figure 6.7.  PA3 CD61 Histogram at R150. 
Post red cell lysis.  Note that the gate, set using the isotype control for this protocol, has a much lower 
threshold than the previous examples.  Red cell lysis has had profound effects on both antigenicity and 
non-specific binding of events in the platelet area.  
Representative of 2 samples at one time point in one animal. 
 
Platelet rich plasma was prepared using a low-g centrifugation technique.(Delgado et 
al., 2003; Lindenblatt et al., 2007)  Analysis of these samples (Figure 6.8) showed loss 
of a considerable part of the CD61+ population, so this approach was abandoned.   
 
 
Figure 6.8.  PA4.  Representative scatter plots at R165 demonstrating the loss of CD61+ subpopulations 
when comparing the whole blood assay (left) and an assay using PRP (right).  Large (possibly aggregated) 
and activated platelets have been lost.  Duplicate assays of paired samples (PRP+ and PRP-) at 8 time 
points in 1 animal.    CD45+,CD61- Red; CD45+,CD61+,CD62P- Yellow; CD45+, CD61+,CD62P+ Magenta. 
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Addition of the leucocyte marker CD45 demonstrated that it was strongly expressed by 
population A (as described above), see Figure 6.9.  This population was excluded from 
further analysis. 
 
 
Figure 6.9   PA5 CD45 at B2 
Left—CD45+ in magenta and CD45- in green.  Most CD45+ events are in the area previously designated 
population A.  Given that they express the leucocyte-specific marker CD45 but are of similar size (judged 
by forward scatter) as CD61+ events (platelets), it seems likely that these represent fragments of 
leucocytes). 
Right—Gating only on the densely CD45+area in the left figure, APC fluorescence (for CD45) is shown: 
No stain control in grey, isotype control in red, positive antibody in blue.  The marked gate includes 1% 
of events from the isotype histogram and 48% of those in the positive antibody histogram.  Non-specific 
binding of isotype antibody (possibly due to Fc receptor expression) and wide variation in surface 
marker expression among fragments would account for these data. 
Representative of 50 assays taken from 5 animals at between 3 and 8 time points in each case. 
 
6.3.1 Antibody and Fixative Concentration and Sample Dilution for Analysis 
 
In parallel with analysis using the FACS Canto II, a collaboration was set up with 
another laboratory to examine the samples with an Imagestream (Amnis, Seattle, WA, 
USA) imaging cytometer.*  The other laboratory requested that sample dilution be 
minimised so that samples could be processed quickly.  However, there are several 
considerations in manipulating sample and reagent volumes and concentrations in 
flow cytometry, the effect of which on the assay had to be assessed: 
                                                 
*
 The Imagestream work affected the development of this protocol but does not itself form a part of this 
thesis. 
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 There is a limit to the ability of the cytometer to deal with numerous, small 
events (such as platelets) which can lead to false negative fluorescence plots. 
o This is compounded by the shape of the laser, as mentioned in 
subsection 5.2.1. 
 High concentrations of fixative can, over time, alter the binding of antibodies to 
epitopes and cause an endogenous signal to appear in FL1 (Shapiro, 2003). 
 
A series of experiments were undertaken to optimise the assay for use with 
Imagestream while addressing these issues.  First, dilution at the end of fixation was 
reduced (PA6).  As shown in Figure 6.10, this led to loss of positive events.  It was not 
clear whether this was due to the effect of storage in more concentrated fixative or to 
high events rates during analysis.  Recorded event rates in some cases approached the 
manufacturer’s specified maximum of 10,000 per second, so the latter was a 
possibility. 
 
 
Figure 6.10.  PA6.  Samples taken at S2 and processed according to the standard protocol except when 
terminating fixation.  Histograms show CD61 FITC fluorescence after termination of fixation using (from 
left to right) 250µL, 500µL and 1mL of buffer.  Note the marked increase in the relative number of 
positive events as the dilution is increased. 
Representative of duplicate assays of each dilution from two time points (twelve assays in total) in 1 
animal. 
 
Second, the event rate was increased while holding fixative concentration (during both 
fixation and storages) constant (PA7).  This was achieved by adding two new protocols 
using more blood and less fixative, albeit at higher concentrations.  The protocols are 
in Table 6.2.  This lead to increased fluorescence of unstained controls (Figure 6.11) 
and to loss of positive events in the assay (Figure 6.12).  However, these changes had 
increased both the concentration of blood (and therefore the event rate during 
analysis) and the ratio of blood to antibody mix. 
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Figure 6.11.  PA7.  Isotype control histograms at R30 for Protocols A (Black-the standard protocol in 
earlier assays), B (Red) and C (Blue).  B and C represent increasing volumes of blood used with smaller 
volumes of more concentrated fixative.  See Table 6.2. 
Representative of duplicate assays of each protocol at 4 time points (24 assays in total) in 1 animal. 
 
 
Figure 6.12  PA7  CD61 FITC fluorescence histograms at R30 for Protocols A (Black), B (Red) and C (Blue).  
See Table 6.2 for protocols. 
The gate was set to include 0.7% of events in the protocol B isotype control at R30 (previous figure). 
Note the right shift of the negative peaks as we move from A to C, consistent with the previous figure. 
In addition, there is a very marked shift from the positive to the negative peak as we move from A to C. 
Representative of duplicate assays of each protocol at 4 time points (24 assays in total) in 1 animal. 
 
In the third experiment (PA8), another protocol was added which corrected for this.  It 
did not restore the positive events, indicating that antibody concentration was not the 
critical issue.  To test for the effect of concentration during analysis (i.e. event rate), 
samples from each protocol were run neat, after the addition of a further 500µL of 
buffer and after the addition of 1mL (total) of buffer.  Protocol C was the “poorest 
performer” for CD61 positivity in the previous experiment.  Figure 6.13 shows analysis 
of a protocol C sample at the three dilutions.  Note the massive shift from a negative to 
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a positive peak.  The dilutions were made immediately before analysis, so the 
differences seen are due to the performance of the analyser, not due to a storage 
lesion.  Although the effect was less dramatic the “best performer”, protocol A, was 
also enhanced by the additional dilution.   
 
 
Figure 6.13.  PA8.  CD61 FITC fluorescence histograms at B2.  Protocol C (table n) was used in each case.  
A) sample analyzed neat. B) sample analyzed after addition of 500µL buffer. C) sample analyzed after 
addition of 1mL (total) of buffer.Representative of duplicate assays using 4 protocols on samples from 3 
time points (24 assays in total) in 1 animal.  Each assay analysed with three different dilutions. 
 
It would appear that at high event rates the cytometer is unable to detect many of the 
positive events.  Therefore subsequent experiments used Protocol A (the existing 
standard protocol) combined with dilution with 1mL buffer, yielding a mean event rate 
of 700 per second. 
 
Table 6.2—Protocols used during PA7 (A to C) and PA8 (A to D).  Protocol A represents the standard 
protocol in use hitherto.  In all cases, fixation was stopped by the addition of 1mL of buffer.  PA8 
samples were further diluted immediately before analysis. 
Name Blood Ab Fixative Fix Volume Fixative 
conc 
Storage fixative 
conc 
A 50µL 40µL 100µL of 2% 190µL 1.05% 0.17% 
B 100µL 40µL 50µL of 4% 190µL 1.05% 0.17% 
C 100µL 80µL 40µL of 6% 220µL 1.09% 0.20% 
D 50µL 60µL* 100µL of 2% 210µL 0.95% 0.17% 
*The antibody mixture for protocol D used 20µL of each mAb without any buffer. 
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6.4 The Activatability Assay 
 
Subsequent experiments confirmed that the developed protocol gave dependable 
rates of CD61 positivity.  The next stage in refining the assay was to select an 
appropriate platelet activation marker and validate the assay using platelet activation 
assays.  Hitherto CD62P antibodies had been used but it was now necessary to check 
that these were useful for detecting platelet activation.  This would require a 
stimulation assay.  It was natural to combine this experiment with an assessment of an 
alternative activation marker (CD31). 
 
Experiments were conducted using a dilution series of TRAP-6* with a maximum 
concentration of 64µM, which was expected to maximally stimulate the platelets.  
There was no apparent reaction.  Figure 6.14 shows CD62P positivity of platelets at a 
representative time point after incubation with buffer and with 64µM TRAP-6.  This 
result was repeated in subsequent experiments.  The experiment was repeated using 
TRAP-6 from a different supplier.  The results were repeated.  As a final check, TRAP-6 
from the same batches, prepared in the same way at the same concentrations, was 
used in a stimulation assay for a study of human platelets that was being developed in 
parallel.  TRAP-6 caused high levels of platelet activation, just as would be expected.  A 
fault with the preparation of TRAP-6 had been excluded.  In fact, this confirms the 
findings of two other groups (Kinlough-Rathbone, Rand and Packham, 1993; Connolly 
et al., 1994) which have demonstrated that pig platelets show only a partial response 
to TRAP-6 characterised by shape change and aggregation but not degranulation. 
 
 
                                                 
*
 i.e. a six-amino acid residue version of Thrombin Receptor Activating Peptide 
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Figure 6.14.  PA10.  Representative histograms of CD62P PE fluorescence for samples taken at B2 and 
stimulated with 64µM TRAP-6 (left) and buffer (right) for 10 min.  Representative of duplicate assays 
analysed with 6 concentrations of TRAP-6 (including control) at 4 time points in 3 animals. 
TRAP-6 was therefore also abandoned in favour of ADP.  PA9 was the first animal used 
for this purpose.  A matrix of assays to be performed at each time point was designed, 
Table 6.3.  The range of ADP concentration used was based on an inspection of the 
literature (Panzer, Höcker and Koren, 2005).  Samples were incubated with one of five 
concentrations of ADP, or with buffer, for 10minutes.  Then they were incubated with 
the standard antibody mixture, with CD31 Ab in place of CD62P Ab or with isotype 
controls. 
 
Table 6.3—PA9 ADP concentration series at time points T0, R30, R60, R105.  Each concentration was 
incubated with sample for 10 minutes before staining with Ab mixtures containing mAb for either CD31 
or CD62P or with isotype controls. 
Name Volume of 
concentrate 
Volume of 
PBS 
Concentration 
of solution 
Final 
concentration 
(with sample) 
A 1mL of Stock Nil 60µM 10µM 
B 500μl of A 500μl 30µM 5µM 
C 500μl of B 500μl 15µM 2.5µM 
D 500μl of C 500μl 7.5µM 1.25µM 
E 500μl of D 500μl 3.75µM 0.675µM 
F Nil 1mL - Control 
 
Table 6.4 shows percentage positivity for CD31 and CD62P for each ADP concentration 
of ADP.  There was poor positivity for CD31 even at high concentrations of ADP.  This 
was representative of all experiments run using the CD31 mAb and consequently this 
was abandoned in favour of CD62P.  While increased expression of CD31 after platelet 
stimulation is established in humans (Cramer, Berger and Berndt, 1994) there is no 
literature to confirm this in swine.  Additionally, there is evidence of reduced CD31 
expression after in vivo stimulation (Metzelaar et al., 1993); the studied platelets had 
been subject to in vivo stimulation and this may have affected their response to in vitro 
stimulation.  Finally, ADP may be an unsuitable agonist to use with CD31, given that it 
only partially stimulates degranulation. (See subsection 5.2.2) 
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Table 6.4—PA9 % of Platelets (CD45-, CD61+) positive for CD62P or CD31 after incubation with different 
concentrations of ADP.  Gate set to include <5% of events from the respective isotype controls. 
Representative of a total 5 samples from three time points in three animals.  Assays completed in 
duplicate (i.e. 10 in total). 
Tube Name Final 
concentration 
(with sample) 
CD62P+ % CD31+ % 
R60 A 10µM 32.5 7.8 
R60 B 5µM 30.3 8.6 
R60 C 2.5µM 26.4 9.6 
R60 D 1.25µM 22.9 8.5 
R60 E 0.675µM 23.5 10.2 
R60 F Control 18.7 10.6 
 
 
6.5 Final Optimisation 
 
The ADP stimulation assay worked and achieved CD62P positivity of the order of 40%, 
consistent with the literature.  Of note, this version of the assay consistently 
(completed in full for 3 animals) found more than 95% of events in the platelet area to 
be CD61 positive, with no variation over the course of the experiment, as had been 
seen earlier (Figure 6.5). 
 
The final step in development was a simplification of the protocol to facilitate its use 
alongside both the existing leucocyte FACS assay and multiple other aspects of 
simultaneous sample preparation and analysis required as part of the proposed trial.  
The platelet FACS protocol remained a developmental tool and a secondary endpoint 
in the trial, the process outlined above having finished just as model development 
reached a conclusion.  Consequently the assay was optimised to allow its validity and 
utility to be assessed, as outlined in Chapter 7, while minimising its impact on 
laboratory and human resources.  As such, only unstimulated and maximally 
stimulated assays were used. 
 
122 
 
The CD45 mAb was being used to exclude the CD45+ events in area A (Figure 6.4).  An 
analysis was conducted to see whether simply excluding area A from the platelet 
population would significantly affect the output, i.e. the % CD62P positivity.  Figure 
6.16 shows a Bland-Altman plot comparing the two methods of excluding the 
presumed white cell fragments.  Gating out area A, rather than using the CD45 marker, 
reduced the measured CD62P positivity by a mean (SD) of 0.825% (0.198), which is 
negligible.  There was no evidence that the difference in output was affected by the 
activation state of the platelets (i.e. there is no correlation between the difference and 
the mean).  The CD45 mAb was removed from the assay. 
 
Figure 6.16  Bland-Altman Plot comparing %CD62P positivity among CD61+ platelets identified by (a) 
excluding all CD45+ events in areas A and B of Fig 4 and (b) only including area B, gating out area A. 
X-axis: mean of (a) and (b).  Y-axis: (a) – (b).  See text above for discussion. 
 
The final protocol for the platelet flow cytometry assay was as shown in Figure 6.1.  
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Chapter 7.  Assay Validation 
 
Development of the flow cytometry assay proceeded in parallel with development of 
the animal model, such that the assay design detailed in the last chapter was 
completed just as the model was finalised.  The animal work then continued with the 
start of the randomised control trial.  Before using the assay to compare platelet 
activity between the groups, an assessment of the function of the assay and its 
interaction with the animal model was required.  Since the platelet assay was a 
secondary outcome of the trial, this was achieved by an analysis of data from six 
animals from early in two arms of the trial.  This chapter sets out the findings of that 
analysis.  This lead to the formulation of a new hypothesis about the effect of surgical 
preparation of the animals on platelet function.  Further assays were conducted to 
examine this hypothesis.  Consequently, methodology and data for this “further 
analysis” appear in their own subsections below. 
 
7.1 Methods 
 
The study* was conducted on terminally anesthetized cross-bred female Large White 
pigs and was ethically reviewed and conducted in accordance with the Animals 
(Scientific Procedures) Act, 1986.  The animals were housed indoors and were fed on a 
complete diet comprising coarse ground mixture of wheat, barley, soya protein, 
vitamins and minerals.  The animals fed ad libitum and consumed approximately 5 kg 
per day.  They were allowed water ad libitum. 
 
7.1.1 Blood bank 
 
Blood was collected by exsanguination from terminally anaesthetised female Large 
White pigs.  Briefly, standard units  of blood were collected from a carotid cannula at a 
flow rate of 65-90 mL/min into citrate, phosphate and dextrose (CPD) blood collection 
                                                 
*
 The design of the animal model and the trial were not the author’s responsibility; descriptions of these 
matters are based on information provided by Dr E Kirkman and therefore align with the methodology in 
his team’s recent paper based on this work (Watts et al., 2015).  The author was on compassionate leave 
at the time that the six experiments detailed in this chapter were conducted and is grateful to his 
colleagues for completing these.  However, all the analysis presented here is the author’s own. 
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bag (RCB434CCL, Pall Medical, UK), with pauses between bag collection resulting in an 
overall bleeding rate of 22.5 mL/min.  The blood was processed according to standard 
UK blood transfusion protocols (UK Blood Transfusion & Tissue Transplantation 
Services, 2013) to separate the red blood cells from the plasma, which was 
leucodepleted, while the packed red cells were stored in saline, adenine, glucose and 
mannitol solution (SAG-M).   The platelets were discarded.  Collected units of blood 
were processed within 90 min of collection.  The resulting units of PRBC were stored at 
4°C (LabCold Blood Bank, UK) and used within 14 days of collection.  The plasma (FFP) 
was fast-frozen (MP1100 Plasma Freezer System, Thermogenesis, US), stored at -30°C 
(LabCold Plasma Freezer, LabCold, UK) and used within 6 months of collection.  FFP 
was thawed at 37°C in a dry plasma thawer (Sahara III Maxitherm, Sarstedt, Germany) 
immediately before use.  Prior to use all donor products were forward and reverse 
matched to recipient blood.  In addition, since PRBC and FFP from different donors 
were used for resuscitation, they were also cross-matched with each other. 
 
7.1.2 Surgical Preparation 
 
The animals were fasted for 18 hours before the surgical procedure, but allowed water 
ad libitum.  After premedication with intramuscular midazolam hydrochloride (0.1 
mg/kg) anaesthesia was induced by mask with isoflurane (5%) in a mixture of oxygen 
and nitrous oxide (1:1) and the animals intubated. Surgical anaesthesia was 
subsequently maintained with isoflurane (1%–2%) in a mixture of oxygen and nitrous 
oxide (1:2) and the animals ventilated using positive pressure ventilation (Blease 
Manley MP3 Anaesthesia Ventilator).  Initial monitoring consisted of end-tidal CO2, 
pulse oximetry through a tail probe and skin surface electrocardiogram electrodes 
(Propac 106EL, Protocol Systems Inc, Oregon).  With the animal positioned supine 
surgical preparation took place after skin preparation with povidone-iodine solution 
(10% wt/vol, Betadine Aqueous Antiseptic Solution, Seaton Healthcare Group plc, UK). 
 
The left carotid artery (Swan Ganz, Edwards Life Sciences Ltd, Newbury, UK), both 
internal jugular veins, left femoral artery and vein were cannulated (Portex 8FG, Hythe, 
UK).  A balloon tipped flow-directed cannula (744MF75 Swan Ganz, Edwards Life 
Sciences Ltd, Newbury, UK) was introduced through a right internal jugular vein 
125 
 
cannula introducer sheath, (Desivalve Catheter Introducer, Vygon, Cirencester, UK) 
and advanced until its tip was in the pulmonary artery.  Cannula placement was 
determined by monitoring pressure changes at the tip. 
 
After venous access had been established, anaesthesia was continued with 
intravenous alphaxalone to maintain a surgical plane of anaesthesia assessed by 
palpebral reflex and jaw tone (Alfaxan®, Jurox (UK) Ltd, Malvern Link, UK), and the 
isoflurane was discontinued. 
 
A midline laparotomy was performed, the spleen contracted by topical application of 
adrenaline (up to 1.5 mL of a 1 mg/mL solution) before removal and the bladder 
catheterized by open suprapubic cystostomy.  All incisions were closed en masse.  
Animals were allowed to breathe spontaneously for the remainder of the experiment 
unless they displayed marked respiratory depression, at which stage Synchronized 
Intermittent Mandatory Ventilation (Drager Evita 2, Draeger Medical UK Ltd, UK) was 
instituted in an attempt to maintain adequate oxygenation and prevent severe 
hypercapnoea.  The animals recovered from surgery under anaesthesia for 1 hour 
before baseline measurements were made.  Anaesthesia and surgical preparation took 
place at in a surgical facility collocated with the animal house.  After surgery, animals 
were transported (while anaesthetised) to the experimental facility adjacent to the 
blast arena. 
 
7.1.3 Cardiovascular Monitoring 
 
Arterial blood pressure was recorded through the carotid artery cannula and 
pulmonary arterial and central venous pressures were recorded via the flow-directed 
balloon-tipped flotation catheter, which was also used to determine cardiac output as 
a 6 minute rolling average (Vigilance Volumetrics CEDV, Edwards Lifesciences, US).  
Physiological pressure measurements were made using strain gauge manometers 
(Sensonor 840, SensoNor a.s., Norway) and zero pressure for all transducers was set at 
heart level.  Body temperature was maintained at approximately 38°C using external 
heating/cooling and blankets as appropriate.  The bladder was drained at hourly 
intervals. 
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All cardiovascular variables were recorded using a computerized data acquisition 
system (Maclab 8/s, ADInstruments, UK) and associated software (Chart v4.2.3, 
ADInstruments) for subsequent analysis. 
 
7.1.4 Blood Gas and Related Chemistry 
 
Arterial and venous blood samples were taken anaerobically into heparinized syringes 
from the carotid and pulmonary artery catheters respectively for blood gas, base 
excess, and lactate analysis (Gem Premier 3000 Blood Gas Analyzer, Instrumentation 
Laboratories, Warrington, UK). 
 
7.1.5 Experimental Protocol 
 
The animals were randomly allocated to one of two treatment groups at the outset 
(Figure 7.1).  The timeline for the experimental protocol is shown in Figure 7.1.   
 
Blast exposure.  After baseline measurement the animals were moved outdoors, 
wrapped in a Kevlar blanket to protect from secondary and tertiary blast effects and 
positioned on a trolley 2.1 m from a cylindrical charge of EDC1S explosive (2.2 kg) 
which was then detonated remotely.  Animals subjected to sham blast were treated 
identically but not exposed to blast. 
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Figure 7.1  Experimental protocol and timeline. Red bordered boxes represent the clinical correlates of 
experimental events. 
Time points: B1—baseline on initial cannulation.  SURGERY (not shown)—blood taken immediately after 
completion of surgery.  B2—baseline after completion of surgical preparation and transportation.  
BLAST—samples taken 15 min after exposure to blast (immediately before injury).  INJURY—samples 
taken after musculoskeletal injury and controlled haemorrhage.  S1 and S2—samples taken after 15 and 
30 min of shock, respectively.  R30, R60 etc—samples taken 30, 60 etc min after onset of resuscitation.  
R90 coincides with the “decision re surgery” clinical event; this time point was used for the primary 
endpoint of the study.  However, this is not relevant to the discussion in this chapter.  Sal—Normal 
Saline 
 
Tissue injury phase.  Immediately after the blast (or sham blast) the animal was 
returned to the physiological monitoring suite and fifteen minutes later, all animals 
were subjected to a controlled soft tissue injury using a blunt captive bolt pistol (CASH 
Special Knocker, Accles & Shelvoke, Sutton Coldfield, UK) delivering 4 standard impacts 
(using 2 Grain .25 cartridges) to the muscle of the right hindquarter.  This resulted in 
widespread deep contusion in the underlying muscle but no fracture to bone.  Five 
minutes after the tissue injury a haemorrhage of 35% of the estimated total blood 
volume was performed over 9 min 40 sec via the femoral arterial cannula, using a 
computer-controlled pump (Masterflex L/S model 7550 –17, Cole Palmer Instrument 
Company, Chicago, IL).  The rate of bleeding reduced exponentially as the 
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haemorrhage progressed to mimic the rate of haemorrhage from a major arterial 
lesion.  For blood volume and bleeding rate equations see Stern et al., 1993 and 
Garner et al., 2010 
 
Shock phase.  Following haemorrhage, the animals underwent a 30 minute shock 
period during which a capped volume of 0.9% saline (500 mL maximum) was 
administered as necessary to maintain a target systolic arterial blood pressure (SBP) of 
60 mmHg, reflecting an aspect of current clinical practice by Combat Medical 
Technicians.  Resuscitation infusions were warmed to 37°C and administered at a rate 
of 200 mL/min (Belmont Rapid Infuser, Belmont Instrument Corporation, US). 
 
Pre-hospital evacuation phase.  The next phase of the protocol represented a 60 min 
pre-hospital evacuation phase.  Warmed resuscitation fluid was administered 
according to the relevant protocol, with a final target SBP of 80 mmHg in each group.  
Group 1 was given aliquots of 0.9% saline (representing standard of care) to attain and 
maintain the target SBP, while Group 2 received Packed Red Blood Cells (PRBC) and 
Fresh Frozen Plasma (1:1 ratio, PRBC and FFP given simultaneously).  The volume of 
blood products in the pre-hospital phase was capped at 4 Units (4x450 mL 
approximately) per animal (2 units PRBC and 2 Units FFP).  Once the maximum amount 
of blood product had been used resuscitation continued to the same pressure target 
using 0.9% saline for the reminder of the pre-hospital evacuation phase.  All infusion 
volumes were measured accurately. 
 
In-hospital phase.  The in-hospital phase represented more aggressive resuscitation to 
a normotensive target (SBP 110 mmHg) using PRBC:FFP (1:1) in all groups.  
Supplementary oxygen (minimum FiO2 0.3) was given and titrated to attain an arterial 
oxygen saturation (SaO2) of 98%.  Due to the limitations of the blood bank the total 
amount of PRBC:FFP used in any one animal was capped at 6 Units of each product (in 
addition to the PRBC used during the pre-hospital phase in Group 2).  Once the total 
permissible amount of PRBC:FFP had been given resuscitation continued to the same 
pressure target using 0.9% saline in all groups.  In practice few animals received saline 
in the in-hospital phase (3/9 in Group 1; 2/9 in Group 2). 
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7.1.6 Sampling and Measurements 
 
Cardiovascular and paired arterial and mixed venous blood gas measurements were 
made before and after injury/haemorrhage, after 15 and 30 min shock, and at 30 min 
intervals during the pre-hospital resuscitation phase and in-hospital resuscitation 
phases.  Blood samples for assessment of clotting were also taken at these time points.  
This included blood for use in the flow cytometry assay, the protocol for which is given 
in Figure 6.1  
 
Thromboelastography (TEG®).  Thromboelastography using a TEG® 5000 Hemostasis 
Analyzer (Haemonetics Ltd., UK) was performed on fresh, un-citrated whole blood.  
Arterial blood was taken from the femoral cannula and analysed immediately using 
dilute Innovin® (1:50887 dilution Dade® Innovin®, Dade Behring; marketed by System 
UK Ltd, UK) as the initiator (Sørensen et al., 2010).  All TEG® analyses were performed 
in triplicate at 37°C. 
 
Prothrombin and activated partial thromboplastin times (PT and aPTT).  Arterial 
blood samples were taken into citrated vacutainers (9NC 0.105M Vacutainer 367691, 
Beckton Dickinson, UK) and centrifuged at 1500 x g for 10 min.  The plasma was 
separated and stored at -80°C for determination of PT and aPTT by turbidometry and 
fibrinogen concentration (Clauss method) using an ACL Elite analyser (Instrumentation 
Laboratories, Warrington, UK). 
 
Blood Counts.  Full blood counts were conducted using an ADVIA 120 (Bayer, Barmen, 
Germany).  The ADVIA 120 is able to measure a parameter known as mean platelet 
component (MPC), which is related to flow cytometry side scatter and therefore to the 
internal complexity of platelets.  MPC falls when platelets degranulate.  To optimise 
MPC measurement, samples were mixed with ethylenediaminetetraacetic acid and 
then with citrate-theophylline-adenosine-dipyridamole (EDTA-CTAD) (Macey et al., 
2003). 
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7.1.7 Study Endpoints 
 
The primary end point of the study was the clotting status assessed using 
thromboelastography (TEG®) after 30 min of in-hospital resuscitation.  Secondary 
endpoints included clotting status throughout the study, physiological status, in 
particular degree of shock assessed by measuring actual base excess and arterial 
lactate and volumes of fluids used to attain the pressure-driven resuscitation targets.  
These endpoints are beyond the scope of this chapter. 
 
At the end of the study all animals were killed humanely using a lethal overdose of 
sodium pentobarbitone (Euthatal, Merial Animal Health Ltd, Harlow, Essex) given 
intravenously.   
 
7.2 Results 
 
It should be noted that animal HR3 died at R149.  Death was by sudden onset VF with 
cardiac arrest, at a time when the animal appeared to be recovering. 
 
7.2.1 Physiological Data 
 
Figure 7.2 shows the base excess of each animal, reflecting global adequacy of tissue 
oxygen delivery, by time point.  All animals sustained a significant physiological insult.  
Figure 7.3 displays the same data but is colourised according to the resuscitation 
strategy to which the animals were randomised. 
 
131 
 
 
Figure 7.2: Base excess by animal and time point 
 
Figure 7.3: Base excess by animal and time point.  Blue lines are the animals that received prehospital blood (group 
2), the red lines those which did not (group 1). 
 
7.2.2 Platelet Data 
 
Figure 7.4 shows the percentage of CD61 positive events from the platelet area that 
were positive for CD62P, by animal and time point, in the unstimulated assay. 
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Figure 7.4: % of CD61 positive events (platelets) that were CD62P positive, by animal and time point.  No ADP 
stimulation. 
 
There are two key findings.  First, there is a wide variation in CD62P positivity at the 
initial time point.  Second, most animals exhibited little change in C62P expression 
over the course of the experiment. 
 
Figure 7.5 shows the stimulated and unstimulated CD62P positivity for each animal by 
time point.  These data demonstrate response to ADP stimulation at all time points of 
the study.  Since there is a large variation in the initial unstimulated CD62P positivity 
(Figure 7.4), relative rather than absolute change on stimulation was used to compare 
the effect of ADP between animals.   
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A-HR1 
 
B-HR2 
 
C-HR3 
D-HR4 
 
E-HR5 
 
F-HR6 
  
 
Figure 7.5: % of CD61 positive events (platelets) that were CD62P positive, by time point.  Each animal’s data are 
displayed in a separate graph.  Data for the unstimulated assay shown in blue.  Results after ADP stimulation shown 
in red. 
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The foldchange (ratio of CD62P positivity between stimulated and unstimulated 
assays) was calculated in each case and these data appear in Figure 7.6a.  Figure 7.6b 
shows the mean foldchange.   
 
Figure 7.6a: Foldchange in % positivity for CD62P of CD61 positive events (platelets) on stimulation with ADP by 
animal and time point. 
 
 
Figure 7.6b: Foldchange in % positivity for CD62P of CD61 positive events (platelets).  Data are displayed as mean 
foldchange; whiskers represent the 95% confidence interval. 
 
There was divergent response to ADP stimulation.  Three animals (HR1, HR3 and HR6) 
began with relatively low activatability (that is ability to respond to agonist by 
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level much closer to the other animals after injury and shock.  Activatability was 
restored in these two cases later in the experiment.  HR2 also showed high 
activatability late in the experiment, having initially followed the pattern of the other 
three animals.  There is no apparent relationship between there different phenotypes 
and the baseline expression of CD62P. 
 
Figure 7.7 shows platelet counts by animal and time point. 
 
Figure 7.7: Platelet count by animal and time point  
 
Two animals began with and maintained relatively low platelets counts, in the region 
of 100x109/L.  The remainder showed a gradual fall in platelet numbers over the 
course of the experiment.  Platelet counts immediately post-injury are only available in 
three cases but there was no significant fall at that time point.  There is no apparent 
relationship between platelet number and either CD62P expression or the effect of 
ADP stimulation. 
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Figure 7.8 shows the Mean Platelet Component (MPC) data. 
 
  
Figure 7.8: Mean Platelet Component by animal and time point. 
 
MPC reflects granularity of platelets.  The lack of a fall in MPC over the study period is 
therefore consistent with the finding that there was no increase in (unstimulated) 
CD62P expression.  Animal HR6 has shown an idiosyncratic pattern of MPC change, 
one not consistent with its very flat CD62P positivity curve (Figure 7.5E). 
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In Figures 7.9 and 7.10, the data on platelet activation (CD62P expression and MPC, 
respectively) are plotted against BE at the same time point.  No correlation is 
observed. 
 
 
Figure 7.9.  Scatter plot of BE versus CD62P expression. 
 
 
Figure 7.10.  Scatter plot of BE versus MPC. 
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7.2.3 Coagulation Data 
 
Figure 7.11a shows the changes in PT during the experiments.  In Figure 7.11b these 
same data are displayed after normalising each animal’s data to the internal control of 
the first blood sample taken at Line in 1.  This will be referred to as normalised PT 
(nPT) 
 
 
Figure 7.11a: Prothrombin time by animal and time point. 
 
 
Figure 7.11b: Prothrombin time, normalised to the value at B1, (nPT) by animal and time point. 
 
Immediately after injury there is the suggestion of a slight increase in the inter-animal 
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between animals.  However, even by R210, three of the animals have only reached an 
nPT in the region of 1.1.  HR3 displayed an unusual peak in PT early during the 
resuscitation phase, before returning to follow the trend seen in other cases. 
 
In Figure 7.12, the nadir BE achieved by each animal is plotted against the nPT at R150 
(the last time point at which data is available on all animals).  There is a clear 
correlation between the depth of the physiological insult and the degree of 
disturbance of coagulation (Pearson’s -0.962, p=0.002). 
 
 
Figure 7.12: Scatter plot showing nadir BE against nPT at R150. 
 
Figure 7.1 demonstrates that all the animals had reached the nadir of BE by R75, but 
the upwards trend in nPT has only just become established at this point and continues 
to the end of the experiment. 
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Figure 7.13 shows aPTT data.  Most animals show a shortening of aPTT after surgical 
preparation and transport and/or after blast.  Amid great variability, aPTT 
measurements then rise again but do not go on to demonstrate any coagulopathy. 
 
 
Figure 7.13 aPTT by animal and time point 
 
Fibrinogen data are shown in Figure 7.14.  There is an increase in fibrinogen 
concentration between B1 (mean [IQR]: 2.49 [2.29-2.77]) and B2 (2.78 [2.51-3.41]), 
which is consistent with the acute phase response to surgery (Wilcoxon signed rank 
test, p=0.048).  Fibrinogen levels then fall to a new low immediately post-injury (2.26 
[1.88-2.69], p=0.028).  There then appears to be a (non-significant trend) towards 
increased fibrinogen concentrations during the shock phase.  This is followed by 
divergent behaviour, with sharp falls in HR3 and HR6, the animals with the greatest 
physiological insult, to levels below the normal range seen in this strain of pig.*  More 
stable values were seen in the others.  However, all animals have broadly stable 
fibrinogen concentrations from R60 inwards.  Despite this, abnormalities in PT 
continue to evolve (Figure 7.11). 
 
                                                 
*
 The 95% reference range for plasma fibrinogen in this strain of pigs was 1.77-3.36 g/l.   
Data based on samples taken after minimal surgery (induction of anaesthesia and insertion of 
carotid cannula) in Large White pigs of similar age that contributed to this and other studies in 
the laboratory (n=147).  Data distribution was normalized with a 1/square root transformation 
prior to determining the reference range.  (Mrs C Wilson, analysis, and Dr R Gwyther, 
statistics.) 
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Figure 7.14: Fibrinogen concentration by animal and time point. 
 
Figure 7.15 plots the Fibrinogen concentration at R150 against the nadir BE.  There is a 
correlation between the animals physiological response and the final fibrinogen 
concentration (Pearson’s 0.822, p=0.045). 
 
 
Figure 7.15. Scatter plot of Fibrinogen concentration against nadir BE 
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Figure 7.16 shows the R time data.  At B1, values vary between 6s and 26.6s but by B2 
(after surgery and transport to the range) they are much more closely grouped at 11s 
to 14s.  Four animals then show little change in R time over the course of the 
experiment.  The principle exceptions are HR3 and HR6, the two animals which 
experience the greatest physiological insult.  Of note, HR3’s early peak in PT is 
associated with a peak in R time, although subsequent raised PTs in several animals 
are not reflected in the R time, which normalises. 
 
 
Figure 7.16: R time by animal and time point. 
 
Figure 7.17 shows changes in the alpha angle.  Again, the range of values narrows 
between B1 and B2.  There is then a marked rise after exposure to blast (i.e. at the pre 
injury time point).  Animals HR3 and HR6, and to a lesser extent HR5, then show a fall 
in alpha angle followed by a return to normal values, the nadir approximating the time 
of the lowest BE (see figure 7.2). 
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Figure 7.17: Alpha angle is plotted by animal and time point. 
 
Figure 7.18 shows a marked fall in MA between B1 and B2.  Five animals show an 
increase in MA after blast exposure (the pre-injury time point), followed by a return to 
values broadly in keeping with that seen at B1. HR4 shows a different pattern of MA 
changes with no significant rise immediately after blast exposure. 
 
  
Figure 7.18: MA by animal and time point 
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stage. Figure 7.19 demonstrates the lack of correlation between Fibrinogen 
concentration and MA. 
 
 
Figure 7.19: Fibrinogen concentration plotted against MA at R150.  There is no positive correlation between 
fibrinogen concentration and MA.  Indeed, if HR4 were excluded, there would be something of a negative 
correlation. 
 
7.3 Discussion 
 
7.3.1 Physiological Response to Injury 
 
Figures 7.2 and 7.3 demonstrate the development of significant shock in all animals.  
Figure 7.20 gives some idea of the amount of tissue injury generated.  There is a 
notable variation in response to the injury, with BE at the end of the shock phase (S2) 
ranging from 1.5 to -13.5 me/L.  In every case, BE began to rise after 30 to 60 min of 
resuscitation.  This allows an assessment of the function of the assay in a range of 
physiological conditions.  It is not intended to compare the two treatment arms in this 
chapter.  With these small numbers, it is not appropriate to make comparisons 
between the animals treated with early blood transfusion and the others. 
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Figure 7.20  Post mortem photograph illustrating the contused and devitalised muscle caused by the 
action of the captive bolt gun. 
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7.3.2 Coagulation 
 
Figures 7.11a and b demonstrate a clear upward trend in PT over the course of the 
experiment.  However, the changes would be considered modest in a human 
polytrauma patient.  Additionally, they are only firmly established quite late in the 
course of the experiment, well after the simulated patient has reached hospital and 
received resuscitation in both treatment groups.  Definitions of acute traumatic 
coagulopathy have varied.  In the initial description by Brohi, coagulopathy was 
defined as PT over 18 seconds, APTT over 60 seconds, or TT over 15 seconds (1.5 times 
normal) (Brohi et al., 2003).  Other studies have tended to use a Prothrombin Time 
Ratio (PTr) of 1.2 as a diagnostic threshold for ATC when using laboratory tests 
(MacLeod et al., 2003; Maegele et al., 2007; Frith et al., 2010; Davenport, Manson, et 
al., 2011).  Caution must be exercised transferring human diagnostic criteria into an 
animal model and PTr is not directly analogous to nPT (the former using an external 
control, the latter an internal control). 
 
It is therefore not possible to define a level of PT or nPT that represents coagulopathy 
in this model.  However, it is reasonable to say that small changes in nPT, e.g. nPT 
remaining near to 1.1 or lower, do not suggest a significant coagulopathy.  Three 
animals achieved nPT>1.2 at any stage.  ATC is defined as an early coagulopathy, 
developing before admission to hospital and in the absence of significant fluid 
resuscitation (Brohi et al., 2003).  The S2 and R30 time points are equivalent to this.  
There was considerable variation in nPT at S2, but none of the animals could be said to 
be coagulopathic by this (crude) measure.  HR3 did show a large rise in nPT at R30 but 
this was unique and part of an aberrant pattern of change in nPT.  aPTT data showed 
no evidence of a coagulopathy.  Consequently, the coagulation changes seen in this 
small group is best characterised as displaying mixed but significant disturbances of 
coagulation.  It cannot be said to accurately recapitulate the human syndrome of ATC. 
 
It may be that the animals should not have been expected to develop ATC.  ATC was 
described in civilian patients.  Admission coagulation abnormalities have been 
reported in military patients (Doran, Woolley and Midwinter, 2010; Morrison, Dubose, 
et al., 2012; Morrison, Ross, et al., 2013).  However, the contribution of primary blast 
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injury to human coagulopathy has not been characterised.  The degree of primary blast 
experienced by patients injured by IEDs is likely to be highly variable.  Animal work at 
Porton Down has previously shown an upregulation of coagulation immediately after 
blast (Harrisson et al., 2008), a finding recently confirmed by French investigators (Prat 
et al., 2015).  Although not reflected in the PT data, this can also be seen in this 
experiment.  There is a clear rise in both alpha angle and MA at the time point 
immediately after blast exposure.  It may be that subsequent changes in coagulation 
are altered by this blast-induced change and that this prevents a more profound, early 
coagulopathy from developing.  In keeping with this suggestion, data from animals 
subjected to this experimental protocol but without blast exposure have subsequently 
been shown to demonstrate a coagulopathy at the end of the prehospital phase 
(Watts et al., 2015).  An intriguing mechanism for this effect can be hypothesised: blast 
exposure leads to a bradycardia mediated by vagal efferents (subsection 3.1.2).  
Recently, a Brazilian group has described attenuation of haemorrhagic shock-induced 
coagulopathy by efferent vagal nerve stimulation (Rezende-Neto et al., 2014).  
However, the bradycardia associated with simple models of blast injury is not seen 
with complex models such as this one, so it is not clear that there is suitable vagal 
signalling in this context. 
 
The R time and alpha angle changes are well correlated to the animals’ physiological 
response.  However, there is a time lag between the nadir of BE and the PT changes.  
Of the standard mechanisms thought to contribute to trauma induced coagulopathy 
(Hess et al., 2008), factor consumption or dilution would seem the most plausible 
causes of these relatively late changes, while acidosis could govern the changes which 
corrected as the animals recovered.  There is also a correlation between the 
physiological response and the final fibrinogen concentration, as shown in Figure 7.15.  
This raises the possibility that the degree of change in nPT is driven by the ability of the 
liver to replenish consumed factors in the face of tissue hypoxia.  (The discordance 
between TEG and laboratory coagulation test results seen in these data is a well-
recognized finding [Ågren et al., 2013; Louis et al., 2014].) 
 
Some other aspects of the coagulation data are notable.  There is a tightening in the 
range of the R time and the alpha angle between B1 and B2.  There is a fall in MA 
148 
 
between B1 and B2.  This suggests that surgical preparation and transport has an 
effect on coagulation.  This accords with the concerns about the effect on platelet 
function raised earlier.  Suggestions of a mechanistic link between these findings must 
be very tentative: Effete or non-responsive platelets could contribute to a reduction in 
MA at B2.  They could also explain later falls in MA that appear to be independent of 
fibrinogen (Figure 7.19). 
 
This discussion has been based on data from a very small sample.  The interpretations 
outlined above were constructed post hoc.  Consequently, only trends can be observed 
and the data can only serve to generate hypotheses. 
 
7.3.2 Platelet Activation 
 
Figure 7.4 shows that CD62P expression remained fairly constant throughout the 
experiment in all animals, with some between-animal variation.  This lack of change in 
the face of injury, shock and resuscitation was unexpected (see subsection 2.7.6).  No 
other study has examined platelet activation and response at multiple time points 
early after trauma, either in animals or humans.  However, it is known that there is 
increased CD62 expression after injury (Jacoby et al., 2001; Ogura et al., 2001) and 
reduced response to platelet agonists (Tschuor et al., 2008).  A primate model has 
shown that a proportion of expressed CD62P can be shed from the platelet surface 
within 2 hours, with preservation of platelet function (Michelson et al., 1996).  It might 
be reasonable therefore to expect the following pattern in these data: 
 
 Increased expression of CD62P after injury 
 A fall in CD62P expression over the course of the experiment 
 A fall in activatability (change in CD62P expression on stimulation) after injury 
 
The first two phenomena were not observed.  The last was observed only in those 
animals which had a high degree of activatability at baseline.  Two explanations need 
to be considered: a) there could be a fault with the assay or b) this finding could reflect 
the physiological reality. 
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There are several findings that support the performance of the assay.  First, the assay 
detected changes in CD62P expression in response to ADP.  Second, the assay detected 
changes in the response to ADP over the course of the experiment in some animals 
(HR1 and HR4, Figure 7.5).  Third, Figure 7.8 shows that, with one exception, there was 
little change in MPC over the course of the experiment.  Changes in MPC have been 
shown to be inversely correlated with changes in CD62P expression (Macey et al., 
1999).  This lack of change in MPC therefore corresponds with the flat CD62P 
expression curves in Figure 7.4.  Therefore two assays (CD62P expression and MPC) 
have indicated that there was little variation in the activation of circulating platelets 
during the experiment.  However, it must be emphasised that MPC is not a gold 
standard against which the assay can be assessed.  As noted at the end of Chapter 6, 
the dose-response curve was removed from the flow cytometry protocol.  This has 
proved unfortunate in the context of these unexpected findings.  It is possible that 
differential response to agonist would have been seen at lower ADP concentrations.  
Equally, the ADP concentration that was used was based on statements in the 
literature indicating that it was associated with maximal response in humans (Panzer, 
Höcker and Koren, 2005).  In the light of these data, an assessment of higher 
concentrations would be justified. 
 
Accepting that the assay has functioned properly, a possible physiological explanation 
is that the surgical preparation and transport of the animals meant that there had 
already been substantial CD62P expression before B2.  Further experimental work was 
carried out to address this hypothesis. 
 
7.3.4 Further Analysis – Materials and Methods 
 
15 animals were used, designated X1 to X15.  10 animals being used for blood 
donation.  These animals underwent induction of anaesthesia and cannulation as 
outlined above.  Only their B1 samples were analysed.  5 animals were being prepared 
for experimental use and therefore completed the full protocol of preparation and 
transplant as outlined above.  B1 and B2 samples were available for assay.  All assays 
were carried out as previously.   B1 samples, taken as soon as arterial access is 
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achieved, are as close as possible to being from normal subjects.  The author’s 
colleagues at Dstl kindly carried out these assays on his behalf. 
 
7.3.5 Further Analysis — Results 
 
Figure 7.21 shows CD62P expression with and without stimulation from a) B2 for the 
six HR subject animals and b) B1 for the 15 other animals (designated X).  The HR B2 
unstimulated data are statistically significantly lower than the X B1 data.  The same is 
true of the ADP-stimulated results. 
 
 
 
Figure 7.21: %CD62P positivity in unstimulated and stimulated assays from X B1 (normal subjects at true baseline) 
and HR B2 (experimental subjects after surgical preparation and transport).  *The HR B2 results are lower than the X 
B1 results in both cases (Mann-Whitney U, p=0.003 in both cases). 
 
While 15 is too small a number to allow a normal range to be established, the B1 data 
in Figure 7.21 indicate where that range would lie.  CD62 expression at B2 in the HR 
animals shown appears to be lower, in both the stimulated and unstimulated assay. 
 
Figure 7.22 A shows CD62P expression in sequential samples taken at B1 and B2 in five 
animals.  These were the five animals mentioned above which were being prepared for 
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experimental use.  Figure 7.22 B shows the results after ADP stimulation.  With the 
exception of unstimulated CD62P expression by platelets taken from X6, all the data 
show either no change or more commonly a fall in between the two time points. 
 
 
 
 
Figure 7.22. A) CD62P expression without ADP stimulation at B1 and B2.  B) CD62P expression with ADP stimulation 
at B1 and B2. 
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Figure 7.23 expresses these data as foldchange in CD62P expression on ADP 
stimulation. 
 
 
Figure 7.23  Foldchange in CD62P expression following ADP stimulation of platelets from animals tested at B1 and 
B2. 
Three of the five animals show a considerable fall in their response to ADP stimulation. 
 
7.3.6 Further Analysis – Discussion 
 
These data (Figures 7.21 to 7.23) suggest that there is an effect of surgical preparation 
and transport on the results of the CD62P assay in some animals.  However, the effect 
is not consistent.  In particular, two HR subject animals had a preserved response to 
ADP at B2.  These were among the three animals which exhibited high activatability at 
the end of the experiment.  This could suggest an inter-subject variability in the ability 
to restore responsiveness to ADP stimulation. 
 
In the light of these data, it was concluded that it would not be appropriate to carry 
out a comparison between the arms of the trial of CD62P expression.  Equally, it is not 
possible to comment on what would otherwise be interesting findings in the present 
data, such as the lack of correlation between physiological derangement and platelet 
activation seen in Figure 7.9.  Further work to establish an assay (or assays) of platelet 
function and a compatible model of coagulopathy after military injury would be 
required.  This is discussed further in Chapter 8. 
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Chapter 8. Implications for Further Research 
 
8.1 Animal Experiments 
 
Platelets are fundamental to coagulation.  The practical difficulties of studying 
platelets and the complexity of their actions (relative to clotting factors) has meant 
that their role in trauma induced coagulopathy remains unclear.  They are implicated 
both by their functional centrality and by some human data.  Translational research 
into platelet function after trauma must lead to an understanding of how platelets 
contribute to coagulopathy and to the identification of potential therapeutic targets.  
However, it is not yet clear which aspects of platelet function are involved and 
consequently which assays will be useful.  Further work in this area must begin with 
broadly based assessment of multiple aspects of: 
 platelet number,  
 stimulation (multiple agonists),  
 degranulation and epitope conformational change (use of multiple expression 
markers),  
 aggregation and adhesion  
both in animal models and humans.  This will make it possible to confirm that animal 
models accurately reflect the human disease and allow identification of the important 
pathways.   
 
The present model and platelet assay may have a role in this process.  The data 
suggest several lines for the possible improvement of both.  This assay can be adapted 
and expanded in several ways.  With optimisation of the cytometer settings and of the 
assay preparation and the addition of uniform sized microspheres, platelet 
microparticles could be detected.  By reintroducing the CD45 specific mAb, platelet-
leucocyte aggregates can be detected.  Given the wide variation in detected platelet 
forward scatter (see Figure 6.8), it seems likely that platelet-platelet aggregates are 
included in the platelet population.  An imaging flow cytometer could be used to 
demonstrate these.  As noted during assay development, porcine platelets do not 
respond to TRAP in the same way as humans (Kinlough-Rathbone, Rand and Packham, 
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1993; Connolly et al., 1994).  Since thrombin is a crucial platelet activator, it would be 
desirable to circumvent this problem.  TRAP does induce a change in platelet shape 
and platelet-platelet aggregation; an imaging flow cytometer would be useful to 
observe these also.  Thrombin itself fully activates porcine platelets, possibly through a 
receptor other than PAR-1.  Thrombin could be used as an agonist if a further 
modification were made to prevent it acting on fibrinogen in the sample (Michelson, 
1994). 
 
Only two CD62P assays were conducted at each time point: unstimulated and 
stimulated.  The concentration of ADP used (10µM) has been shown to be sufficient to 
stimulate significant platelet activation, including CD62P expression, in several studies 
(Janes et al., 1994; Daniel et al., 1998; Panzer, Höcker and Koren, 2005).  However, 
these all used human subjects.  Further work to establish whether higher 
concentrations of ADP would have a further effect on porcine platelets, particularly in 
those showing little response at 10µM, is required. 
 
Extending this, dose-response curves for ADP stimulation could be used.  Figure 8.1 
illustrates data from two of the developmental animals.*  It shows the percentage 
CD62P positivity of platelets at each ADP concentration at three time points: B2—
before injury; S1—during the shock phase; R30—30 min into resuscitation.  There was 
a differential response to progressively increasing concentrations of ADP and this 
reversed the relationship.  At maximal ADP concentration, there was a greater CD62P 
positivity in the samples from the uninjured animal than the later samples.  In the first 
animal, there is the suggestion that response to ADP after injury was maximal at a 
lower agonist concentration than before injury (i.e. the lines plateau). 
 
                                                 
*
 Dose response curves were not included after initial assay development (i.e. in Chapter 6) as it would 
not have been physically possible to run these in parallel with other assays using available staff and 
equipment. 
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Figure 8.1.  PA9 (left) and PA10 (right).  % of platelets (CD45-, CD61+) positive for CD62P.  Gates were 
set to include <5% of events from the relevant isotype control.  Samples from 3 time points are shown.  
Each sample was incubated with ADP at the concentration shown for 10min before Ab staining. 
 
No conclusion can be drawn from this finding where n=2, and indeed it is not 
consistent with subsequent findings.  However, it indicates how the use of dose-
response curves could enhance the assay.  Figure 8.2 illustrates how these could 
identify subtle changes in the effect of ADP. 
 
 
Figure 8.2.  Hypothetical dose-response curves for possible post-injury platelet phenotypes. 
 
The assay uses a single marker of platelet activation, CD62P.  The use of additional 
markers of other aspects of activation would be useful.  In particular, it would be 
desirable to establish a marker of GPIIa/IIIb conformational change equivalent to PAC-
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1 (see subsection 5.2.2).  In parallel with the continued use of flow cytometry, it would 
also be desirable to use other means of detecting disparate aspects of platelet 
function, such as platelet-inhibited thromboelastography and functional analysers such 
as aggregometers. 
 
The preparation of the animal subject appears to have an effect on platelet and 
coagulation function.  This should be minimised.  At present, the splenectomy and 
suprapubic catheterisation are conducted via a full length laparotomy.  All could be 
achieved by laparoscopy (Morrison et al., 2014), which is known to cause less 
inflammatory activation (Jacobi et al., 1998; Pascual et al., 2011).  Topical adrenaline, a 
platelet agonist, is applied to the spleen before removal (to make it contract, with the 
intention of reducing variation in haemoglobin concentration between subjects); this 
may promote platelet activation.  An assessment should be made as to whether 
removing this step would adversely affect the model in other ways.  Vascular access, 
particularly in the neck, is achieved by surgical cut down.  Porcine anatomy means that 
this is an extensive procedure.  Minimal access techniques are possible (Fudge, 
Coleman and Parker, 2002), could be enhanced with ultrasound guidance and would 
reduce the amount of tissue trauma.  While possibly desirable, it is not practical to 
house animals at the experimental location on the range at Porton Down, so remote 
preparation and transportation will continue.  Despite these possible improvements, it 
may be that pigs are not a suitable model for studying this aspect of trauma-induced 
coagulopathy and that alternative animal models are required. 
 
8.2 Human Studies 
 
The results of the study in Chapter 5 demonstrate some of the difficulties that attend 
research involving trauma patients and of retrospective studies.  It would have been 
more appropriate for a prospective study of the impact of PHBTx to have been 
conducted.  In particular, this could have improved the ascertainment of pre-hospital 
physiology data, by allowing feedback from data collectors to clinicians in real time.  
This would not have altered the confounding changes in hospital resuscitation practice 
but would have allowed an assessment of the effect of PHBTx on physiology between 
initial medical care and hospitalisation.  The implication for future major innovations in 
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care is clear.  Where possible, high level evidence (i.e. randomised trials) should be 
established to support changes.  Where this is impractical, high quality, prospective 
observational evaluations should be instituted.* 
 
More narrowly, the investigation of the platelet contribution to coagulopathy requires 
human observational and, in due course, interventional studies.  The high throughput 
of severely injured patients at the hospital in BASTION provided the Defence Medical 
Services with an opportunity to contribute to this process.  Studies using ROTEM data 
have already been cited (Doran, Woolley and Midwinter, 2010; Woolley et al., 2013).  
The Platelet Function in Acute Traumatic Coagulopathy study (PATCH)† was initiated to 
supplement the existing ROTEM work with a flow cytometry-based assay of platelet 
function.  This used a PAC-1 mAb to measure platelet activation using admission blood 
samples.  TRAP-6 was used to produce stimulation dose-response curves.  A Cyflow 
flow cytometer (Partec UK Ltd, Canterbury, UK) was acquired and deployed to 
Afghanistan where it was used alongside a Multiplate analyser (Roche International 
Diagnostics, Rotkreuz, Switzerland) by a team of Dstl and military researchers.  Analysis 
is ongoing. 
 
  
                                                 
*
 None of this should be taken as criticism of the enormous hard work of the trauma nurse coordinators in 
Afghanistan, Iraq, the USA and Birmingham who maintain the trauma registries and whose efforts made 
Chapter 5 possible. 
†
 This study will need to be renamed since the previously mentioned Australian study of TXA usage has 
the same acronym (Mitra et al., 2014). 
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Appendix. Injury Scoring 
 
In Afghanistan, the UK Joint Theatre Trauma Register (JTTR) and the US JTTR, now 
known as the Department of Defence Trauma Register (DoDTR) record injury, 
treatment and outcome data on a) all injured military personnel of the respective 
nations, wherever they were treated and b) all injured patients treated in medical 
facilities staffed by the military medical services of the respective nations, regardless of 
the nationality of the casualty.  Since the hospital at Camp BASTION was staffed by 
both countries for much of the period covered by the study in Chapter 4, patients were 
entered into both systems.  Local nationals were soon lost to follow up but UK and US 
casualties were followed throughout their care to, where appropriate, discharge in the 
home nation.  Consequently, the databases contain more accurate injury and follow up 
data about servicemen of their own nationality. 
 
In both cases, injuries are recoded using the abbreviated injury score (AIS) of the 
American Association for the Advancement of Automotive Medicine.  This is a 
codification of all injuries which assigns each a 7 digit code.  For example a femoral 
shaft fracture is coded as 851814.3.  “8” represents the body region (lower limb), 
“518” represents the anatomical structure (“5”-skeletal, “18”-femur), “14” the 
particular injury, in this case its level (shaft) and “3” is a measure of the severity and 
appears after the dot.  There are 9 body regions in AIS. 
 
Severity is coded from 1 to 6, where 6 is unsurvivable.  This is an ordinal not an interval 
scale; i.e. AIS 5 injuries are supposed to be all roughly equivalent and to be worse than 
AIS 4 injuries but the difference between AIS 5 and AIS 4 is not the same as between 
AIS 4 and AIS 3.  Severity in AIS codes is similar to that found in the injury grade system 
of the American Association for the Surgery of Trauma. 
 
The AIS code book has been repeatedly updated since its introduction in 1969.  The 
2005 edition contained a separate military AIS coding to account for difference 
between military and civilian trauma (Champion et al., 2010).  This version was used in 
the work presented in Chapter n. 
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AIS codes are used to calculate the Injury Severity Score (ISS).  AIS codes are regrouped 
into 6 body regions and the highest severity in the three most severely injured regions 
are used.  The three numbers are squared and summed.  Any AIS 6 leads to an ISS of 
75, which is the limit of the scale.  ISS is open to criticism on several counts (Lefering, 
2002).  First, it ignores severe injuries coexisting in the same body region; the New ISS 
(NISS) ignores the body region to use the three most severe codes in order to address 
this.  Second, it takes data from an ordinal scale, transforms them and purports to 
produce an interval scale.  Third, it conflates injury patterns, which both loses 
information about particular injuries and makes very different injuries (e.g. severe 
head injury and proximal limb amputation) essentially interchangeable (Russell et al., 
2004).  Despite these concerns, use of the ISS is almost universal in trauma research 
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